Cephalon, Inc. (CEPH) and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals, Inc. (MYL) and Barr Pharmaceuticals, Inc. (BRL)

FRAZER, Pa. and PHILADELPHIA — 26-Nov-2008

FRAZER, Pa. and PHILADELPHIA, Nov. 26 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH - News) and Eurand, Inc. (Nasdaq: EURX - News) today announced that they have filed a lawsuit in U.S. District Court in Delaware against Mylan Pharmaceuticals, Inc. and its subsidiary, Mylan, Inc., and Barr Pharmaceuticals, Inc. and its subsidiary, Barr Laboratories, Inc., for infringement of Eurand\'s U.S. Patent Number 7,387,793.

Roche wins European approval for hepatitis drug

By Staff Writer — 5-Dec-2008

Roche has announced that the European Commission has approved Pegasys plus Copegus for the re-treatment of hepatitis C patients who were not successfully treated with an initial course of interferon alpha, either alone or in combination with ribavirin.

Alnylam Pharmaceuticals (ALNY) Strengthens Intellectual Property Estate through Acquisition of Nucleonics Inc. Patent Assets

CAMBRIDGE, Mass — 8-Dec-2008

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, announced today that it has acquired the intellectual property (IP) assets of Nucleonics, Inc., a privately held biotechnology company. The Nucleonics IP estate includes over 100 active patent filings, including 16 that have granted worldwide and 6 that have been granted in the U.S., Europe, or Japan – the world’s largest pharmaceutical markets.

Gilead accuses Teva of patent infringement

Foster City-based Gilead — 12-Dec-2008

Foster City-based Gilead (NASDAQ:GILD) said the suit, filed in U.S. District Court in New York, centers on patents associated with emtricitabine, a component of Truvada and licensed exclusively to Gilead by Emory University.

Sanofi-Aventis (France) (SASY.PA) And Bristol-Myers Squibb Company (BMY) Prevail Before the U.S. Court of Appeals for the Federal Circuit in the U.S Plavix(R) Patent Infringement Case

PARIS & NEW YORK — 14-Dec-2008

Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb (New York: NYSE: BMY) announced today that the U.S. Court of Appeals for the Federal Circuit has upheld the June 19, 2007 decision by the U.S. District Court for the Southern District of New York holding the U.S. patent 4,847,265 covering clopidogrel bisulphate, the active ingredient in Plavix®, valid and enforceable. As a result of this ruling, the ‘265 patent protection for this product is maintained in the United States until November 2011.

Gilead Sciences Files Patent Infringement Lawsuit Against Teva Pharmaceuticals

FOSTER CITY, Calif — 15-Dec-2008

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has filed a lawsuit in U.S. District Court in New York against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. for infringement of U.S. Patent Numbers 6,642,245 and 6,703,396. Both patents are associated with emtricitabine, a component of Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), and are licensed exclusively to Gilead Sciences by Emory University. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Transcept: Intermezzo accepted for review by the FDA

By Charlotte Dumezy — 18-Dec-2008

Transcept\'s insomnia drug, Intermezzo, has been accepted for review by the FDA. This sublingual reformulation of zolpidem, designed for the treatment of middle-of-the-night awakenings, provides a fast onset of action and maintains sleep for only four hours. It is not clear that Intermezzo fulfils a significant unmet need and Datamonitor believes the market for such a treatment will be limited.

FDA approves Gleevec (imatinib mesylate) to prevent gastrointestinal stromal tumor

Pharmaceutical News — 21-Dec-2008

The U.S. Food and Drug Administration has approved Gleevec (imatinib mesylate) for a new indication - keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor or GIST.

Pressure BioSciences, Inc. And Battelle Memorial Institute Sign Exclusive Patent License Agreement

Pressure BioSciences, Inc. — 22-Dec-2008

Pressure BioSciences, Inc. (\"PBI\" or the \"Company\") today announced that they have entered into an exclusive patent license agreement with the Battelle Memorial Institute (\"Battelle\"). The licensed technology is described in the patent application filed by Battelle on July 31, 2008 (US serial number 12/183,219). This application includes subject matter related to a method and a system for improving the analysis of protein samples, including through an automated, in-line system utilizing pressure and a pre-selected agent to obtain a digested sample in a significantly shorter period of time than current methods, while maintaining the integrity of the sample throughout the preparatory process.

AstraZeneca and MAP Pharmaceuticals announce collaboration on Unit Dose Budesonide

Pharmaceutical News — 22-Dec-2008

AstraZeneca and MAP Pharmaceuticals, Inc. have announced an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB), MAP Pharmaceuticals\' proprietary nebulized formulation of budesonide.

AstraZeneca submits sNDA for NEXIUM (esomeprazole magnesium)

Pharmaceutical News — 22-Dec-2008

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) (esomeprazole magnesium) to seek approval for the short-term (up to 6 weeks) treatment of gastroesophageal reflux disease (GERD) in pediatric patients ages 0 to 1 year old.

Glenmark may beat rivals in novel chemical entity sale

P B Jayakumar / Mumbai — 23-Dec-2008

Glenmark Pharmaceuticals, India’s 11th biggest drug maker by sales, may beat bigger rivals, including Ranbaxy, Dr Reddy’s and Nicholas Piramal, in selling an original drug, or novel chemical entity (NCE), by 2010.

AVI BioPharma Strengthens Its Patent Position in RNA Therapeutics

PORTLAND, OR - AVI BioPharma Inc. — 23-Dec-2008

PORTLAND, OR - AVI BioPharma Inc. (AVII), a developer of RNA–based drugs, announced the issuance of a US patent protecting the composition of matter of its RNA–based therapeutic agent AVI–5126.

Sun Pharmaceutical extends tender offer for Taro

By Staff Writer — 23-Dec-2008

India-based Sun Pharmaceutical Industries has announced that its subsidiary Alkaloida Chemical Company Exclusive Group has extended the expiration date of the tender offer for the purchase of all outstanding ordinary shares of US-based Taro Pharmaceutical Industries.

Bill to amend Apeda Act in LS

New Delhi — 23-Dec-2008

A Bill seeking to amend the Agricultural and Processed Food Products Export Development Authority (Apeda) Act 1985 to empower the Authority to undertake steps for registration and protection of intellectual property rights in respect of specified agricultural and processed food products, including basmati rice, was introduced in the Lok Sabha on Monday.

Aurobindo Pharma gets Canada nod for Terbinafine

Reuters,Mumbai — 24-Dec-2008

Drug maker Aurobindo Pharma said on Wednesday it received the Canadian regulatory approval to sell terbinafine hydrochloride tablets in multiple strengths.

Warner Chilcott Files Lawsuits for Infringement of DORYX Patent

ST. DAVID\'S, BERMUDA — 24-Dec-2008

Warner Chilcott Limited (WCRX) announced in a press release that one of its subsidiaries and Mayne Pharma International Pty. Ltd. (\"Mayne\"), a subsidiary of Hospira, Inc., have filed lawsuits against each of Mutual Pharmaceutical Company Inc. (Mutual), Mylan Pharmaceuticals Inc. (Mylan) and Impax Laboratories Inc. (Impax).

Teva wins approval for generic Seroquel tablets

By Staff Writer — 24-Dec-2008

Teva Pharmaceutical Industries has announced that the FDA has granted tentative approval for the company\'s abbreviated new drug application to market its generic version of AstraZeneca\'s antipsychotic agent Seroquel tablets, equivalent to 25mg base, 50mg base, 100mg base, 150mg base, 200mg base, 300mg base and 400mg base.

Bill to change Apeda Act to protect trade mark interests

G. Srinivasan, New Delhi — 25-Dec-2008

Indias case for safeguarding its specified agricultural and processed food products such as basmati rice, Darjeeling tea or Alfonso mango which have been increasingly challenged by other countries would get a real booster dose once the Agricultural and Processed Food Products Export Development Authority (Amendment) Bill introduced in the just-ended Parliament session gets into the statute

Bristol-Myers to pay $1.1 million as settlement charges in Plavix case

By Staff Writer — 26-Dec-2008

Bristol-Myers Squibb has agreed to pay $1.1 million as part of settlement charges in the Plavix case, which was being investigated by the New York State Attorney General\'s Office, reported Reuters

Dr Reddy\'s resolves patent litigation with Schering and Sepracor

Datamonitor staff writer — 28-Dec-2008

Dr Reddy\'s Laboratories has entered into agreements with Schering and Sepracor which is expected to allow Dr Reddy\'s to manufacture and market generic versions of the Clarinex-D 12 hour and Clarinex-D 24 hour products, with six months marketing exclusivity, and the Clarinex Reditabs product, with six months marketing co-exclusivity, starting in 2012.

US’ Alcon wins case against Ajanta Pharma

Paramita Chatterjee & Khomba Singh, ET Bureau — 29-Dec-2008

US’ Alcon wins case against Ajanta Pharma 29 Dec 2008, 0022 hrs IST, Paramita Chatterjee & Khomba Singh, ET Bureau Print EMail Discuss Share Save Comment Text: NEW DELHI: US-based drugmaker Alcon has won a trademark case against its Indian counterpart Ajanta Pharma preventing the latter from selling its popular eyedrop under the brand ‘Travaxo’ here. The Bombay High Court (HC) granted an injunction in favour of Alcon, restricting Ajanta Pharma from using its product Travaxo on grounds of trademark infringement. The medicine directly competes with Alcon’s Travatan in the highly competitive Rs 33,000-crore drug retail market.

Cree Settles Patent Litigation with Bridgelux

DURHAM, NC — 30-Dec-2008

Cree Inc. announced in a press release that the company and Boston University have agreed with Bridgelux Inc. to settle the parties’ patent infringement litigation and to dismiss all claims and counterclaims in the suits.

Apeda moves Sindh HC against basmati trademark

Chennai — 30-Dec-2008

The Agricultural and Processed Food Products’ Export Development Authority (Apeda) has moved the Sindh High Court in Pakistan against the trademark right given by the Registrar of Trademark, Karachi, to Basmati Growers’ Association, Lahore, for basmati rice. The registrar, in fact, has allowed only the growers to use the trademark. The case is slated to come up for hearing in January.

Aurobindo Pharma gets US nod for Stavudine

Reuters,Mumbai — 31-Dec-2008

Drug firm Aurobindo Pharma said on Wednesday it received the final nod from the US Food and Drug Administration for its stavudine tablets and oral solution.

Bayer sues Abbott, alleging patent infringement

By LINDA A. JOHNSON — 31-Dec-2008

Pharmaceutical and chemical maker Bayer AG has filed a federal lawsuit alleging that drugmaker Abbott Laboratories\' best-selling drug, Humira, infringes on a decade-old Bayer patent.

Novartis Girds for the Day Blockbuster Loses Patent

LONDON — 31-Dec-2008

Sales of Novartis\'s blockbuster drug, Diovan, are expected to tumble when the high-blood-pressure pill\'s patent expires in four years

Akorn-Strides, LLC Announces FDA Approvals for Sterile Vancomycin HCl USP, 500 mg/Vial; 1 g/Vial and Sterile Vancomycin HCl USP, 5 g/Vial Pharmacy Bulk Package

LAKE FOREST, Ill.(BUSINESS WIRE) — 31-Dec-2008

Akorn-Strides, LLC today announced that the U.S. Food and Drug Administration has granted approvals for two Abbreviated New Drug Applications (ANDAs) for Sterile Vancomycin HCl USP, 500 mg/vial, 1 g/vial and Sterile Vancomycin HCl USP, 5 g/vial Pharmacy Bulk Package. Akorn-Strides, LLC is a Joint Venture that was formed in 2004 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE: STAR) (BSE: 532531). The primary mission for the Joint Venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and CNS medicines.

IMPAX Sued Based on ANDA for Generic Doryx®

HAYWARD, Calif.(BUSINESS WIRE) — 01-Jan-2009

IMPAX Laboratories, Inc. today announced that Warner Chilcott Laboratories Ireland Limited, Warner Chilcott Company, Inc., Warner Chilcott (US) LLC, and Mayne Pharma International PTY. LTD have filed suit for patent infringement in the United States District Court for the District of New Jersey based on the Company’s submission of Abbreviated New Drug Application (“ANDA”) for doxycycline hyclate delayed-release tablets (75 and 100 mg), generic of Doryx®, to the Food and Drug Administration. In connection with this ANDA, IMPAX provided notice that its submission includes a Paragraph IV certification stating the Company believes its product does not infringe U.S. Patent No. 6,958,161, or the patent is invalid or unenforceable.

Cipla pips Ranbaxy in domestic market

P B Jayakumar — 2-Jan-2009

Veteran industrialist Y K Hamied-led Cipla has edged out Daiichi-Sankyo-owned Ranbaxy Laboratories as the largest player in the domestic pharmaceutical market in the January-November period, according to data compiled by ORG-IMS..

Ranbaxy misses deadline for migraine drug launch

Khomba Singh, ET Bureau — 2-Jan-2009

NEW DELHI: India\'s largest drugmaker, Ranbaxy Laboratories, has missed its December 2008 deadline to launch an anti-migraine drug as the US regulator has yet to give its approval. Ranbaxy was expecting to earn almost $100 mn from the drug, a low-cost version of GlaxoSmithKine-owned Imitrex.

Labopharm wins FDA approval for pain drug

By Staff Writer — 02-Jan-2009

Labopharm, a Canadian specialty pharmaceutical company, has announced that the FDA has approved Ryzolt, the company\'s once-daily formulation of the analgesic tramadol.

FDA extends review of King Pharmaceuticals\'s Embeda extended release capsules

By Staff Writer — 2-Jan-2009

King Pharmaceuticals has announced that the FDA is continuing its review of the company\'s new drug application for Embeda extended release capsules. It is likely that this review will extend into early 2009.

FDA extends review of King Pharmaceuticals

By Staff Writer — 05-Jan-2009

Imitrex delay: Ranbaxy\'s loss may be Dr Reddy\'s gain

Press Trust Of India / New Delhi — 5-Jan-2009

The delay in Ranbaxy Laboratories getting approval from the USFDA for launching the generic version of GlaxoSmithKline’s (GSK) migraine and headache drug Imitrex could turn out to be a gain for Dr Reddy’s Laboratories, which has already launched the drug in the United States.

Acura and King Pharmaceuticals file NDA for pain drug

By Staff Writer — 05-Jan-2009

Acura Pharmaceuticals and King Pharmaceuticals have submitted a new drug application for Acurox tablets to the FDA including a request for priority review.

Orexigen Therapeutics Issued a Key Fourth US Patent

SAN DIEGO — 05-Jan-2009

Orexigen Therapeutics Inc. announced in a Monday press release that the United States Patent and Trademark Office (USPTO) has issued a patent for what the company refers to as the \"Weber/Cowley methods patent\" (US Patent No. 7,462,626), which provides coverage for Contrave, the company\'s lead obesity product candidate now in Phase 3 clinical trials.

Alexion and PDL BioPharma Resolve Patent Dispute

NCLINE VILLAGE, NEV., and CHESHIRE, CONN — 05-Jan-2009

PDL BioPharma Inc. and Alexion Pharmaceuticals Inc. today jointly announced that the companies have entered into a definitive license agreement and settlement agreement that resolve the legal disputes between them relating to Alexion\'s humanized antibody, Soliris (eculizumab) and PDL\'s patents known as the Queen et al. patents.

Pronova BioPharma ASA Files a Terminal Disclaimer

LYSAKER, NORWAY — 06-Jan-2009

Pronova BioPharma ASA announced in a Tuesday press release that it has filed a Terminal Disclaimer in US Patent No. 5,656,667 (\'667 Patent) with the US Patent and Trademark Office.

Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment

Warner Chilcott Limited — 06-Jan-2009

Warner Chilcott Limited today announced that it has signed an agreement with Dong-A PharmTech Co. Ltd., based in Korea, to develop and market their orally-administered udenafil product, a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED) in the United States. Dong-A has successfully completed Phase 2 studies of the product in the United States.

Pfizer Wins New Lipitor Patent Expiring in June 2011

Susan Decker — 6-Jan-2009

Pfizer Inc. won new protection on the cholesterol pill Lipitor, the world's best-selling drug, after the U.S. agreed to reissue a patent on the drug's key ingredient that had been invalidated by an appeals court. The U.S. Patent and Trademark Office today said it would reissue a patent that expires in June 2011 after the company altered what an appeals court had called inconsistent language that made the patent invalid.

Sun Pharmaceutical receives FDA approvals for 4 generics

Pharmaceutical News — 7-Jan-2009

Pharmaceutical Industries Ltd. announced that together with its subsidiaries, it has received final approval from U.S. FDA for several Abbreviated New Drug Applications (ANDA).

Marshall Edwards wins IND approval for cancer drug

By Staff Writer — 8-Jan-2009

Marshall Edwards, an oncology company, has received an investigative new drug approval from the FDA to undertake clinical studies with triphendiol as a chemosensitizing agent in combination with gemcitabine.

Adhezion wins FDA clearance for SurgiSeal topical skin adhesive

By Staff Writer — 8-Jan-2009

Adhezion Biomedical, a medical device company, has announced that the FDA has provided marketing clearance for its SurgiSeal topical skin adhesive.

Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication

SOUTH SAN FRANCISCO — 9-Jan-2009

Anesiva, Inc. (Nasdaq: ANSV) today announced that the U.S. Food and Drug Administration (FDA) has approved Anesiva\'s supplemental New Drug Application (sNDA) to expand the indication for Zingo(TM) to treat the pain associated with blood draws to include adults. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system was previously approved to treat the pain associated with peripheral IV insertions and blood draws in children three to 18 years of age. The notification was received according to PDUFA deadlines.

Silence Therapeutics Granted New Patent

LONDON — 10-Jan-2009

Silence Therapeutics plc, the leading European biopharmaceutical company focused on RNA interference, announced that the European Patent Office (EPO) has granted a patent to Silence that covers the company‘s lead product candidate, Atu027, a press release by the company stated.

Genta Announces Issuance of Two Key US Patents

BERKELEY HEIGHTS, NJ — 10-Jan-2009

Genta Incorporated announced in a press release that two new patents related to the company\'s franchise in gallium-containing products have issued in the United States.

Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin® 24 and Femcon® Fe Patent Litigation

Watson Pharmaceuticals, Inc.; Warner Chilcott Limited — 12-Jan-2009

Watson Pharmaceuticals, Inc. and Warner Chilcott Limited announced today that they have entered into Settlement and License Agreements to resolve pending patent litigation related to Warner Chilcott\'s oral contraceptive products, Loestrin® 24 and Femcon® Fe. Separately, Warner Chilcott and Watson have entered into a Co-Promotion Agreement relating to Warner Chilcott\'s Femring® product and License and Supply Agreements relating to a Warner Chilcott development-stage oral contraceptive product.

VIVUS Announces Issuance of Key European Patent for Qnexa

MOUNTAIN VIEW, CA — 13-Jan-2009

VIVUS Inc.announced in a Tuesday press release that the European Patent Office has granted a patent for Qnexa, an investigational, oral weight loss product for the treatment of obesity and related conditions.

Dey L.P. Granted Three Additional US Patents

PITTSBURGH — 13-Jan-2009

Mylan Inc. announced in a Tuesday press release that its subsidiary Dey L.P. has been issued several additional US patents protecting the company\'s Perforomist Inhalation Solution, a chronic obstructive pulmonary disease (COPD) treatment.

Bavarian Nordic\'s patent infringement suit against Oxford BioMedica

Medical Patent News — 13-Jan-2009

Bavarian Nordic owns several United States patents relating to an attenuated strain of the company\'s core technology, MVA-BN(R), which is the basis for its smallpox vaccine, IMVAMUNE(R).

Oncolytics Biotech issued new U.S. patent \"Reovirus for the Treatment of Neoplasia\"

Medical Patent News — 14-Jan-2009

Oncolytics Biotech Inc. has announced that it has been granted its 31st U.S. Patent, # 7,476,382, entitled \"Reovirus for the Treatment of Neoplasia.\"

Vical Announces Issuance of New US Patent

SAN DIEGO — 14-Jan-2009

Vical Incorporated announced in a Wednesday press release the issuance of US Patent No. 7,470,675 covering the composition, delivery and use of gene-based interferon-omega.

China Pharma wins approval for Tiopronin enteric-coated capsules

By Staff Writer — 14-Jan-2009

China Pharma Holdings, a developer, manufacturer and marketer of specialty pharmaceuticals, has received approval from China\'s State Food and Drug Administration for the production of Tiopronin enteric-coated capsules. Tiopronin is listed in the National Medical Insurance Program, thus allowing patients to obtain reimbursement.

Eli Lilly Said to Be Near $1.4 Billion U.S. Settlement

By GARDINER HARRIS and ALEX BERENSON — 14-Jan-2009

Eli Lilly, the drug company, is expected to agree as soon as Thursday to pay $1.4 billion to settle criminal and civil charges that it illegally marketed its blockbuster antipsychotic drug Zyprexa for unauthorized use in patients particularly vulnerable to its risky side effects.

Not a patent process

New Delhi — 15-Jan-2009

Our patent regime is yet to gain full credibility although the patent law conforms to global norms

Dr Reddy’s consignment of drugs to Brazil seized

Radhieka Pandeya — 15-Jan-2009

This is the first time a shipment of a large Indian company has been held on charges of patent infringement

Oscient files patent lawsuit against another drug firm

Boston Globe Business Team — 15-Jan-2009

Oscient Pharmaceuticals Corp. of Waltham said it has filed a patent infringement lawsuit against Lupin Pharmaceuticals Inc., which is seeking to market a generic version of one of Oscient\'s drugs.

India to drag EU to WTO over the issue of patents

PTI — 16-Jan-2009

NEW DELHI: The tussle between Indian generic drug industry and western innovative pharmaceutical firms is set to get stronger as India is considering dragging the European Union to WTO on the issue.

No antidote to stop copies of patented drugs: Health min

Khomba Singh & Sushmi Dey — 17-Jan-2009

NEW DELHI: The health ministry has said it is not equipped with technical expertise to stop domestic pharmaceutical companies from copying patented drugs.

Drug cos concerned over definition of counterfeits

P.T. Jyothi Datta,Mumbai — 18-Jan-2009

The seizure of a transiting export consignment belonging to Dr Reddy’s Laboratories by customs authorities in Netherlands, barely two months after another local drug-maker Ind-Swift faced a similar situation, has the domestic pharmaceutical industry concerned about what they say are efforts to block the movement of generic drugs.

\'Uniform patent policy needed for cheaper drugs\'

AHMEDABAD — 18-Jan-2009

Chief justice of Gujarat High Court, KS Radhakrishnan has called for a uniform patenting policy in order to curtail price rise of life saving drugs.

Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent

HAMILTON, Bermuda — 19-Jan-2009

Warner Chilcott Limited announced today that one of its subsidiaries and Mayne Pharma International Pty. Ltd. (\"Mayne\"), a subsidiary of Hospira, Inc., have filed a lawsuit against Sandoz Inc. (\"Sandoz\") in the District Court for the District of New Jersey for infringement of Mayne\'s U.S. Patent No. 6,958,161 (the \"\'161 Patent\") which covers DORYX, a tetracycline-class oral antibiotic.

Oscient and Ethypharm file lawsuit against Lupin

Datamonitor staff writer — 19-Jan-2009

Oscient Pharmaceuticals, a commercial-stage pharmaceutical company, has announced that the company, its wholly owned subsidiary Guardian II Acquisition, and its licensor, Ethypharm, have filed a lawsuit against Lupin Limited and its subsidiary Lupin Pharmaceuticals in the US District Court of Maryland for the infringement of a US patent which covers Antara (fenofibrate) capsules.

CSL Behring\'s bleeding disorder drug RiaSTAP gets US FDA marketing nod

King of Prussia, Pennsylvania — 20-Jan-2009

US Food and Drug Administration (FDA) has granted marketing approval to CSL Behring for RiaSTAP, the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Alexza Pharmaceuticals (ALXA) Initiates AZ-104 Phase 2b Clinical Trial in Patients With Migraine Headaches

Corporate News — 20-Jan-2009

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has initiated a Phase 2b clinical trial with AZ-104 (Staccato loxapine) in patients with migraine headaches.

Corgenix Receives Two Additional Patents on AtherOx® Technology

Corgenix Medical Corporation — 20-Jan-2009

Corgenix Medical Corporation , a worldwide developer and marketer of diagnostic test kits, has received notification of two new patents for technology to which Corgenix holds exclusive worldwide licensing rights outside of Japan.

Geneart wins new European patent

By Staff Writer — 20-Jan-2009

Geneart, a provider of DNA engineering and processing solutions, has received a new patent for selective evolution of proteins from the European Patent Office.

Dr Reddy\'s Labs back in the black

BS Reporter / Mumbai — 21-Jan-2009

Dr Reddy’s Laboratories, India’s biggest drug maker by sales, said it turned to profit in the third-quarter, helped by higher sales of an authorised generic drug in the US, even as it set aside money for foreign exchange losses.

King Pharma Has A Patent Problem

Lisa LaMotta — 21-Jan-2009

King Pharmaceuticals was looking a little less than regal Wednesday when a court invalidated two patents for its best-selling drug.

GeoPharma Announces Settlement of Clarinex ANDA Patent Litigation

LARGO, FLA — 21-Jan-2009

GeoPharma, Inc. announced in a Wednesday press release that it has reached agreement with the Schering Corporation, and Sepracor Inc. and the University of Massachusetts settling all Hatch-Waxman litigation relating to Desloratadine tablets (5 mg), with the Company receiving a license under all relevant patents.

HC allows CPAA to join Bayer-Cipla case

Khomba Singh & Sushmi Dey — 21-Jan-2009

NEW DELHI: The Delhi High Court (HC) has allowed cancer patient group Cancer Patients Aid Association (CPAA) to join the Bayer AG and Cipla case. The German drugmaker Bayer AG had sued the Indian government, its drug regulator and domestic drug company Cipla for giving marketing approval to Cipla for Bayer\'s patented cancer drug Nexavar.

Silence Therapeutics announces favorable ruling in European patent lawsuit

By Staff Writer — 21-Jan-2009

Silence Therapeutics, a UK-based RNAi-focused biotechnology company, has announced that a second member of the Kreutzer-Limmer patent family has been revoked in its entirety.

Drugs regulator issues warning letters to Wyeth pharma, GVK

Radhieka Pandeya — 22-Jan-2009

Office of the drugs controller general of India issued warning letters asking for explanations, based on the audit findings

GSK wins European approval for weight loss drug

By Staff Writer — 22-Jan-2009

GlaxoSmithKline has received a non-prescription license for alli, a drug indicated for weight loss in adults, with a BMI 28kg/m2 or more, when used along with a reduced calorie, lower-fat diet.

Alnylam Provides Update on Kreutzer-Limmer Patent Family

CAMBRIDGE, MASS — 22-Jan-2009

Alnylam Pharmaceuticals Inc., a leading RNAi therapeutics company, announced in a press release that the European Patent Office (EPO) has ruled in favor of the opposing parties in oral proceedings before the European Opposition Board related to the \'945 (EP 1214945) patent in its Kreutzer-Limmer patent estate.

Ranbaxy losses mount on forex hit

BS Reporter / New Delhi — 23-Jan-2009

Ranbaxy Laboratories, India’s biggest drug maker, posted a loss for the second straight quarter on adverse foreign exchange fluctuations.

Lilly, Bristol withdraw FDA Erbitux lung cancer application

By Wallace Witkowski — 23-Jan-2009

SAN FRANCISCO (MarketWatch) -- ImClone Systems, which was recently acquired by Eli Lilly & Co.and Bristol-Myers Squibb Co. said Friday they decided to withdraw a Food and Drug Administration application to market cancer drug Erbitux for a type of advanced lung cancer.

GSK wins European positive opinion for pneumococcal vaccine

By Staff Writer — 23-Jan-2009

GlaxoSmithKline has announced that the European Medicines Agency\'s Committee for Medicinal Products for Human Use has issued a positive opinion and recommended the approval of GSK\'s pediatric pneumococcal candidate vaccine Synflorix.

GeoPharma settles patent litigation with Schering and Sepracor

Datamonitor staff writer — 23-Jan-2009

GeoPharma has reached an agreement with Schering, Sepracor and the University of Massachusetts settling all Hatch-Waxman litigation relating to desloratadine tablets 5mg, with the company receiving a license under all relevant patents.

A Pfizer-Wyeth Merger Isn\'t the Cure-All

By Catherine Arnst — 24-Jan-2009

Buying Wyeth would boost Pfizer\'s revenues, but it won\'t help with the litany of marketing challenges and other problems plaguing Big Pharma

Pfizer, Wyeth close to deal: reports

AP / PTI / New York — 26-Jan-2009

Drugmakers Pfizer and Wyeth are closing in on a deal worth $68 billion that could be announced before the markets open today, according to published reports.

Stromedix awarded U.S. patent for antibody-based therapeutics

Medical Patent News — 26-Jan-2009

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, has announced that the U.S. Patent Office has granted patent number US 7,465,449, which broadly covers monoclonal antibodies to integrin ávβ6, including compositions related to its lead product, STX-100.

\'Ranbaxy\'s investments in Indian drug cos yet to pay off\'

Khomba Singh — 27-Jan-2009

NEW DELHI: Ranbaxy Laboratories\' strategic investments in Indian drug companies have so far not delivered desired results, feel industry analysts.

Indian arms of Pfizer, Wyeth to merge soon

BS Reporter / New Delhi — 27-Jan-2009

The decision of Pfizer to acquire rival drugmaker Wyeth in a $68-billion cash-and-stock deal will also see merger of the listed Indian subsidiaries of both US multinationals soon.

WHO won\'t redefine fake drugs

Sushmi Dey & Khomba Singh — 27-Jan-2009

NEW DELHI: In a major victory for India\'s cheap but high quality generic drug industry, the World Health Organisation (WHO) has decided to shelve its plans of redefining counterfeit medicines-a move that could have posed a threat to sale and export of legitimate generic medicines, a government official said.

Pfizer-Wyeth may climb to No 2 spot

P B Jayakumar / Mumbai — 28-Jan-2009

The merger of Pfizer and Wyeth is expected to create the second-biggest drug maker among multinational companies in India. The world\'s largest drug maker Pfizer yesterday announced a $68-billion acquisition of US-based Wyeth.

Jannssen-Cilag\'s Stelara approved in EU for psoriasis

Katie McQue- Reporter — 28-Jan-2009

The European Commission has approved Janssen-Cilag\'s (Johnson & Johnson) novel human monoclonal antibody drug Stelara (ustekinumab) for the treatment of moderate-to-severe plaque psoriasis in adults who have failed to respond to, are intolerant to, or have a contraindication to other systemic therapies including ciclosporin, methotrexate and psoralen plus ultraviolet light (PUVA).

Drug prices increased

Our Bureau ,New Delhi — 28-Jan-2009

Drug price regulator National Pharmaceutical Pricing Authority (NPPA) has revised the price of 174 formulation packs and three bulk drugs. Prices of most of the drugs have been revised upward.

Mylan receives final FDA approvals for generic Lamictal tablets

Pharmaceutical News — 29-Jan-2009

Mylan Inc has announced that its subsidiaries Mylan Pharmaceuticals Inc. and Genpharm ULC received final approvals from the U.S. Food and Drug Administration (FDA) for their Abbreviated New Drug Applications (ANDAs) for Lamotrigine Tablets.

Medarex announces allowance of IND application for antibody-drug conjugate, MDX-1203

Pharmaceutical News — 29-Jan-2009

Medarex, Inc. has announced the allowance of an investigational new drug (IND) application filed with the U.S. Food & Drug Administration (FDA) for MDX-1203, the Company\'s first Antibody-Drug Conjugate (ADC) candidate generated from its proprietary technology.

Cadila to strengthen US reach with fresh approvals

BS Reporter / Mumbai/ Ahmedabad — 30-Jan-2009

Ahmedabad based pharma major Zydus Cadila has got a shot in the arm as it has received three product approvals from the United States Food and Drug Administration (USFDA) in quick succession.

Merck eyes Indian drug biggie, brands

P B Jayakumar / Mumbai — 30-Jan-2009

Germany-based Merck KGaA, the world’s oldest multinational pharmaceutical company, is eyeing to acquire a prominent Indian pharmaceutical company and established drug brands.

Pfizer\'s acquisition of Wyeth brings scale but will fail to deliver sustainable sales growth

By Datamonitor staff writer — 30-Jan-2009

The Pfizer-Wyeth merger will create a prescription pharmaceutical company of unprecedented scale. The combined entity would have recorded total company sales in excess of $70 billion and prescription pharmaceutical sales of over $60 billion in 2008.

Patents grant for mere change under scanner

C.H. Unnikrishnan — 30-Jan-2009

Mumbai: The Mumbai patent office has initiated an inquiry into alleged violations in granting patents for modified forms of existing drugs, even as newly available documents related to these present evidence of negligence.

Seattle Genetics\'s lymphoma drug wins orphan designation

By Datamonitor staff writer — 30-Jan-2009

Seattle Genetics, a clinical stage biotechnology company, has announced that its antibody-drug conjugate SGN-35 has received the orphan drug designation from the European Medicines Agency for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma, or ALCL, and from the FDA for the treatment of ALCL.

Pfizer pancreatic cancer drug fails, trial halted

NEW YORK — 30-Jan-2009

Pfizer Inc (PFE.N), in its latest research setback, said on Friday it stopped a late stage study of an experimental drug to treat advanced pancreatic cancer after an independent monitoring board found no evidence that it prolongs survival.

Warner Chilcott files patent suit against Actavis

Hamilton, Bermuda — 30-Jan-2009

Warner Chilcott Limited announced today that one of its subsidiaries and Mayne Pharma International Pty. Ltd. (\"Mayne\") have filed a lawsuit against Actavis Elizabeth LLC (\"Actavis\") in the District Court for the District of New Jersey for infringement of Mayne\'s U.S. Patent No. 6,958,161 (the \"\'161 Patent\") which covers DORYX, a tetracycline-class oral antibiotic.

Shah Rukh in legal soup over copyright

Vignesh Iyer, Mumbai — 31-Jan-2009

A petition has been filed against Shah Rukh Khans Red Chillies Private Ltd, TV channel NDTV Imagine and Sunanda Oberai by Neha Joshi for making a serial Ghar Ki Baat, based on the script written by her father, Sharad, for a comedy serial called Yeh Jo Hai Zindagi, without obtaining any prior permission and violating the Copyright Act

India to move WTO on Dutch drug seizure

New Delhi — 31-Jan-2009

India and Brazil have decided to mount a joint offensive at the World Trade Organisation against the Netherlands for seizing a consignment in transit, which was on its way from India to Brazil.

FTC challenges Par Solvay patent settlement

Vidya L Nathan, Bangalore — 2-Feb-2009

Par Pharmaceutical Cos Inc said federal and state regulators filed an antitrust lawsuit against it related to its patent settlement over Belgian drugmaker Solvay\'s testosterone gel, AndroGel.

New Trademarks Act in Force in Dominica

ROSEAU — 3-Feb-2009

The final deadline by which granted UK marks can be registered in Dominica will expire on February 1, 2010 - one year from the date of entry into force of the new legislation.

US lawmakers propose bill to stop generic drug patent deals

Diane Bartz, Washington — 3-Feb-2009

Two senior senators have introduced a bill that would make it illegal for pharmaceutical companies to pay generic drugmakers to keep lower priced alternatives off the market.

Intellectual property rights issues stall Bhel-NTPC project

Utpal Bhaskar — 04-Feb-2009

New Delhi: An alleged dispute over intellectual property rights has stalled a joint initiative between Bharat Heavy Electricals Ltd (Bhel) and NTPC Ltd to build less-polluting power generation plants.

India, Brazil slam Dutch govt for seizing drugs

D Ravi Kanth — 04-Feb-2009

India and Brazil today strongly denounced the Netherlands Customs authorities at the World Trade Organization for seizing several consignments of generic medicines from the two countries.

The IAS grabs the patent office too

Latha Jishnu — 04-Feb-2009

India’s patents office, or the Office of the Controller General of Patents, Designs and Trademarks to give its full title, was one of those dreary government departments, badly-equipped and poorly-staffed, its decrepit state of little interest to officialdom — or to the media — till January 1, 2005.

Cipla export consignment too seized at Amsterdam

P.T. Jyothi Datta — 04-Feb-2009

It is not just drug makers Ind-Swift and Dr Reddy’s Laboratories’ export consignments that were confiscated by Customs authorities in Amsterdam in the last three-odd months on the grounds of patent infringement.

EpiCept receives permission to file leukemia drug NDA

By Datamonitor staff writer — 04-Feb-2009

EpiCept a specialty pharmaceutical company has announced that the FDA indicated that the company has the necessary pivotal data to file a new drug application for Ceplene in conjunction with interleukin-2 as a remission maintenance treatment of acute myeloid leukemia.

Antarctic patents strain goals of shared science

Alister Doyle, Environment Correspondent, Rothera Base, Antarctica — 05-Feb-2009

An increasing number of companies developing new products through biological discovery or \"bioprospecting\" are trying to file patents on Antarctic organisms or molecules for items from cosmetics to medicines, putting new strains on the treaty.

Wockhardt launches Sanofis Lantus generic in India

REUTERS — 10-Feb-2009

Drugmaker Wockhardt Ltd said on Tuesday it has launched a new insulin Glaritus in India for the treatment of diabetes.

Geneart wins European patent for new screening system

By Datamonitor staff writer — 10-Feb-2009

Geneart a provider for DNA engineering and processing services has received a patent from European patent office for a new screening system based on synthesized virus like reporter genes with which a new class of antiviral drug candidates may be identified.

Wockhardt launches Sanofis Lantus generic in India

REUTERS — 10-Feb-2009

Drugmaker Wockhardt Ltd said on Tuesday it has launched a new insulin Glaritus in India for the treatment of diabetes.

Ranbaxy gets USFDA approval for migraine drug

Khomba Singh — 10-Feb-2009

The company had earlier missed its December 2008 launch date as it did not get approval from the US drug regulator.

OSI Pharmaceuticals Announces Notification of ANDA Filing for Tarceva

MELVILLE, NY — 11-Feb-2009

OSI Pharmaceuticals Inc announced the receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals USA Inc submitted an Abbreviated New Drug Application to the US Food and Drug Administration requesting permission to manufacture and market a generic version of Tarceva.

Global drug majors slow R&D offshoring to India

P B Jayakumar — 12-Feb-2009

New drug discovery and contract research have taken a back seat as global drug majors have slowed down their research and development offshoring to India.

Dr Reddys Losing the edge

Shobhana Subramanian & Varun Sharma — 12-Feb-2009

The upside from generic Imitrex will be lower with Ranbaxy also selling the 100mg dosage in the US market.

Teijin Pharma and Takeda Announces ULORIC Received FDA Approval for the Chronic Management of Hyperuricemia in Patients with Gout

TOKYO & OSAKA, Japan — 13-Feb-2009

Teijin Pharma Limited and Takeda Pharmaceutical Company Limited announced today that on February 13 2009 Teijin Pharmas US licensee for febuxostat and Takedas wholly owned subsidiary Takeda Pharmaceuticals North America Inc received FDA marketing approval for ULORIC for the chronic management of hyperuricemia in patients with gout.

Cubist plans to file patent infringement lawsuit against Teva

By Datamonitor staff writer — 13-Feb-2009

Cubist Pharmaceuticals a biopharmaceutical company has said that it intends to file a patent infringement lawsuit against Teva Parenteral Medicines in response to the abbreviated new drug application filing that TPM had submitted to the FDA for approval to market a generic version of Cubicin.

Glaxo proposes patent pool for neglected diseases

By Lisa Richwine — 13-Feb-2009

GlaxoSmithKline Plcs chief executive urged creation of a voluntary patent pool to spark development of new treatments for neglected diseases in the worlds poorest countries.

GlaxoSmithKline vows cheap medicine for the poor

AFP,LONDON — 14-Feb-2009

The head of British drugs giant GlaxoSmithKline said in a British newspaper Saturday he would cut prices for medication in developing countries and share knowledge of patented treatments.

FDA nod key to drug cos US growth

P B Jayakumar / Mumbai — 16-Feb-2009

Ranbaxy Dr Reddys and other Indian drug makers which earn a third of their earnings from selling products in the US need higher drug approvals from the Food and Drug Administration of that country in the next financial year to maintain 20 per cent sales growth.

As valuations dip Sun Pharma is in M&A mode

Ruchita Saxena — 16-Feb-2009

With valuations in the Indian pharmaceutical sector correcting in the last few months Sun Pharmaceutical is aggressively looking for an acquisition.

Piramal Glaxo deal may trigger top level exits

Mahima Puri — 16-Feb-2009

Many top executives of Mumbai based generic drug maker Piramal Healthcare and the Indian arm of British pharma company GlaxoSmithKline Formula for successful business are exploring exit options following reports of a possible acquisition of the Indian firm according to head hunters.

New norms for MNC drug prices

Sushmi Dey — 16-Feb-2009

In a move that would prevent MNCs such as GlaxoSmithKline Eli Lilly Roche and Pfizer from selling their drugs at a huge premium in India the government may soon finalise norms for monitoring prices of costly imported patented medicines for diseases such as diabetes arthritis obesity cancer and heart diseases.

Alnylam wins new patent for RNAi therapeutics

By Datamonitor staff writer — 16-Feb-2009

Alnylam Pharmaceuticals an RNAi therapeutics company has announced the first grant for the Kay & McCaffrey patent an early fundamental patent in the RNAi therapeutics field.

Pirate Bay copyright test case begins in Sweden

Simon Johnson, Stockholm — 19-Feb-2009

A copyright test case involving one of the world\'s biggest free file-sharing websites that could help music and film companies recoup millions of dollars in lost revenues started on Monday in Stockholm.

Gilead Receives Response From US FDA on Companys Request for Formal Dispute Resolution for Aztreonam for Inhalation Solution

FOSTER CITY, Calif — 18-Feb-2009

Gilead Sciences Inc today announced that the company has received a response from the US Food and Drug Administrationto its appeal submitted under the formal Dispute Resolution process regarding the Agencys Complete Response Letter for its New Drug Application for aztreonam for inhalation solution.

Teva to seek US approval for Neupogen biosimilar

By Lewis Krauskopf — 18-Feb-2009

Teva Pharmaceutical Industries Ltd hopes to seek US approval for its version of Amgen Incs Neupogen this year company officials said on Wednesday as it seeks to establish leadership in the emerging field of generic biotech medicines.

To GSK with awe and some scepticism

Latha Jishnu / New Delhi — 18-Feb-2009

Pharmaceutical giant GlaxoSmithKline appears to have knocked almost everyone into a cocked hat with its announcement last week of slashing prices of drugs for the poorest countries and sharing part of the profits with these countries to beef up health facilities.

Most trials conducted under strict FDA European rules

C.H. Unnikrishnan — 19-Feb-2009

India has been a preferred destination for clinical trials ever since pharmaceutical outsourcing picked up at the start of the decade.

GSK Pharma scouts for domestic buys

P B Jayakumar / Mumbai — 19-Feb-2009

GlaxoSmithKline Pharmaceuticals the Indian arm of global drug major GlaxoSmithKline is scouting for acquisitions in the domestic market to consolidate its Indian business.

Vion files new drug application for leukemia drug

By Datamonitor staff writer — 19-Feb-2009

Onrigin injection a single agent for remission induction treatment for acute leukemia

Pharma industry may see more consolidation

C.H. Unnikrishnan & Nesil Staney — 19-Feb-2009

3 multinationals said to be looking to expand India businesses GlaxoSmithKline Sanofi Aventis Merck

Schering Takeda Unit Sue Teva Over Snake Drug Patent

By Phil Milford — 19-Feb-2009

Schering Corp and Takeda Pharmaceutical Cos Millennium unit accused Israels Teva Pharmaceutical Industries Ltd of infringing their US patent for Integrilin anti clotting agent made from rattlesnake venom.

Tweaking inputs no ground for raising drug prices NPPA

Sushmi Dey & Khomba Singh — 20-Feb-2009

The drug price regulator has ruled that pharma companies cannot unilaterally increase prices of medicines that are under price control by merely tweaking their composition.

Endo and Penwest Pharmaceuticals Settle Opana ER Litigation with Actavis South Atlantic LLC

Corporate News — 20-Feb-2009

Endo Pharmaceuticals and Penwest Pharmaceuticals have settled litigation with Actavis South Atlantic LLC regarding the production and sale of generic formulations of Opana ER Extended Release Tablets CII.

USV to sell generic version of cancer drug bicalutamide in US

P.T. Jyothi Datta — 20-Feb-2009

USV Ltd will be able to see its generic version of bicalutamide the active pharmaceutical ingredient in Astra Zenecas prostate cancer drug Casodex when the patent on this drug expires in the US in April.

Patent office to dispose of all pending cases by March end

PTI, New Delhi — 20-Feb-2009

Though the all India numbers of the pending cases were not disclosed but an official said that in Delhi alone there are roughly 154 cases

Pharma companies eye new markets to drive sales

Joe C Mathew / New Delhi — 21-Feb-2009

Indian pharmaceutical companies whose global revenues were affected by their exposure to foreign currencies and slump in the US sales have seen significant revenue growth in the newer or emerging markets across continents.

Aurobindo gets nod for HIV drug

Our Bureau — 21-Feb-2009

Aurobindo Pharma Ltd has received tentative approval for Tenofovir Disoproxil Fumarate tablets in 300 mg dosage from the US Food & Drug Administration.

Daiichi Sankyo to launch flu preventive drug

Nikkei,TOKYO — 22-Feb-2009

Japans Daiichi Sankyo Co plans to launch as early as 2011 a new influenza preventive drug that could be effective against a strain unresponsive to widely used Tamiflu of Roche the Nikkei business daily said.

Merck girds to battle Tevas generic Singulair

By Ransdell Pierson — 22-Feb-2009

Although many analysts expect the larger Merck to prevail in the trial at federal court in Trenton New Jersey a victory by Teva could allow the Israeli company to launch its generic well before Singulairs US patent lapses in August 2012.

Gen Next turns its back on small medium pharma companies

P B Jayakumar / Mumbai — 23-Feb-2009

India was import dependent on drugs till 1970 when Indira Gandhi the then prime minister decided to amend the Patent Act to legalise process patenting or copying of drugs innovated by multinationals.

Cordex files amended SPA for tachycardia drug to FDA

By Datamonitor staff writer — 23-Feb-2009

Cordex Pharma a developer of new cardiovascular medicines has submitted to the FDA an amended Phase III protocol for ATPace to be reviewed as a special protocol assessment.

LG Electronics asks for patent suit against Kodak

Diane Bartz, Washington — 23-Feb-2009

LG Electronics has asked a trade panel to investigate possible digital camera patent infringement by Eastman Kodak, the International Trade Commission announced.

Sun Taro chiefs meet for out of court settlement

BS Reporter / Mumbai — 24-Feb-2009

Sun Pharmaceutical Industries and Israel based Taro Pharmaceutical have started fresh rounds of negotiations to settle their differences over a takeover by the Indian company out of court.

Pharma cos may face penalties for overpricing

Sushmi Dey,NEW DELHI — 24-Feb-2009

Drugmakers such as Dr Reddys Laboratories Wyeth GlaxoSmithKline Pharmaceuticals and Alkem Laboratories may now have to face state officials for failing to pay up penalties for overpricing.

US companies get Cuba trademarks wait for change

Esteban Israel, Havana — 24-Feb-2009

As recently as December the Cuban Office of Intellectual Property registered trademarks for new products for Coca-Cola, Google and Ford Motor Co.

Genentech says US patent office upholds key patent

Bill Berkrot, New York — 24-Feb-2009

Genentech Inc said on Tuesday that the US Patent and Trademark Office has confirmed its claims of the validity of a key patent that governs the biotechnology company\'s method of producing some of its drugs.

Endo and Penwest settle litigation with Actavis

By Datamonitor staff writer — 25-Feb-2009

Endo and Penwest have agreed to dismiss their suit with prejudice and Actavis has agreed to dismiss its counterclaims with prejudice.

Cipla opposes GSKs patent on Tykerb in India

Anju Ghangurde — 25-Feb-2009

Cipla has filed a post grant opposition against GlaxoSmithKline s patent on the breast cancer drug Tykerb in India.

Will continue to cooperate with USFDA Ranbaxy

BS Reporter / Mumbai — 26-Feb-2009

Ranbaxy has just received a letter and information indicating that all pending and approved ANDAs from Ranbaxys Paonta Sahib facility have been added to a list maintained under a policy entitled Application Integrity Policy or AIP.

VIA Pharmaceuticals Announces Grant of New Patent

SAN FRANCISCO, CA — 26-Feb-2009

VIA Pharmaceuticals Inc announced the issuance of United States Patent No 7495024 entitled Phenylalkyl N Hydroxyureas for Combating Atherosclerotic Plaque covering the use of VIAs lead compound VIA 2291 for the treatment of atherosclerosis.

Genentech Receives Final Notification Upholding Cabilly Patent in Reexamination Proceeding

SOUTH SAN FRANCISCO, Calif.(BUSINESS WIRE) — 26-Feb-2009

Genentech Inc today announced that the US Patent and Trademark Office has issued a Notice of Intent to Issue a Reexamination Certificate confirming the patentability of all claims of the Cabilly et al patent US Patent No 6331415 of which claims 21 through 32 were amended in a manner that does not affect the commercial importance of the patent.

Ranbaxy to isolate Canada bound drugs from HP unit

Press Trust of India / Toronto — 27-Feb-2009

Indian pharmaceutical firm Ranbaxy has agreed to a Health Canada request to quarantine all drugs coming into the North American country from the Paonta Sahib manufacturing facility in Himachal Pradesh Canadian Press reported on Thursday quoting the company.

Pfizer close to deal with Nigeria in drug lawsuit

By Mike Oboh — 27-Feb-2009

Nigeria is close to a settlement in a multi billion dollar lawsuit against Pfizer Inc over a 1996 drug trial it says caused the death of 11 children and left dozens more disabled lawyers said on Friday.

Daiichi Ranbaxy form joint team to counter FDA charges

BS Reporters / New Delhi/mumbai — 27-Feb-2009

Daiichi Sankyo which owns Indias biggest drug maker said it had formed a team with Ranbaxy Laboratories to address the data falsification charges levied by the US Food and Drug Administrationeven as analysts foresaw more trouble for the drug maker.

Suit against Amgen for drug marketing unsealed

LOS ANGELES,Reuters — 27-Feb-2009

A whistle blower lawsuit accusing Amgen Inc of illegally marketing its blockbuster drugs Enbrel and Aranesp has been unsealed a company spokesman said on Friday.

USFDA action against Ranbaxy based on false drug stability data

Our Bureau — 27-Feb-2009

The action by the US Food and Drug Administration against Ranbaxy on Wednesday was triggered after it was found out that the company had given incorrect data to prove drugs are stable over a certain time period.

Obama calls for generic biotech drugs

By RICARDO ALONSO-ZALDIVAR, — 27-Feb-2009

President Barack Obamas budget aims to foster generic competition for costly biotech drugs used to treat cancer and other intractable ailments.

Kissei and Takeda win Japanese approval for diabetes treatment

By Datamonitor staff writer — 27-Feb-2009

Japan based Kissei Pharmaceutical and Takeda Pharmaceutical Company have announced that an additional indication of combination therapy with insulin sensitizer for Glufast 5mg tablet and 10mg tablet which is being co marketed by both the companies was approved by the regulatory authorities in Japan.

Pfizer generics chief eyes licensing injectables

By Lewis Krauskopf — 27-Feb-2009

Pfizer Inc is seeking licensing deals to help turn its burgeoning business focused on generic drugs into a growth engine for the worlds largest drug maker over the next several years.

Another jolt for Ranbaxy Labs

BS Reporter / Mumbai — 28-Feb-2009

Ranbaxy Laboratories which has been charged by the US Food and Drug Administration with falsifying data has agreed to a Canadian governments request to quarantine all drugs coming into Canada from its drug making facility in Himachal Pradesh.

AstraZeneca FDA approves Symbicort

Edited Press Release — 02-Mar-2009

AstraZeneca Monday announced that the US Food and Drug Administration has approved SYMBICORT 160 45 mcg for the twice daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease including chronic bronchitis and emphysema.

DoJ files suit against KV Pharma

BANGALORE — 02-Mar-2009

The US Department of Justice said it sued KV Pharmaceutical Co to block the drugmaker from making and distributing adulterated and unapproved drugs.

SC asks Roche not to pursue Cipla case until patent examination

Khomba Singh — 02-Mar-2009

The Supreme Court has asked Swiss company Roche not to pursue the patent violation case against the generic version of Ciplas anti infection drug Valcept until the Chennai patent office re examines the patent granted to Roche.

SC asks Chennai patent office to hear Roche

Khomba Singh — 02-Mar-2009

The Supreme Court on Monday asked the Chennai patent office to hear and take a final view for all post grant oppositions for a patent it had granted to Swiss company Roche for its anti infection drug Valcyte .

Jubilant gets Canadian nod for anti heart disease generic

Agencies ,Mumbai — 02-Mar-2009

Drug maker Jubilant Organosys on Monday said its Canadian subsidiary has received approval from Canadian health regulator for its anti heart disease generic Sestamibi in that country.

Pfizer Expands Portfolio of Generic Medicines in the US and Europe

NEW YORK — 03-Mar-2009

Pfizer Inc announced that it has entered into a series of agreements with Aurobindo Pharma Ltd a pharmaceutical company based in India to commercialize medicines that are no longer patent protected and have lost market exclusivity in the United States and Europe further progressing its Established Products Business Unit strategy.

Basilea Pharmaceutica files claims against Johnson & Johnson

By Datamonitor staff writer — 03-Mar-2009

Basilea Pharmaceutica has filed claims in arbitration against Johnson & Johnson and affiliated companies related to delays in approval of ceftobiprole.

Congress takes up patent redo damages fight looms

WASHINGTON — 3-Mar-2009

Senior US lawmakers launched a new patent reform attempt on Tuesday with controversial legislation that would reduce damages paid for infringement.

Pfizer to license 50 generics from Aurobindo

BS Reporter / New York — 4-Mar-2009

Pfizer Inc has agreed to license an array of generic pills and injectable medicines from Indias Aurobindo Pharma Ltd as the worlds largest drugmaker looks to off patent medicines for growth.

Aurobindo gets USFDA nod for anti depressant

ET Bureau,MUMBAI — 04-Mar-2009

Drug major Aurobindo Pharma on Wednesday said it has got tentative USFDA approval to market escitalopram oxalate tablets.

Way to go New patents for old drugs

Latha Jishnu / New Delhi — 04-Mar-2009

It is one of the great ironies of this country that regulations put together after careful thought and debate to prevent their misuse by smart companies are carelessly flouted by the implementing agency.

Cordex Pharma Files ATPace Formulation Patent

LA JOLLA, Calif — 04-Mar-2009

Cordex Pharma Inc announced today that it has filed a formulation patent covering its lead product ATPace.

Aussie regulator puts Ranbaxy under scanner

ET Bureau,NEW DELHI — 5-Mar-2009

The Australian drug regulator Therapeutic Goods Administration said it is reviewing 62 drugs sold in the country which are made by Ranbaxy at its Paonta Sahib plant.

Pharma to get new regulatory regime

Gireesh Chandra Prasad — 05-Mar-2009

Drug makers in the country will get a new regulatory regime that is more friendly for investing heavily into high risk research testing experimental drugs on animals protecting the costly research data shared with the regulators and everything needed to lead them to the global league of drug inventors.

USFDA door wide open for Indian pharma cos

Joe C Mathew / New Delhi — 6-Mar-2009

The trend is likely to continue as Indian companies account for 35 per cent of all ANDA approvals given by the FDA in the first two months of 2009. ANDA is an application for a generic drug approval for an existing licensed medication or an approved drug.

Slowdown pill chokes Reliance Pharma

C.H. Unnikrishnan — 6-Mar-2009

Reliance Pharmaceuticals Pvt Ltd a generics or off patent drug manufacturing and exporting firm that is being set up at a cost of at least Rs1000 crore may start functioning later than originally envisaged.

Indian firms expect US FDAs local office to speed up approvals

Nina Mehta — 6-Mar-2009

The US Food and Drugs Administrations new office in India could likely boost local pharma companies efforts to process their applications and speed up approvals for marketing in the global market.

Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium

CORONA, Calif. — 6-Mar-2009

Watson Pharmaceuticals Inc a leading specialty pharmaceutical company announced today that it has reached a settlement with Elan Corporation Plc on outstanding patent litigation related to Watsons generic version of Naprelan tablets.

Ranbaxy gets approval to market anti fungal drugs in Australia

PTI,NEW DELHI — 6-Mar-2009

Drug major Ranbaxy Laboratories on Friday said it has received approval from the Australian health regulator to market its anti fungaltablets Serbifin Terbinafine in that country.

New drug regulatory norms on cards

Gireesh Chandra Prasad — 7-Mar-2009

The government is putting finishing touches on a new regulatory regime for the countrys pharmaceutical sector that will seek to catapult domestic drug makers into the global league of inventors from being successful copiers of expensive multinational brands.

UN agency protests Dutch seizure of Indian HIV drugs

Radhieka Pandeya — 7-Mar-2009

The purchase by the Clinton Foundation through UNITAID was confiscated at Amsterdams Schiphol airport on 12 November on grounds that it contained counterfeit goods and infringed IPRs

Watson to pay $18 million to Elan to settle patent suit

By Kathy Shwiff — 7-Mar-2009

Watson Pharmaceuticals Inc will pay $18 million to Elan Corp PLC to settle patent litigation related to Watsons generic version of Naprelan or naproxen sodium tablets.

Takeda stock sold off on key drug approval concerns

Nathan Layne — 9-Mar-2009

Shares of Japanese drugmaker Takeda Pharmaceutical Co were untraded due to a glut of sell orders on news that US regulators have asked for more data to complete a review of a key diabetes drug candidate.

Indias Ranbaxy gets US FDA nod for ramipril

Janaki Krishnan — 9-Mar-2009

Indian drug maker Ranbaxy Laboratories Ltd said on Monday it had received approval from the US Food and Drug Administration to manufacture and market ramipril capsules.

For Big Pharma the playfields here

Priyanka Golikeri & C Chitti Pantulu — 9-Mar-2009

Multinational drugmakers are taking Masefield a little too seriously. They are fast moving eastward with India in the periscope.

Merck Schering Plough deal What happens to subsidiaries

P.T. Jyothi Datta — 09-Mar-2009

Early days yet to map how the acquisition will pan out in India.

Drug Mergers Killers for Research

By Catherine Arnst — 09-Mar-2009

Further out however Merck may find itself in the same wobbly boat its in now No big drugs to replace the best sellers that are on the verge of losing patent protection.

Ranbaxy gets USFDA nod for heart drug

Our Bureau ,New Delhi — 09-Mar-2009

Ranbaxy Laboratories Ltd announced on Monday that it has received an approval from the US Food and Drug Administration to market and manufacture cardiovascular drug Ramipril Capsules

Pfizer Aurobindo pact may expand to CIS Asian markets

Joe C Mathew / New Delhi — 10-Mar-2009

Pfizer the worlds largest drug maker which announced a licensing and supply pact on March 3 with Aurobindo Pharma to source over 50 generic medicines for sale in the US and Europe will expand this to about 30 countries in Asia and the CIS region soon.

Tax free bonds to fund drug research venture

Sushmi Dey & Gireesh Chandra Prasad — 10-Mar-2009

Much of Indias strengths in this sector are in making copycat versions of popular drugs discovered abroad and making medicines whose patents have expired.

Cordex files patent application for anti arrhythmic drug

By Datamonitor staff writer — 10-Mar-2009

Cordex Pharma a developer of cardiovascular medicines has filed a formulation patent covering its lead product ATPace.

USPTO Issues Notice of Final Determination for Patent Term Extension for NAMENDA

Forest Laboratories — 10-Mar-2009

Forest Laboratories Inc Forest Laboratories Holdings Ltd Merz Pharma GmbH & Co KGaA and Merz Pharmaceuticals GmbH announced today that the US Patent and Trademark Office has issued a Notice of Final Determination granting the full five years of patent term extension for US Patent No 5061703 which is listed in the US Food and Drug Administration Orange Book for NAMENDA.

Merck deal puts pressure on drugmakers AstraZeneca Sanofi J&J

Bloomberg / New Delhi — 11-Mar-2009

The worlds biggest drugmakers armed with about $100 billion in cash and short term investments are seeking acquisitions to replace $84 billion in sales from products nearing the end of their patent life.

Moodys cuts Pfizer as Lipitor patent nears expiry

Karen Brettell,NEW YORK — 13-Mar-2009

Moodys Investors Service on Wednesday cut its ratings on Pfizer citing declining credit quality at the pharmaceutical company due to the upcoming expiration of its patent for cholesterol drug Lipitor.

India Brazil protest seizure of generic drugs by Dutch

Sheila Mathrani,GENEVA — 11-Mar-2009

India and Brazil have expressed their deep concern over the public health implications of the seizure of generic drugs in transit by European nations and its systemic implications.

Mercks Schering Plough buy is a win win deal

Pillman,Mumbai — 12-Mar-2009

To make the going tough patent expiries burnt a major hole into Mercks revenues.

Sepracor Inc Reaches Xopenex Deal with Teva Pharmaceutical Industries Limited

MARLBOROUGH, Mass,BUSINESS WIRE — 12-Mar-2009

Sepracor Inc today announced that it has entered into a Settlement and License Agreement with Teva Pharmaceuticals USA Inc and Barr Laboratories Inc a wholly owned subsidiary of Teva to resolve the patent litigation against Barr involving Sepracors XOPENEX brand levalbuterol HCl Inhalation Solution products and to grant a license to Barr and Teva.

Pharma MNCs want to take a shot at Indias vaccine market

Nina Mehta,MUMBAI — 12-Mar-2009

MSD Pharmaceuticals GlaxoSmithKline Novartis and Pfizer are some of the companies that want to be a part of this story.

Strides Arcolab to launch over 25 products this year

Dow Jones — 13-Mar-2009

Bangalore Mumbai 12 Pharmaceutical company Strides Arcolab Ltd expects new product launches mainly in the US and Europe to drive its revenue growth this year its Vice Chairman and Chief Executive said.

Pfizer says CEOs 2008 pay over $13 mln

By Ransdell Pierson — 13-Mar-2009

Pfizers biggest challenge comes in 2011 when its $12 billion a year Lipitor cholesterol fighter loses US patent protection and confronts cheaper generic competition.

Govt to spend $2 b annually till 20 on drug discovery

ET Bureau,AHMEDABAD — 14-Mar-2009

We have ability of backward engineering but we lack innovation he added Mr Kumar said about $103 billion worth of patented drugs will go off patent in the years to come.

Dr Reddys wins drug patent case in US

Our Bureau — 14-Mar-2009

Hyderabad March 13 A US District Court has granted a summary judgment that pharma major Dr Reddys Laboratories Ltd does not infringe the patents in its Abbreviated New Drug Application for Omeprazole.

Glaxo proposes patent pool for new treatment of neglected diseases

REUTERS — 15-Mar-2009

GlaxoSmithKline Plcs chief executive urged creation of a voluntary patent pool to spark development of new treatments for neglected diseases in the worlds poorest countries.

Pfizer to give data on smoking cessation drug impact in India

C.H. Unnikrishnan — 16-Mar-2009

Indian drug regulator has askedPfizer Ltd the Indian arm of the worlds largest drug maker Pfizer Inc to submit data of a compulsory post sales study on its smoking cessation drug Champix

Tatas seek patent security for Nano against copycats

Kala Vijayraghavan & Lijee Philip — 16-Mar-2009

Tata Motors has applied for patent protection for over 37 inventions and innovations linked to its high profile affordable car Nano aggressive move to protect the brand against imitation in the ultra competitive car industry.

Natco successfully opposes patent application

BS Reporter / Hyderabad — 16-Mar-2009

Hyderabad based Natco Pharma limited said that it had successfully opposed a patent application in India that covers the composition of Glatiramer Acetate the generic version of Teva Pharmaceutical Industries Copaxone.

Patent offices asked to clear opposition cases by 31 March

C.H. Unnikrishnan — 17-Mar-2009

The new controller general of patents designs and trademarks has ordered the heads of all four regional offices to issue final orders in some 600 patent and trademark opposition cases by 31 March.

IIT B to encash its intellectual bonds

Mumbai — 17-Mar-2009

Converting their ideas into monetary value will now become easier for the IIT Bombay faculty thanks to a partnership between the institute and Intellectual Ventures IV.

USPTO Grants Reissue Patent Relating to Lipitor

NEW YORK — 17-Mar-2009

Pfizer Inc announced in a press release that the US Patent and Trademark Office has granted reissue patent RE40667 relating to Lipitor.

Drug Firms Bet Big on High Risk Deals

By RON WINSLOW and AVERY JOHNSON — 17-Mar-2009

Amid the biggest financial crisis since the Great Depression drug giants Pfizer Inc Merck & Co and Roche Holding AG are pulling off an impressive feat

Shire Files Lawsuit Against Barr for Infringement of FOSRENOL Patents

WASHINGTON, DC — 17-Mar-2009

Shire plc announced in a press release that it has filed a lawsuit in the US District Court of the Southern District of New York against Barr Laboratories Inc for infringement of three of Shires patents US Patent No 5968976 US Patent No 7381428 and US Patent No 7465465.

Warner Chilcott faces new patent dispute

Associated Press — 17-Mar-2009

Warner Chilcott Ltd said Tuesday Impax Laboratories has challenged the drug developers patent on another dose of the antibiotic Doryx.

First to file Para IV suits on steady rise along with patent settlements

Kiran Kabtta Somvanshi — 17-Mar-2009

A latest study conducted in US by Stanford Group Company a member of the Stanford Financial Group shows that patent challenges as well as settlements continue to be on the rise.

Samsung to file fresh petition in dual SIM case

C.H. Unnikrishnan — 18-Mar-2009

The firm is challenging a law that linked a patent enforcement provision in import rules under which Samsung mobile phones that use double SIM were seized in Mumbai and Chennai

Hope is a patent troll for IIT Bombay

Latha Jishnu / New Delhi — 18-Mar-2009

The patent trolls main activity is seen as litigation and thus the reason for its unsavoury reputation.

Genzyme sues Impax in patent fight

Bloomberg News ,WASHINGTON — 18-Mar-2009

Genzyme Corp the worlds largest maker of drugs for rare genetic disorders sued Impax Laboratories Inc for allegedly infringing a patent used for its Renagel kidney medicine.

Medicis Teva end dispute relating to Solodyn

Helen Chernikoff — 18-Mar-2009

Israels Teva the worlds largest generic drugmaker confirmed that Medicis patents relating to Solodyn Extended Release Tablets are valid and enforceable and has agreed to stop all further shipments of its generic version of the drug.

Cadila moves SC against Dabur Baidyanath on trademark

Press Trust of India / New Delhi — 18-Mar-2009

Pharma major Cadila Healthcare has moved the Supreme Court seeking to restrain Dabur India and Shree Baidyanath Ayurved from using its trademark Sugar free used for artificial sweeteners.

Merck gives malaria drug to non profit group

Ben Hirschler — 18-Mar-2009

Last month GlaxoSmithKlines chief executive urged the creation of a voluntary patent pool to spark development of new treatments for neglected diseases including malaria.

EU Patent Court drug rulings must consider public interest

By Lynne Taylor — 18-Mar-2009

The European Union Patent Court proposed by the European Commission must crucially take due care of the public interest in its considerations regarding pharmaceutical patents say generic drugmakers.

Strides Acrolab receives US FDA approval

Kiran Kabtta Somvanshi — 18-Mar-2009

Amidst stringent US Food & Drug Administration compliance Bangalore based Strides Acrolab has reasons to cheer.

US bill may dent Dr Reddys growth plans

Amriteshwar Mathur — 19-Mar-2009

Dr Reddys Laboratories could be affected if a recent US bill that seeks ban on MNC pharma companies from transferring authorised generics to third parties becomes a law.

Chennai tops in filing of trademarks

Our Bureau — 19-Mar-2009

In India the Chennai branch of the Patent and Trademark Office has the highest number of trademarks filed and Bangalore stands first in the e filing of trademarks

Warner Chilcott sues Impax over acne drug Doryx

NEW YORK — 19-Mar-2009

Warner Chilcott Ltd said Thursday it is suing Impax Laboratories Inc accusing Impax of infringing a patent supporting 150 milligram tablets of Warner Chilcotts acne medication Doryx.

OSI Pharma files suit against Teva Mylan

Helen Chernikoff — 19-Mar-2009

OSI Pharmaceuticals Inc on Thursday announced that it filed two lawsuits against rival drug companies regarding patents associated with Tarceva OSIs cancer drug the company said in a statement.

Dr Reddys to exit small generic drug markets abroad

Our Bureau — 20-Mar-2009

Dr Reddys Laboratories Ltd has decided to exit from the small distributor driven markets in its global generics business.

Global pharma consolidates

ET Bureau — 20-Mar-2009

Big pharma is set to lose nearly $100 billion in sales as many blockbuster drugs are set to lose patent protection over the next five years.

Epix Pharmaceuticals wins new US patent

Datamonitor staff writer — 20-Mar-2009

The granted claims of this patent are directed to the highly selective 5HT4 small molecule agonist, PRX03140, and to compositions that include PRX03140 as one of the active ingredients. Epix also has pending patent applications relating to compositions and methods of using PRX03140.

US court rules largely for patent office on Glaxo

By Diane Bartz — 20-Mar-2009

A US appeals court largely overturned on Friday GlaxoSmithKline Plcs summary judgment win in a fight against new patent office rules.

Appeals Court Revives Some Patent Rules Attacked By Glaxo

Dow Jones,WASHINGTON — 20-Mar-2009

GlaxoSmithKline PLC and an independent inventor challenged the rules before they went into effect arguing that Congress had not given the patent office the authority to make substantive changes to the patent process.

Sepracor sues to suppress generic copies of Lunesta

Bloomberg News — 21-Mar-2009

Sepracor Inc said it filed a lawsuit to prevent companies from selling generic versions of its top selling sleep drug Lunesta.

Pharma lobby wants a probe into delayed orders

C.H. Unnikrishnan, — 23-Mar-2009

The Indian Pharmaceutical Alliance or IPA has sought an investigation into several delayed orders in patent opposition cases.

Ricoh and Taisei Join Eco Patent Commons

Press Releases — 23-Mar-2009

Ricoh Company Ltd a global leader in office solutions and Taisei Corporation a leading engineering construction company have joined the Eco Patent Commons a first of a kind business effort coordinated by the World Business Council for Sustainable Development to help the environment by pledging environmentally beneficial patents to the public domain.

Drug makers get ready to work on vaccine for cervical cancer

P.T. Jyothi Datta — 23-Mar-2009

Gennovas patent team had given the research team the go ahead Dr Singh said responding to whether their vaccines could infringe the innovators patents.

Patent filing facility soon

Shastry V. Mallady — 23-Mar-2009

Micro Small and Medium Enterprises in the State will soon have a patent filing facility as the Tamil Nadu State Council for Science and Technology is launching an initiative in this direction.

Cubist Pharma Files Patent Infringement Lawsuit Against Teva Update

by RTT Staff Writer — 23-Mar-2009

Monday drug maker Cubist Pharmaceuticals Inc said it filed a patent infringement lawsuit against Teva Parenteral Medicines Inc or TPM Teva Pharmaceuticals USA Inc alleging violation of its US patents related to daptomycin.

American Bio Medica to receive two new US patents

By Datamonitor staff writer — 23-Mar-2009

American Bio Medica a biotechnology company has received notification from the US Patent & Trademark office that it will be granted two new patents one for its oral fluid drug testing product line and the other for its all inclusive urine point of collection drug test cup product line.

Lillys Zyprexa Prozac combo wins expanded use

Lewis Krauskopf — 23-Mar-2009

US regulators have expanded the approval of Eli Lilly and Cos Symbyax which combines the active ingredients of its Zyprexa antipsychotic and Prozac antidepressant for treatment resistant depression the company said on Monday.

Court Denies Wyeth Bid For Patent Extension On Cydectin

By Brent Kendall — 24-Mar-2009

A US trial judge on Monday denied Wyeths bid for a 10 month extension on its patent rights to Cydectin an animal health drug.

Glaxo pools 800 patents cuts drug prices for poor

Ben Hirschler — 24-Mar-2009

GlaxoSmithKline Plc will share more than 800 of its patents with others seeking to develop new medicines for neglected tropical diseases and slash the cost of many of its drugs in poor countries from next week.

Plexxikon wins key patents for new drug compounds

By Datamonitor staff writer — 24-Mar-2009

Plexxikon a developer of small molecule pharmaceuticals has received key composition of matter patents covering novel compounds discovered through the companys Scaffold based Drug Discovery platform.

Allergan soars on Glaxo takeover speculation

Val Brickates Kennedy — 24-Mar-2009

An Allergan buy would immediately bolster Glaxos lucrative migraine headache franchise as a key patent for Imitrex is set to expire this year.

Patent for Making Combination Chemotherapy Work Better

NexGen Biomedical, Inc — 24-Mar-2009

Patent 7507704 issued on 03 24 09 to NexGen Biomedical Inc founder Mark Zamoyski of San Jose California discloses an improved method of treating lung brain pancreatic breast and colon cancers that are driven by a mutation known as HER1 overexpression.

Foreign drug companies gain sales muscle following mergers

C.H. Unnikrishnan — 25-Mar-2009

The growth of local drug firms had actually begun in the 1970s following the abolition of the product patent regime.Coincidentally foreign drug makers are set to gain market share after the reversal of the patent regime in 2005.

Ranbaxy gets Australia nod for antipsychotic drug

Devidutta Tripathy — 25-Mar-2009

Indian drug maker Ranbaxy Laboratories said on Wednesday it had received the Australian drug regulators approval to market a generic version of Johnson & Johnsons antipsychotic drug Risperdal.

New diabetes drug approved without trial

Radhieka Pandeya — 26-Mar-2009

A new drug to combat diabetes which is administered orally and not injected was given a marketing approval by the Drugs Controller General of India without being put through the mandatory human clinical trials highlighting a possible lapse in Indian laws dealing with the testing and approval of drugs.

India may drag EU to WTO on seizure of drugs in transit

ET Bureau — 26-Mar-2009

EU authorities have been seizing cargoes of drugs from India because they believe these medicines infringe local patent laws while transiting from its customs.

Pantaloon 1 a or 2 the names mine

Rasul Bailay — 26-Mar-2009

Firm seeks cancellation of registrations granted to R Adag for using the Reliance Big Bazar trademark

UK discovers counterfeit Novo Nordisk insulin pens

Ben Hirschler — 27-Mar-2009

Britains medicines watchdog said on Friday it had discovered a batch of counterfeit Novo Nordisk insulin pen needles circulating in the country and urged diabetics not to use them.

Teva gets FDA approval on version of J&Js Topamax

Associated Press — 27-Mar-2009

The drugs key patents expired in March.

BCCI Zee fight over Twenty20 trademarks

Rasul Bailay & — 28-Mar-2009

Over the past 15 months the Essel Group popularly referred to as Zee Group after the television channels it runs has filed at least four dozen applications with the countrys trademark office seeking registration of various combinations of Twenty20.

Local companies blocked from selling cheap lifesaving drug

Janet Silvera — 29-Mar-2009

JAMAICAN pharmaceutical company Indies Pharma is gearing up for a court battle with international drug manufacturing giant Pfizer USA over local distribution of hypertension medication used by thousands of Jamaicans living with the debilitating illness.

US FDA approves Suns new drug to market Topamax topiramate

PTI,MUMBAI — 29-Mar-2009

Sun Pharma today said the US Food and Drug Administration has granted an approval for its abbreviated new drug application to market generic Topamax topiramate tablets.

Cadila Pharma to launch product to curb sudden cardiac death

BS Reporter / Mumbai/ Ahmedabad — 30-Mar-2009

Leading pharma company Cadila Pharmaceuticals in collaboration with McMaster University of Hamilton Canada has announced its plans to launch a product worldwide to bring down cardiovascular morbidity and mortality.

Ranbaxy Aurobindo get US FDA nod for epilepsy drug

PTI — 30-Mar-2009

Pharma firm Ranbaxy on Monday said it has received US regulatory approval for Topiramate tablets used in the treatment of epilepsy.

Unichem Lab gets FDA nod for Topiramate tablets

Agencies ,Mumbai — 30-Mar-2009

Pharma company Unichem Laboratories on Monday said it has received US regulatory approval for Topiramate tablets used for the treatment of epilepsy.

Eli Lilly eyes acquisitions WSJ

Ajay Kamalakaran — 31-Mar-2009

Lillys best selling drug the antipsychotic Zyprexa loses patent protection in 2011.

New Cadila combo pill may cut risk of stroke by half

Sangeeta Singh,New Delhi — 31-Mar-2009

Medical professionals have long theorized on the benefits of a combination pill in cardiac disorders but it wasnt known if such a drug could be formulated and at the same time be effective

Amicus Therapeutics wins new US patent

By Datamonitor staff writer — 31-Mar-2009

Amicus Therapeutics a biopharmaceutical company has received a new US patent isofagomine the active ingredient in the companys investigational drug Plicera and its use for the treatment of Gaucher disease.

Aurobindo Pharma gets tentative US nod for HIV drug

REUTERS — 31-Mar-2009

Drug maker Aurobindo Pharma said on Tuesday it secured a tentative approval from the US Food and Drug Administration to sell its emtricitabine and tenofovir disproxil fumarate combination drug in tablet form.

US FDA warns firms selling unapproved narcotics

Lisa Richwine — 31-Mar-2009

US regulators warned nine companies on Tuesday to stop selling 14 unapproved narcotic pain medicines part of an ongoing effort to rid the market of drugs without proper clearance.

Matrix Labs gets USFDA nod for HIV infection tablets

PTI,MUMBAI — 31-Mar-2009

Drug manufacturer Matrix Laboratories on Tuesday said it has received US regulators approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets used in controlling HIV infection.

Eli Lilly looks to make more deals

INDIANAPOLIS — 31-Mar-2009

Lilly will lose patent protection for its best selling drug the antipsychotic Zyprexa in 2011.

Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta and Declares Patent Invalid

Patty Eisenhaur — 31-Mar-2009

Watson Pharmaceuticals Inc a leading specialty pharmaceutical company announced today that the United States District Court for the District of Delaware has ruled that Watsons generic version of Concerta does not infringe United States Patent No 6919373 and that the 373 Patent is invalid.

Clearance for only one Ranbaxy site

Radhieka Pandeya — 1-Apr-2009

Information provided by Ranbaxy Laboratories Ltd in filings to the stock exchanges and a press release issued on 23 March has led some analysts and at least one international news agency into assuming that the companys Paonta Sahib facility censured by the US Food and Drug Administration had been subsequently given the all clear by the drug regulators of the UK and Australia.

Glenmark to stop sale of its pain killer in US

Radhieka Pandeya — 01-Apr-2009

Glenmark Pharmaceuticals Ltd said it will stop selling its morphine sulfate drug in the US complying with a warning by that countrys drugs regulator

District Court decision received in Concerta patent sase

Medical Patent News — 01-Apr-2009

The US has rendered a decision in the patent litigation between Alza Corporation McNeil PPC Inc and Andrx Pharmaceuticals LLC McNeil Pediatrics Division of Ortho McNeil Janssen Pharmaceuticals Inc which markets Concerta Extended Release Tablets CII said the court held that the patent in suit is not valid or infringed by the filing of Andrxs Abbreviated New Drug Application.

Mylan confirms four first to file ANDA lawsuits

By Datamonitor staff writer — 01-Apr-2009

Believes it to be the first to have filed substantially complete ANDAs containing Paragraph IV certification.

US senators agree on patent changes

By Diane Bartz — 01-Apr-2009

Leaders of the US Senate Judiciary Committee said on Wednesday they had reached agreement on key elements of a bill to revise US patent law.

US Senate panel approves patent reform

By Diane Bartz — 02-Apr-2009

The Senate Judiciary Committee voted on Thursday to approve a patent reform bill that has had drug high tech and other industries at loggerheads for several years.

Watson Does Not Infringe Patent Related to Generic Version of Concerta

CORONA, CA — 2-Apr-2009

Watson Pharmaceuticals Inc announced in a press release that the United States District Court for the District of Delaware has ruled that Watsons generic version of Concerta does not infringe United States Patent No 6919373 and that the 373 Patent is invalid.

Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL Patents

Shire Plc — 2-Apr-2009

Shire plc announces that it has filed a lawsuit in the US District Court for the Southern District of New York against Natco Pharma Limited for infringement of two of Shires patents US Patent No 5968976 and US Patent No 7381428.

MNC drug makers eye generics in India other emerging countries

PB Jayakumar / Mumbai — 3-Apr-2009

Multinational drug makers such as Pfizer and GlaxoSmithkline are planning large scale forays into generic manufacturing or the reverse engineered cheap drugs business threatening the growth prospects and survival of Indian generic companies such as Ranbaxy Laboratories Dr Reddys Laboratories and Sun Pharma and global generic leaders like Teva Sandoz and Mylan.

Better protection of intellectual property to boost indigenous innovation

Ayushman Baruah — 3-Apr-2009

According to a BSA IDC global software piracy study the Indian software industry lost around $2 billion due to software piracy last year.

Patent to Bajaj could mean trouble for TVS

Shally Seth — 3-Apr-2009

Indias patents office has granted exclusive rights to an engine technology Bajaj Auto Ltd uses in all its motorcycles which could land its rival TVS Motor Co Ltd into trouble since it also uses the same technology in some of its bikes.

What is the Satyam Upaid case about

Raghuvir Srinivasan — 3-Apr-2009

Armed with the patent Upaid filed a suit against Qualcomm and Verizon Wireless in 2005 alleging that they were using the patented technology.

Acquisition overdose Worries over future of pharma industry

P.T. Jyothi Datta — 3-Apr-2009

Challenges are in store for local drug companies also in the form of patent related challenges in India and abroad.

Court rules for Lilly in patent fight with Ariad

Diane Bartz — 03-Apr-2009

Eli Lilly did not infringe a patent owned by Ariad Pharmaceuticals when it made its Evista osteoporosis drug and Xigris sepsis treatment a US appeals court said on Friday.

Boston Scientific announces key rulings in stent litigation with J&J

By Datamonitor staff writer — 03-Apr-2009

Boston Scientific a developer manufacturer and marketer of medical devices has reported that the Court of Appeals for the Federal Circuit has issued a positive ruling in the companys stent litigation with Johnson and Johnson or J&J.

AstraZeneca sues Apotex over generic asthma drug

Bill Berkrot — 03-Apr-2009

Pulmicort had US sales of $982 million in 2008 with about 90 percent of that coming from the form of the medicine that is being disputed in the patent case.

Patent to Bajaj will not affect us TVS Motor

Our Bureau — 4-Apr-2009

Mumbai April 3 TVS Motor Company has stated that the grant of the ExhausTEC patent to Bajaj Auto does not in any way impact its products in the market.

Nomadix Wins Patent Enforcement Action Against Second Rule LLC

NEWBURY PARK, CA — 4-Apr-2009

DOCOMO interTouch announced that its subsidiary Nomadix Inc has won a patent enforcement action against Second Rule LLC the maker of the IP3 NetAccess gateway a press release by Nomadix stated.

Five Indian inventions win US patent

NEW DELHI (Xinhua) — 5-Apr-2009

Five inventions by a New Delhi resident named Anadish Pal have won patent from the United States government Navbharat Times reported on Sunday.

Gilead Reviews Tevas Generic Application May File Suit

DOW JONES NEWSWIRES — 06-Apr-2009

Gilead Sciences Inc said it is reviewing a notice letter and has 45 days to file a patent infringement lawsuit against Teva Pharmaceutical Industries Ltd following Tevas submission to manufacture and market a generic version of HIV drug Atripla.

Impax sued by Genzyme in patent challenge

Associated Press — 06-Apr-2009

Drug developer Impax Laboratories Inc said Monday it is being sued by Genzyme Corp over a patent challenge to that companys kidney condition drug Renvela.

Sepracor files NDA for seizure drug

By Datamonitor staff writer — 06-Apr-2009

Sepracor a research based pharmaceutical company has submitted a new drug application to the FDA for the use of eslicarbazepine acetate as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.

Arrow Coated Products gets patent for specialised films

BS Reporter / Mumbai — 06-Apr-2009

Arrow Coated Products Ltd one of Indias leading and pioneering manufacturers of pressure sensitive adhesive coated films has been granted patent for Embedded Water Soluble Films by Australian Patent office Patent Grant No 2002356417 till October 07 2022 the company said in a BSE filing.

Teva Pharma A Safe Prescription

RTTNews — 6-Apr-2009

Hit by a triple whammy of pipeline woes an onslaught of blockbuster patent expiries and regulatory stringency the once invincible branded drugs giants are engulfed in a fog of uncertainty.

Ex Bristol Myers Executive Pleads Guilty In Plavix Patent Case

DOW JONES NEWSWIRES — 6-Apr-2009

Andrew Bodnar a former executive of Bristol Myers Squibb Co pleaded guilty Monday to a charge related to his role in a patent deal the drug maker struck to keep a generic competitor to its popular blood thinning drug Plavix off the market.

Impax Confirms Patent Challenge Relating to Renvela

HAYWARD, CA — 07-Apr-2009

Impax Laboratories Inc confirmed that it has initiated a challenge of the patents listed by Genzyme Corporation in connection with its Renvela 800 mg tablets a press release by Impax stated.

Rambus Buys Inapac Patents

Corporate News — 07-Apr-2009

Rambus Inc announced it has acquired a number of patents from Inapac Technology Inc to broaden its offerings for the mobile memory market.

Gilead Sciences Announces Notification of ANDA Filing for Atripla

BUSINESS WIRE — 07-Apr-2009

Gilead Sciences Inc today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application to the US Food and Drug Administration requesting permission to manufacture and market a generic version of Atripla.

AstraZeneca Files Suit Against Apotex

LONDON — 07-Apr-2009

AstraZeneca has filed a lawsuit in the US District Court for the District of New Jersey against Apotex seeking a declaration of patent infringement a press release by AstraZeneca stated.

Indian drug makers welcome to join patent pool prog GSK

PTI — 07-Apr-2009

Global drug major GlaxoSmithKline has said Indian drug makers and research firms can join its patent pool programme aimed at developing low cost drugs for 16 neglected tropical diseases.

Re evaluating pharma

Business Standard / New Delhi — 8-Apr-2009

The last avenue has been opened up with patent protection taking root in India.

Pfizer reorganizes units for Wyeth buy

Shannon Pettypiece — 8-Apr-2009

Pfizer the worlds biggest drug maker needs to ramp up new drug development as it braces to lose $10 billion in annual sales in 2011 when patent protection ends for its cholesterol pill Lipitor analysts said.

Many Drug Prescriptions are Now Going Unfilled

By JONATHAN D. ROCKOFF — 08-Apr-2009

That isnt good news for drug makers already struggling to replace the sales of top selling medicines losing patent protection over the next several years.

Affitech wins new European patent for antibody screening technology

By Datamonitor staff writer — 08-Apr-2009

Affitech an antibody R&D company has reported that the European Patent Office has granted a European patent on the use of phagemid particles having an antibody coliphage pIII fusion protein to identify tumor associated antigens on cells by negative selection.

Are Patent Problems Stifling US Innovation

Damian Joseph. — 08-Apr-2009

The US Patent and Trademark Office is drowning in applications while its budget shrinks.

Microsoft ordered to pay Uniloc $388 million

SEATTLE — 08-Apr-2009

A federal judge on Monday ordered Microsoft Corp to pay $388 million in damages after finding the worlds largest software maker infringed on a patent held by Uniloc Inc.

Mylan Announces Clarinex Settlement Agreement

Mylan Inc. — 8-Apr-2009

Mylan Inc today announced the settlement of all patent litigation relating to Desloratadine Tablets 5 mg the generic version of Schering Ploughs Clarinex allergy medication.

Aurobindo gets nod from Swissmedic

Agencies — 8-Apr-2009

Drug maker Aurobindo Pharma on Wednesday said it has received approval from the Switzerland government for marketing Finasteride APL a drug used for treating enlarged prostate in men.

Wockhardt to hive off biotech division

P B Jayakumar / Mumbai — 9-Apr-2009

Wockhardt has one of the largest off patent biotech drugs under development in India.

Takeda takes back Actos rights from Lilly

Yumiko Nishitani — 9-Apr-2009

Like its peers Takeda Japans largest drugmaker faces pressure from the economic slowdown in the United States the biggest market for Actos and it will lose patent protection on the drug there in 2011.

Cipla can benefit if Medpro acquisition goes through

P.T. Jyothi Datta — 10-Apr-2009

Mumbai based drug maker Cipla Ltd can look to expand its presence in South Africa and indeed other parts of the region if South Africa s Adcock Ingram Healthcare Ltds $233 million proposal to acquire generic drugs player Cipla Medro goes through.

Novartis retailers lock horns over direct sales

Khomba Singh, — 10-Apr-2009

An open battle has erupted between drug retailers in Mumbai and Novartis a Swiss company and its subsidiary Sandoz.

Samsung files appeal with board against dual SIM patent

C.H. Unnikrishnan — 10-Apr-2009

The firm filed a petition with IPAB asking it to revoke the existing patent for issued toan Indian inventor

Natco Lupin tie up for generic drug to treat kidney failure

Our Bureau — 10-Apr-2009

Natco Pharma Ltd has tied up with Lupin Ltd to jointly commercialise generic equivalents of Lanthanum Carbonate tablets used to treat kidney failure.

Wockhardt to foray into biosimilar market

Nina Mehta,MUMBAI — 10-Apr-2009

Wockhardt is planning to tap the $33 billion biosimilar market and focus on products that lose patent protection in 2013 2015.

We will be back to normal soon

P. T. Jyothi Datta — 10-Apr-2009

Wockhardt watchers also observe that the company like many corporates in and outside the pharmaceutical segment went on an acquisition over kill and worse funded it through debt when the going was good.

United Treatment Centers Inc Acquires a Stake in Bel Ea Co and Its Trademarks

ASTORIA, NEW YORK -- (MARKET WIRE) — 10-Apr-2009

United Treatment Centers Inc today announced it has acquired a 50% stake of Bel Ea Co from an existing shareholder.

Daiichi Sankyo Files Patent Infringement Actions Against 11 Generics Companies

ag-IP-news — 11-Apr-2009

Daiichi Sankyo Ltd announced in a press release that it has brought patent infringement litigations against 11 generics companies for the substance patent 2008845 and usage patent 1659502 for Levofloxacin Hydrate brand name Cravit tablets and Cravit fine granules.

HP Files Appeal in Patent Dispute with Cornell University

PALO ALTO, CA — 12-Apr-2009

HP announced in a press release that it has filed an appeal in its patent dispute with Cornell University and the Cornell Research Foundation Cornell.

J&J expected to report lower earnings

Val Brickates Kennedy — 12-Apr-2009

J&Js pharmaceutical division once its core business has been hit in recent quarters by the loss of patent exclusivity on such brand names as Risperdal and Topamax.

Defensive pharma promises solid Q1 results

Ben Hirschler and Lewis Krauskopf — 12-Apr-2009

A looming cliff of patent expiries growing political pressure in the United States and elsewhere and a lack of new drugs coming out of research labs mean drug companies are struggling with over capacity just like other industries.

Sun loses US patent case for lucrative drug

PB Jayakumar / Mumbai — 12-Apr-2009

Sun Pharmaceutical Industries has lost a patent infringement case in the US on Cardene a drug for controlling high blood pressure.

HC to hear dual SIM patent case today

Niranjana Ramesh, — 13-Apr-2009

The Madras High Court will hear a petition filed by a Madurai based engineer Somasundaram Ramkumar seeking the enforcement of patent protection for his invention the dual SIM card technology used in mobile phones.

Cadila looking at global tie ups for Polycap

Press Trust Of India / New Delhi — 13-Apr-2009

Ahmedabad based Cadila Pharmaceuticals is looking for global tie ups to market its new patented product Polycap a combination of five medicines that prevents heart attack.

Indias Sun Pharma gets FDA nod for generic Roxicodone

Prashant Mehra — 13-Apr-2009

The generic oxycodone hydrochloride tablets are used as a painkiller.

CoolTouch Inc Settles Diomed Lawsuit Files Re examination Request for Cynosure 873 Patent

CoolTouch Inc. — 13-Apr-2009

ROSEVILLE Calif PRNewswire On April 7 2009 the Boston District Court dismissed the Diomed lawsuit between Endolaser Associates LLC and CoolTouch Inc after CoolTouch signed a settlement agreement with Dr Luis Navarro.

US rejects Alcatel patent could affect award

Bill Rigby — 13-Apr-2009

The US Patent and Trademark Office has rejected two patents claimed by French telecoms equipment Alcatel Lucent which could end up nullifying a multi million dollar damages award against software maker Microsoft Corp.

Alcatel Patent in $358 Million Suit Rejected by US

By Susan Decker — 14-Apr-2009

An Alcatel Lucent SA patent that resulted in a $358 million jury verdict against Microsoft Corp was rejected by the US Patent and Trademark Office after the agency took a second look at the invention.

These are quality medicines Indias success formula

Daara B Patel, — 14-Apr-2009

Fixed Dose Combinations have been manufactured successfully in India and abroad for many years.

We should properly evaluate these combination drugs

M Venkateswarlu, — 14-Apr-2009

Any drug before being permitted for marketing in the country for the first time undergoes a series of scientific studies pre clinical studies or M Venkateswarlu Former Drugs Controller General of India animal model studies and clinical trials carried out in three phases.

Zydus Pharma sued in US over anti depressant

Reghu Balakrishnan — 14-Apr-2009

Zydus Pharma Inc the US subsidiary of the Ahmedabad based pharma major Zydus Cadila has been sued by US major Wyeth following the latters paragraph IV ANDA submission for the marketing approval of Effexor a leading anti depressant drug with $4 billion sales revenue owned by Wyeth in the US market.

Mylan challenges patent sued by Roche

Associated Press — 14-Apr-2009

Mylan Inc said Tuesday it is being sued by Roche after challenging the Swiss drug developers patent on the cancer treatment Xeloda.

Mylan Confirms First To File Patent Challenge Relating To Xeloda Cancer Treatment

Mylan Inc. — 14-Apr-2009

Mylan Inc today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc have been sued by Hoffmann La Roche Inc in connection with the filing of an Abbreviated New Drug Application with the US Food and Drug Administration for Capecitabine Tablets 150 mg and 500 mg the generic version of Xeloda Tablets a chemotherapy treatment for breast and colorectal cancer.

Samsung files appeal against dual SIM

Bettina Wassener — 15-Apr-2009

Prateek Garg a 26 year old software engineer who lives in Delhi has been unemployed since September and has had only two job interviews since then.

Rib X Granted Key Antibiotic Patent in China

NEW HAVEN, Conn. — 15-Apr-2009

Rib X Pharmaceuticals Inc a development stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic resistant infections today announced the issuance of a key antibiotic patent in China.

Peregrine wins new US patent

By Datamonitor staff writer — 15-Apr-2009

Peregrine Pharmaceuticals a biopharmaceutical company has received a new US patent that is expected to strengthen the companys intellectual property in the field of phospholipid targeting agents for the treatment of life threatening diseases.

CORRECT Sales forecast haunts Abbott shares

By Val Brickates Kennedy — 15-Apr-2009

Abbott Laboratory shares moved notably lower Wednesday as investors reacted negatively to news that sales growth for the companys popular rheumatoid arthritis drug Humira might not be as robust as previously expected.

India rejects patent to Glivecs second variant

Joe C Mathew / Bangalore — 15-Apr-2009

Ruling intended to prevent patenting of inventions known earlier.

New drug research is a high risk game

P B Jayakumar / Mumbai — 16-Apr-2009

Lupin Ltd one of the top five drug companies in India grew over 30 per cent yearly in the past four years and maintained 38 per cent growth in turnover and 49 per cent growth in profits in the first nine months of 2008 09.

Troikaa Pharma launches cancer drug

Our Bureau — 16-Apr-2009

The lozenges and their holders are indigenously designed and patented.

AstraZeneca India announces CRESTOR tablets launch

Sushmi — 16-Apr-2009

AstraZeneca India announced the launch of CRESTOR rosuvastatin 5 10 20 and 40 mg tablets today.

Piramal gets injunction in drug trademark case

C.H. UnnikRishnan — 16-Apr-2009

The injunction temporarily restrains these companies from using brand names similar to Esgipyrin for marketing the same drug combination

Pig patent row upsets top EU producer Germany

By Brian Rohan — 16-Apr-2009

A test to check pigs for a gene that makes them produce more meat has sparked a row in Germany where farmers ecologists and politicians filed objections to its patent before an appeals deadline on Thursday.

Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation

AstraZeneca — 16-Apr-2009

On 16 April 2009 the US District Court for the District of New Jersey granted AstraZenecas request for a temporary restraining order barring Apotex from launching a generic version of AstraZenecas PULMICORT RESPULES until further order of the court.

Rib X granted patent for novel oxazolidinone in China

Medical Patent News — 16-Apr-2009

Pharmaceuticals Inc has announced the issuance of a key antibiotic patent in China.

Roches Hepatitis drug patent upheld

Joe C Mathew / Bangalore — 17-Apr-2009

The patent office has upheld the validity of Roches patent rights over Pegasys pegylated interferon alfa2a a Hepatitis C medicine.

Sepracor disputes patent on Wyeths Pristiq

Associated Press — 17-Apr-2009

Sepracor Inc on Friday took a step toward a potential challenge of patents supporting Pristiq an antidepressant marketed by Wyeth.

Patentholder asks Noida excise dept to cancel Samsung licence

C.H. Unnikrishnan — 17-Apr-2009

A Madurai based engineer has asked authorities to cancel Samsungs licence to manufacture dual SIM mobile phones as he holds the local patent for such mobiles

Nobel Biocare wins patent ruling in Germany

Katie Reid — 17-Apr-2009

Swiss dental implant maker Nobel Biocare said on Friday it had won a German court ruling in a patent infringement case brought by Materialise Dental in relation to Nobel Biocares NobelGuide software.

Glaxo Pfizer to merge HIV drug units in challenge to Gilead

Bloomberg / London — 18-Apr-2009

GlaxoSmithKline Plc once the worlds biggest maker of AIDS drugs will form a new company with rival Pfizer Inc to increase its share of the $12.3 billion HIV market now dominated by Gilead Sciences Inc.

Drug patents India to take EU to WTO

Arun S — 18-Apr-2009

The patents battle between India and the European Union in the pharmaceutical space will soon reach the dispute settlement body of the World Trade Organisation.

Adcocks plan to buy Medpro hits Cipla hurdle

ET Bureau — 18-Apr-2009

South African company Adcock Ingrams plans to buy Cipla Medpro with whom Indian pharma major Cipla has a 20 year drugsupply agreement has run into trouble with the Mumbai based company opposing the $228 million takeover.

Sepracor Announces Patent Interference Proceedings Against Wyeth

MARLBOROUGH, MASS — 18-Apr-2009

Sepracor Inc announced that the Board of Patent Appeals and Interferences of the US Patent and Trademark Office has combined three patent interferences into a single interference between Sepracor and Wyeth and set a date for oral arguments.

Indian pharma industry may gain $18.4 bn from global mkt

PTI,NEW DELHI — 19-Apr-2009

With the global pharmaceutical market likely to witness products worth 123 billion dollars loosing patents by 2012 the generics driven Indian drugs industry could get benefit of around 18.4 billion dollars about Rs 91576 crore from those products.

Pharma MNCs ask DCGI to liaison with patent offices

Reghu Balakrishnan — 19-Apr-2009

In the backdrop of Wednesdays Delhi High Court verdict that allowed Cipla to manufacture and sell a patented cancer drug in India multinational pharma companies plan to urge the Drug Controller General of India to improve its co ordination with patent offices across the country.

Pharma companies headed for slower earnings growth analysts

C.H. Unnikrishnan and Radhieka Pandeya — 20-Apr-2009

Average growth in sales for the quarter likely to be less than 11% compared with 14% in the year ago period

Govt protests as generic drugs get bitter pill in Africa

Arun S — 20-Apr-2009

India has called an extraordinary meeting of the ambassadors of all African countries in the Capital this week to register its strong protest against a recently passed Anti Counterfeit Act in Kenya that could severely restrict the market for Indian generic drugs into Africa.

Scope to improve in big markets where the firm is already present

Radhieka Pandeya — 20-Apr-2009

Russia has been a good market for us. It is a branded generics market and we have been in the market for long

Drug firms may exceed growth targets

PB Jayakumar / Mumbai — 20-Apr-2009

Despite forex losses and currency fluctuations impacting profitability leading Indian drug companies such as Cipla Sun Pharma Dr Reddys Laboratories and Wockhardt are likely to exceed revenue growth targets set for financial year 2008 09.

Indian lawyer turns IPR into a board game

Malathi Nayak — 20-Apr-2009

The game is the brainchild of Pravin Anand one of Indias best known IPR lawyers.

IPR course for women

STAFF REPORTER — 20-Apr-2009

The training is aimed at having a pool of resources trained in scientific and technical aspects of intellectual property rights.

Achillion wins new US patent

By Datamonitor staff writer — 20-Apr-2009

Achillion Pharmaceuticals a US based biopharmaceutical company has announced that the US Patent & Trademark Office has granted Achillion a US patent related to the companys NS4A antagonists to treat the hepatitis C virus.

Glaxo to buy skin care firm for at least $2.9 billion

By Steve Goldstein — 20-Apr-2009

Companies in the sector have been looking for deals to boost their stable of new products as the patent protection for older medications expire.

Expert committee suggests patenting microorganisms too

C.H. Unnikrishnan — 21-Apr-2009

An expert group has suggested significant changes to Indias patent regime that will address contentious provisions that barred the issue of patents to anything that isnt a new chemical or medical entity and to drugs built around microorganisms.

Covidien Files Patent Infringement Lawsuit over Davols Mesh Fixation Device and Applier

NORTH HAVEN, Conn — 21-Apr-2009

The lawsuit contends that Davols recently released Sorbafix device infringes multiple claims of Covidiens US Patent Number 6562051.

Par Pharma settles patent dispute with Reliant

Associated Press — 21-Apr-2009

Generic drug developer Par Pharmaceutical Cos said Tuesday it settled a patent dispute with Reliant Pharmaceuticals Inc over the abnormal heart rhythm treatment Rythmol SR.

Glaxo Pfizer HIV research JV may harm generic cos

Nina Mehta — 22-Apr-2009

Ranjit Kapadia a pharma analyst with HDFC Securities said that the formation of the new firm will affect Indian companies if they are violating or challenging patents.

Big Pharma evergreening nixed

Priyanka Golikeri — 22-Apr-2009

Introducing highly expensive patented drugs that show little or no improvement over existing ones or attempts to evergreen patents is getting tougher for multinationals.

Glaxo Pfizers patent claims turned down

ET Bureau — 22-Apr-2009

Indian authorities have rejected the patent applications of GlaxoSmithklines anti diabetic drug Avandia and Pfizers cholesterol lowering drug Caduet allowing other companies to sell generic versions of these drugs.

ACTA to fight copyright infringement

PK Vasudeva — 22-Apr-2009

The US is considering bringing an Anti Counterfeiting Trade Agreement.

The US Is Losing Its Lead in Patents

By Michael Arndt — 22-Apr-2009

Innovation is coming from abroad these days and foreign applications are coming faster and faster.

Dr Reddys launches Redispar in India

Press Trust of India / Mumbai — 22-Apr-2009

Pharmaceutical firm Dr Reddys Laboratories today said it has launched Redispar drugs used in the treatment of chronic kidney diseases in the country.

IMS Health Cuts Pharma Growth Forecast

By Catherine Arnst — 22-Apr-2009

Big Pharma isnt so immune to the recession after all.

Piramal Health eyes acquisitions in US Europe

Reuters — 22-Apr-2009

Piramal Healthcare and a related firm Piramal Life Sciences Ltd would together invest about Rs1 billion during the 12 months to March 2010 mostly on new drug development and research.

Lilly says judge prevents launch of generic Evista

by Deena Beasley — 22-Apr-2009

Eli Lilly and Co said on Wednesday that a federal judge issued a preliminary injunction preventing the launch of a generic version of osteoporosis drug Evista.

NicOx acquires Nitromeds NO donating patents

SOPHIA ANTIPOLIS, FRANCE, MARKET WIRE — 23-Apr-2009

NicOx SA today announced it has agreed to purchase Nitromeds unlicensed patent estate covering nitric oxide donating compounds.

Teva Glenmark call an end to patent dispute

Nina Mehta — 23-Apr-2009

Israeli generic major Teva and Mumbai based Glenmark Pharmaceuticals have settled a patent dispute over various generic versions of Corega drug used for treating congestive heart failure out of court.

Gilead to challenge Tamiflu verdict

Reghu Balakrishnan — 23-Apr-2009

The patent office had recently rejected Gileads patent application owing to lack of inventiveness in the drug.

Teva to appeal against preliminary injunction for Generic Evista update

by RTT Staff Writer — 23-Apr-2009

Teva Pharmaceutical Industries Ltd said Thursday that it plans to appeal the Courts order in the litigation with Eli Lilly & Co.

Intellectual property report favours conditional patenting of micro organisms

P.T. Jyothi Datta — 24-Apr-2009

Mumbai April 23 Without much ado the Technical Expert Group on Patent Law Issues headed by Dr R A Mashelkar has resubmitted its report to the Union Ministry of Commerce.

Delhi High Court dismisses Roche plea on patent

PTI — 24-Apr-2009

The Delhi High Court on Friday allowed Indian pharmaceutical company Cipla to manufacture and sell the generic version of patented lung cancer drug Erlotinid of Swiss pharma firm Hoffman La Roche Ltd.

J&J Wins Approval to Sell Arthritis Drug in US

By Shannon Pettypiece and Alex Nussbaum — 24-Apr-2009

Remicades patent will expire in 2018 said Brian Kenney a spokesman for J&Js Centocor Ortho Biotech unit.

Cipla gets HC relief in Roche case

Radhieka Pandeya — 25-Apr-2009

In a ruling that could encourage more generic or off patent drug makers here to challenge patents held my multinational pharma firms the Delhi high court dismissed a patent infringement suit filed by Swiss pharma company Hoffman La Roche Ltd for its lung cancer drug Tarceva thereby allowing Indian drug maker Cipla Ltd to continue marketing the generic version of the drug.

Govt gives diplomatic push to pharma exports to Africa

Amiti Sen & Sushmi Dey — 25-Apr-2009

India has started a diplomatic exercise to counter a propaganda by multinational pharmaceutical companies against Indian generics or off patent drugs exported to Africa.

Govt to create 1380 patent examiners posts

Our Bureau — 27-Apr-2009

The Centre plans to create 1380 patent examiners posts during the 11th Plan period of which 414 will be filled up this year alone.

Sanofi Rebuffed by US High Court on Lovenox Patent

By Greg Stohr and Susan Decker — 27-Apr-2009

The US Supreme Court rejected an appeal by two Sanofi Aventis SA units refusing to reinstate a patent that prevented generic competition to the companys top selling product the blood thinner Lovenox.

Not too enticing

Ram Prasad Sahu / Mumbai — 27-Apr-2009

Going ahead although there are issues pertaining to patent registration and pricing if the company does manage to sort out these and use the listed arm for new launches sales could witness a jump considering its presence in high growth areas of anti diabetic cardiovascular gynaecology and anti ulcerants.

Qualcomm and Broadcom Settle Patent

Corporate News — 27-Apr-2009

Qualcomm Incorporated and Broadcom Corporation entered into a settlement and multi year patent agreement with Qualcomm paying Broadcom $891 million over a four year period.

FTC focused on drug pay for delay settlements

By Diane Bartz — 27-Apr-2009

The FTC while watching legislative efforts to ban the practice of big drug companies paying off generics as part of patent lawsuits has challenged the deals in court with mixed success.

Sinobiopharma Secures Rights to Seven Key Patents

NANJING, China — 27-Apr-2009

The patents that will significantly enhance Sinobiopharmas ability to execute on its mission of bringing safe low cost high efficacy biopharmaceuticals to market.

L&T unit files for 108 patents in 2008 09

Our Bureau — 28-Apr-2009

Mumbai April 27 Larsen and Toubros Electrical and Electronics Division has filed 108 patents applications in 2008 09 for its electrical and electronic products.

Cipla ready to supply generic drug to West

Corporate Bureau — 28-Apr-2009

Early this month the Delhi patent office had rejected the application of Gilead Sciences the manufacturer of Tamiflu for a patent considering Ciplas arguments that the drug lacked inventiveness.

Local drug cos may chip in to treat swine flu

Khomba Singh & Sushmi Dey — 28-Apr-2009

Cipla and other Indian pharma majors can now legally manufacture generic versions of Tamiflu after the patent office in Delhi last month rejected a patent application by Swiss company Roche which markets the antiviral in India.

US watch list on patents irks India

PTI ,New Delhi — 28-Apr-2009

India has conveyed its big disappointment to the US for retaining New Delhi on the Priority Watch List which binds Washington to exert pressure on Americas trade partners to improve their copyright and patent regimes.

US approval for Glenmark cholesterol drug

BS Reporter / Mumbai — 28-Apr-2009

Sources said Zetia had sales of $1.5 billion in 2008 and the main patent for this drug would expire in 2014.

Watson and Novartis battle over Enablex patent

Associated Press — 28-Apr-2009

Watson Pharmaceuticals Inc is disputing the patent on Novartis AGs extended release overactive bladder treatment Enablex Watson said Tuesday.

AVI BioPharma Receives Key Patents

PORTLAND, OR — 28-Apr-2009

AVI BioPharma Inc a developer of RNA based drugs announced in a Tuesday press release the issuance of the second of two key US patents covering the companys candidate drug for the treatment of Ebola Zaire infection.

NicOx to acquire NO donating patents from Nitromed

By Datamonitor staff writer — 28-Apr-2009

France based NicOx has agreed to purchase US based Nitromeds unlicensed patent estate covering nitric oxide donating compounds.

Dr Reddy launches anti acne drug Nexret in India

Agencies — 28-Apr-2009

Pharmaceutical firm Dr Reddy said it has launched a variety of gel Nexret used in the treatment of skin diseases.

Watson Confirms Filing of Abbreviated New Drug Application for Generic Enablex

CORONA, Calif — 28-Apr-2009

Watson Pharmaceuticals Inc a leading specialty pharmaceutical company today confirmed that it has filed an Abbreviated New Drug Application with the US Food and Drug Administration seeking approval to market its darifenacin hydrobromide extendedrelease 7.5 mg and 15 mg product prior to the expiration of a patent owned by Novartis AG.

i2 Files Intellectual Property Lawsuit

DALLAS--(BUSINESS WIRE) — 29-Apr-2009

i2 Technologies Inc announced today that it has filed a suit for patent infringement against Oracle Corporation.

McCurry beats McDonald in Malaysia lawsuit

David Chance, Kuala Lumpur — 29-May-2009

Fast food chain McDonald\'s lost a lawsuit in Malaysia on Wednesday after an appeals court overruled a decision that its trademark had been infringed by a local restaurant called McCurry.

The Patent Reform Act Means Progress

by Senator Patrick Leahy — 29-Apr-2009

Ingenuity and innovation have been cornerstones of the American economy from the time Thomas Jefferson issued the first patent.

FDAs Tamiflu move to spur generics mkt

Reghu Balakrishnan — 30-Apr-2009

Earlier this month the Delhi patent office had rejected the patent application for Tamiflu filed by Gilead Sciences while considering the pre grant opposition of Cipla.

The Patent Reform Act Means Progress

by Senator Patrick Leahy — 30-Apr-2009

Ingenuity and innovation have been cornerstones of the American economy from the time Thomas Jefferson issued the first patent.

Wockhardt may get rights for two Parkinsons drugs

BS Reporter / Mumbai April 30 — 30-Apr-2009

Settles 3 patent infringement cases out of court.

Ready to supply anti flu drug at short notice says Ranbaxy

ET Bureau — 30-Apr-2009

The timely rejection of Gileads other patent application for Tamiflu in India has come as a shot in the arm for Indian generic players.

Warner Chilcott Files New Lawsuit for Infringement of DORYX Patent

HAMILTON, Bermuda — 01-May-2009

Warner Chilcott Limited announced today that one of its subsidiaries and Mayne Pharma International Pty Ltd have filed a second lawsuit against Mylan Pharmaceuticals Inc and Mylan Inc in the District Court for the District of New Jersey for infringement of Maynes US Patent No 6958161 which covers DORYX a tetracycline class oral antibiotic.

New Delhi rejects American firms plea to patent Hepatitis B drug

Khomba Singh — 01-May-2009

The Delhi Patent Office has rejected American company Gilead Sciences plea to patent its Hepatitis B drug adefovir dipivoxil sold under the brand name Hepsera.

ImmunoCellular Therapeutics wins new patent for monoclonal antibody technology

By Datamonitor staff writer — 01-May-2009

ImmunoCellular Therapeutics a biotechnology company has received a new US patent relating to the companys monoclonal antibody therapeutics.

Gileads Hepatitis patent plea rejected

Khomba Singh, — 2-May-2009

The Delhi Patent Office has rejected American company Gilead Sciences plea to patent its Hepatitis B drug adefovir dipivoxil sold under the brand name Hepsera.

Indian pharma emerges big player in Japan

PB Jayakumar / Mumbai — 2-May-2009

Leading Indian drug makers such as Ranbaxy Lupin Zydus Cadila and Dishman which forayed into Japan in the past three years have emerged as important players in the generic or copycat drug business of patented medicines in that market the second largest in the world.

Ranbaxy recalls Nitrofurantoin capsules from US market

ET Bureau,NEW DELHI — 2-May-2009

Indias largest drug company by sales Ranbaxy Laboratories is voluntarily recalling its entire lots of Nitrofurantoin 100 mg capsules from the US retail market after it was discovered that the drugs did not meet the US drug manufacturing standards.

Patent office lets Roche keep Hepatitis C drug

Priyanka Golikeri — 02-May-2009

According to the World Health Organisation as many as 180 million people worldwide have been infected by the hepatitis C virus with 3 4 million being added to the list every year.

India to move WTO against EU MNCs blocking its generics

Sushmi Dey — 02-May-2009

India along with Brazil will lodge a complaint with the World Trade Organisation against the European Union alleging that Europe based multinational pharmaceutical firms are persuading African nations to enact anti counterfeit laws.

Google and other firms sued over use of Android name

TEL AVIV — 3-May-2009

An Illinois software developer sued some four dozen companies including Google Inc claiming that they infringed his trademark on the word Android weekend media reports said.

20th Century Fox sues B R Films for plagiarism

Press Trust of India / Mumbai — 3-May-2009

Hollywoods famous studio Twentieth Century Fox has moved the Bombay High Court against B R Chopra Films seeking Rs 7 crore damages and an injunction against the release of the Hindi film Banda Yeh Bindaas Hai alleging it was a remake of Oscar winning My Cousin Vinny.

IPL brands work on intellectual property bouquets

Malathi Nayak — 04-May-2009

Rodney D Ryder partner at law firm Kochhar and Co refers to the Indian Premier League the popular Twenty20 cricket tournament as the intellectual property league.

Pharma The 10 Most Promising New Drugs

By Arthur Wong — 04-May-2009

The pharmaceutical industry continues to march toward the patent cliff in 2010 2012 when a record amount of drug sales will lose patent protection in the US.

Hetero Drugs close to receiving orders for its swine flu medicines

Khomba Singh — 04-May-2009

Its patent application was rejected by the India patent office in March 2009 which paved the way for Indian companies to legally manufacture and sell their generic version of the drug.

Acclarent Inc Granted Key Patent Covering Balloon Sinuplasty Technologies

MENLO PARK, Calif — 04-May-2009

Acclarent Inc the pioneer of Balloon Sinuplasty technologies for use in the treatment of chronic sinusitis announced today that the US Patent and Trademark Office awarded US Patent Number 7500971 entitled Devices Systems and Methods for Treating Disorders of the Ear Nose and Throat to the company.

Indian drugmakers facing takeover threat says Govt panel

PTI — 04-May-2009

With a large number of drugs going off patent in developed markets like the US and Europe Indian companies are expected to garner a lions share in the segment.

Hetero bags mega chunk of govts anti flu drug deal

Khomba Singh — 5-May-2009

Roche does not hold a patent for Tamiflu in India.

India may ask Kenya to review drug law

Amiti Sen & Sushmi Dey, — 05-May-2009

India is likely to ask Kenya to make amendments in its recent anti counterfeit law to protect Indian pharmaceutical exports.

Takeda Lilly Lead $28.5 Billion in Biotech Deals Report Says

By Lisa Rapaport — 05-May-2009

Drugs with about $24 billion in annual sales are set to lose patent protection this year according to IMS Health Inc the Norwalk Connecticut based research firm.

3 Monsanto DuPont bicker over herbicide tolerant tech

By Steve James — 05-May-2009

This violates Monsantos contract rights and US patents it said in the suit demanding DuPont honor its agreements and respect patented technologies.

NanoLogix Inc to Exhibit at The American Society for Microbiology General Meeting in Philadelphia Announces Two New Patents

Carol Surrena — 05-May-2009

NanoLogix recently received two patents.

Warner Chilcott files new patent infringement lawsuit against Mylan

By Datamonitor staff writer — 05-May-2009

Warner Chilcott a Bermuda based specialty pharmaceutical company has reported that one of its subsidiaries and Mayne Pharma International have filed a second lawsuit against Mylan Pharmaceuticals Inc and Mylan Inc in the District Court of New Jersey for infringement of Maynes US patent which covers Doryx a tetracycline class oral antibiotic.

Biotech Pharma Docket

By Suresh Pillai — 5-May-2009

In the lawsuit filed in July 2008 Norvartis alleges that Roxane infringed Novartis patents covering Famvir a treatment for genital and oral herpes.

Patent law again

Business Standard / New Delhi — 6-May-2009

The revised report of the technical expert group on patent law issues is not very different from the one that the group had to withdraw in 2007.

Global model to give instant patent relief to drug cos

Khomba Singh — 6-May-2009

In what will pave the way for global pharma firms to obtain patents in India easily the United Nations arm on intellectual property is planning to implement a global patenting model that will mandate all member countries including India to grant patent to drugs approved by any two international patent offices.

Pfizer sues Sun Wockhardt Lupin in US

Joe C Mathew / Bangalore — 6-May-2009

Files patent infringement suits against generic versions of best selling nerve drug.

Pharma cos seek retail opening for swine flu drug

Nina Mehta & Khomba Singh, — 6-May-2009

This time though the timely rejection of Roches patent in March has allowed Indian companies to manufacture the product and sell it in India and the countries where Roche does not have patent protection.

Teva says Parkinsons drug patent extended to 2017

Associated Press — 06-May-2009

Drugmaker Teva Pharmaceutical Industries Ltd said Wednesday that one of the patents on Azilect its Parkinsons disease drug has been extended by five years into 2017.

10 Q PAR PHARMACEUTICAL COMPANIES INC

EDGAR Online via COMTEX — 6-May-2009

Certain statements in this Report constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including those concerning managements expectations with respect to future financial performance trends and future events particularly relating to sales of current products and the development approval and introduction of new products.

Wockhardt seeks to sell animal healthcare biz

BS Reporter / Mumbai — 7-May-2009

Wockhardt has one of the largest number of off patent biotech drugs under development in India.

Wi LAN settles patent litigation with Infineon

by Krishna Chaithanya — 07-May-2009

Technology licensing firm Wi LAN Inc said it settled a patent litigation with German chipmaker Infineon Technologies AG for an undisclosed amount.

IL wins patent infringement lawsuit against Diagnostica Stago

By Datamonitor staff writer — 07-May-2009

Instrumentation Laboratory and its parent company Instrumentation Laboratory SpA or IL have reported that the Paris First Level Civil Court has determined that Diagnostica Stago infringed the French counterparts of two European patents licensed exclusively to IL and committed acts of unfair competition due to denigrating advertisements.

China drug maker Zensun eyes Nasdaq listing in 2011

by David Lin — 7-May-2009

Zhou also the chief executive of the firm said that he is in talks with several US pharmaceutical firms to sell the patent of Neuregulin and hopefully to gain the Food and Drug Administrations approval to sell it in the United States.

India pips US UK in IP laws enforcement practices

PTI — 7-May-2009

Indian has been ranked top globally for enforcing intellectual property laws ahead of some of the most advanced nations like the United States and the United Kingdom a survey says.

Indian pharma cos upbeat on biogenerics

Joe C Mathew / Bangalore — 8-May-2009

Even as the substitutability of biogeneric or biosimilar medicines with their original patented counterparts continues to be a matter of debate world over Indian drug companies which have introduced biogeneric products or copies of biotechnology drugs in the country are bullish over the marketing prospects of biogenerics after patents expire in developed markets.

Wyeth sues Sun and its US subsidiary over Protonix drug

Radhieka Pandeya — 8-May-2009

US based Wyeth Pharmaceuticals has sued Mumbai based Sun Pharmaceutical Industries Ltd and its US subsidiary Caraco Pharmaceutical Laboratories Ltd for claiming that their heartburn drug was a generic version of its Protonix drug.

Gucci sues Guess for trademark infringement

Bloomberg / New York — 8-May-2009

Guess Inc was sued by Gucci Groups US unit for trademark infringement over allegations the Los Angeles based apparel company uses a network of wholesale buyers to sell imitations of Guccis best selling designs.

Gene Network Sciences wins new US patent

By Datamonitor staff writer — 08-May-2009

Gene Network Sciences a biotechnology company has received a US patent that covers the companys core model learning and simulation platform REFS.

The war for intellectual property

Latha Jishnu / New Delhi — 9-May-2009

At the Geneva headquarters of the World Intellectual Property Organisation skirmishes between rich nations and the developing world take place with predictable regularity.

Pfizer counters Dr Reddys claims against its anti smoking drug

ET Bureau — 9-May-2009

Pfizer has responded to the post grant opposition filed by Dr Reddys Laboratories against its anti smoking drug Champix.

Cadila expects Rs 100 cr revenue from Policap

PTI,NEW DELHI — 9-May-2009

Ahmedabad based Cadila Pharmaceuticals on Saturday said it is expecting a revenue of Rs 100 crore from the sale of its patented combination drug Policap which it expects to launch by the middle of next month.

The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica

Bavarian Nordic — 9-May-2009

Oxford Biomedicas second attempt to dismiss Bavarian Nordics patent infringement suit in the United States has failed.

India asks Africa to keep doors open to generic drug imports

Addis Ababa (IANS) — 10-May-2009

India has urged African countries not to put barriers on the production and import of generic drugs to the continent especially in the current economic slowdown which could adversely affect the purchasing power of patients.

Drug to curb Diabetes gets patent rights

KAKINADA,TNN — 11-May-2009

Chintaluru village in East Godavari district which had become a popular place in the state for the manufacture of ayurvedic drugs for several decades has earned a rare distinction of getting patent rights for one of its product meant for curbing diabetes.

Pharma cos seek rise in prices of regulated drugs

Khomba Singh & Sushmi Dey — 11-May-2009

The domestic pharma industry is going to seek an upward revision in drug prices by submitting a report on the increase in conversion and packaging costs to the Indian drug price regulator National Pharmaceutical Pricing Authority.

Takeda Q4 profit more than doubles sees growth ahead

by Yumiko Nishitani — 11-May-2009

Joining other drugmakers using acquisitions to stave off earnings declines on patent expirations Takeda bought US biotech firm Millennium Pharmaceuticals and absorbed its part of former US joint venture TAP Pharmaceuticals.

SISVEL Patent Pool for 3G Long Term Evolution LTE

TURIN, Italy — 11-May-2009

Following talks with the stakeholders in the LTE field worldwide that began last year and culminated in April 2009 in a presentation on the benefits of an LTE patent pool delivered to the IPR Plenary Assembly of the Next Generation Mobile Network Alliance today SISVEL issued a call for patents and patent applications that are essential to the LTE standard.

Nanosys Licenses Nanowire Technology to QuantuMDx Group for Next Generation Diagnostic and Sequencing Technologies

PALO ALTO, Calif. and LONDON,PRNewswire — 11-May-2009

Nanosys Inc and QuantuMDx Group today announced that QMDx has signed a non exclusive license agreement with Nanosys for several patents and patent applications related to the use of nanowires for biosensors.

AstraZeneca shares jump on blood thinner drug study

Val Brickates Kennedy — 11-May-2009

Plavix is due to lose patent protection in late 2011.

WIPO clarifies

IST,NEW DELHI — 11-May-2009

This is with reference to the story Global model to give instant patent relief to drug cos which purports to relate to matters under discussion this week in the Patent Cooperation Treaty Working Group at WIPO.

Concert Pharmaceuticals Granted Patents on Deuterium Modified Compounds

LEXINGTON, Mass — 11-May-2009

Concert Pharmaceuticals Inc announced today that its first patents have been granted by the US Patent and Trademark Office.

Lupin settles antidepressant drug litigation with Wyeth

BS Reporter / Mumbai — 12-May-2009

Lupin a generic drug maker has settled all patent litigation with US drug maker Wyeth for Effexor XR capsules the US firms branded anti depressant.

Japans Daiichi says deep in red due to Ranbaxy deal

REUTERS — 12-May-2009

Ranbaxy which derives 80 percent of its sales from abroad has grown by selling cheap copies of branded drugs that have gone off patent and through successful challenges to patents owned by Western companies.

Cancer Patients Challenge the Patenting of a Gene

By JOHN SCHWARTZ — 12-May-2009

On Tuesday Ms Girard 39 who lives in the Austin Tex area filed a lawsuit against Myriad and the Patent Office challenging the decision to grant a patent on a gene to Myriad and companies like it.

Global HIV AIDS initiative to help Indian pharma

PB Jayakumar / Mumbai — 13-May-2009

Global healthcare aid agencies such as UNITAID and Medicines Sans Frontieres have begun to lobby for a patent pool of HIV AIDS drugs.

Satyam Upaid get chance to try out of court settlement

Andy Mukherjee & Jessica Mehroin Irani — 13-May-2009

Satyam Computer Services and UK based mobile solutions company Upaid have been offered a chance to settle their dispute out of court.

OMAX Announces Settlement in Patent Litigation

KENT, Wash — 13-May-2009

OMAX has announced the settlement of the outstanding patent litigation with Flow Corporation along with the cessation of merger negotiations with the company.

ACLU and PUBPAT Challenge Patents on Breast Cancer Genes

ag-IP-news Agency — 13-May-2009

The American Civil Liberties Union and the Public Patent Foundation at Benjamin N Cardozo School of Law filed a lawsuit charging that patents on two human genes associated with breast and ovarian cancer stifle research that could lead to cures and limit womens options regarding their medical care.

Procter & Gamble Wins Patent Infringement Lawsuit for Osteoporosis Therapy Actonel

The Procter & Gamble Company — 13-May-2009

Today the United States Court of Appeals for the Federal Circuit ruled in favor of The Procter & Gamble Company in the patent infringement lawsuit filed by P&G against Teva Pharmaceuticals USA Inc.

Bajaj gets patent for multi spring shock absorbers

PTI — 14-May-2009

Pune based Bajaj Auto today said it has received patent for its invention multi spring vehicle shock absorber used in its motorcycles with which it hopes to counter cheap Chinese copycats.

Indian group to sell copy of Tamiflu

By Andrew Jack in London — 14-May-2009

An Indian pharmaceutical company is gearing up to sell a cheap version of Tamiflu the leading patented antiviral flu drug to emerging economies in a move that will pit intellectual property rights against affordable access to drugs.

Teva wins a round in court in Protonix fight

by Diane Bartz — 14-May-2009

A US appeals court refused on Thursday to give drugmakers Altana AG and Wyeth a preliminary injunction in a patent fight with Teva Pharmaceutical Industries over the ulcer drug Protonix.

Piramal Healthcare launches ActiPatch for pain therapy

PTI — 14-May-2009

Its unique delivery system using patented technology provides a cost effective patient friendly method to reduce soft tissue pain and swelling Piramal said.

Gilead sues Teva in Atripla patent dispute

Associated Press — 14-May-2009

Gilead Sciences Inc said Thursday it is suing Teva Pharmaceuticals Industries Ltd over the drugmakers plans to make a generic version of the blockbuster HIV treatment Atripla.

UCB stock rises as US clears arthritis drug

By Philip Blenkinsop and Antonia van de Velde — 14-May-2009

The news will reduce UCBs reliance on older drugs some of which have lost patent protection and is a vindication of its investment in biotechnology.

Competitive Technologies wins new patent for nanoparticle bone biomaterial

By Staff Reporter — 15-May-2009

Third patent supports first two patents and provides additional claims regarding the preparation of the primary components of bone cement

Indian drug seizure by EU may force firms to change routes

Press Trust Of India / New Delhi — 16-May-2009

Frequent seizure of Indian drug consignments in Europe may force domestic pharmaceutical firms to avoid the European sea routes to destinations in Africa and Latin America Commerce Secretary G K Pillai said.

USPTO Upholds StemCells Patents

PALO ALTO, CA — 16-May-2009

StemCells Inc announced in a press release that the US Patent and Trademark Office has upheld the validity of the remaining two neural stem cell patents which were subjected to reexamination proceedings commenced by Neuralstem Inc.

22 patent department officers transferred

C.H. Unnikrishnan — 18-May-2009

However the transfers have drawn criticism from within the office on the grounds that some of the officials are wrong targets

Calcutta HC Bench admits ITC appeal

Our Bureau — 18-May-2009

ITC had moved the High Court against Godfrey Phillips alleging infringement of copyright and illegal use of a registered trademark of ITC products.

Wealth of microbes

Surinder Sud / New Delhi — 19-May-2009

Many feel that microbes being live forms should not be patented as these are the creations of nature and not of man.

US firm sues Lupin over patent infringement

By fe Bureau — 19-May-2009

Lupin Pharmaceuticals the US subsidiary of Indian pharma major Lupin has been sued by US firm Genzyme.

Madras HC allows TVS to use Bajajs patented tech

T E Narsimhan & Swaraj Baggonkar / Chennai/mumbai — 19-May-2009

The Madras High Court today set aside its earlier order restraining countrys third largest two wheeler manufacturer TVS Motors from manufacturing and marketing vehicles with twin spark technology.

Atherotech receives patent for ApoB measurement for determining heart disease risk

Medicinal Patent News — 19-May-2009

Atherotech Inc developer of the VAP Cholesterol Test has announced it has received a patent on its method to derive and report apolipoprotein B100 using the Vertical Auto Profile technology.

A patent attempt at cultural sensitivity

Leslie D`Monte / New Delhi — 19-May-2009

You may soon get an email with a colour that suits your culture and nerves now that IBM the over $100 billion IT giant which has a current active portfolio of about 26000 patents in the US and over 40000 patents worldwide has applied for a patent to cover a method for customising colour in an email message based on the cultural perspective of each recipient.

Intradigm Announces Issuance of RNA Interference Patent Covering Potent siRNA Sequence

Intradigm Corporation — 19-May-2009

Intradigm Corporation a leading developer of targeted systemic RNA interference therapeutics today announced the issuance of United States patent 7534878 titled Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases.

Bulk drug firms want pollution norms relaxed

B Krishna Mohan / Hyderabad — 19-May-2009

Bulk drug manufacturers see a business opportunity arising when many drug patents expire next year.

DVD patent violation Toshiba sues Moser Baer

Corporate,NEW DELHI — 19-May-2009

Japanese electronics major Toshiba Corporation has filed a lawsuit against optical storage device maker Moser Baer India for alleged DVD patents infringement.

SanDisk Samsung talking over patents

By Anupreeta Das — 19-May-2009

SanDisk Corp continues to negotiate with rival Samsung Electronics Co Ltd over renewing their patent licensing agreement that is set to expire this August SanDisk Chief Executive Eli Harari said.

Resverlogix files two patents on compounds for inflammatory diseases

Medical Patent News — 20-May-2009

Two new patent applications have been filed for novel compounds and their use in regulating inflammatory markers.

Avigen Granted AV411 Patent for Neuropathic Pain

ALAMEDA, CA - — 20-May-2009

Avigen Inc announced in a press release that it has been granted United States Patent No 7534806 entitled Method for Treating Neuropathic Pain and Associated Syndromes.

HC lifts stay against TVS on Flame

Agencies, fe Bureau — 20-May-2009

TVS has been a licencee of patent dated May 25 2000 and Bajaj held the patent as of July 1 2002.

Court grants AstraZeneca preliminary injunction against Apotex in PULMICORT RESPULES patent litigation

Wilmington, DE — 20-May-2009

No trial date for the patent litigation has been set.

GenVault Receives Four Critical US and EU Patent Allowances for Key Biosample Management Technologies

Bret Dash — 20-May-2009

GenVault Corporation is pleased to announce notice of allowance for four key patents in its growing portfolio.

Microsoft ordered to pay $200 million in patent case

by Bill Rigby — 20-May-2009

Microsoft Corp said on Wednesday a Texas federal jury ordered the company to pay Canadian software firm i4i Ltd $200 million in damages for infringing a patent.

Indian pharma players to benefit from generic drugs in US

Nina Mehta — 20-May-2009

According to GPhAs analysis high growth rates were driven by factors such as increase in the overall percentage of generic utilisation and loss of patent protection by several brand name blockbusters such as Pravachol Ambien Fosamax Zoloft and Zocor.

Qualcomm others found to infringe Tessera patents

By Diane Bartz — 20-May-2009

Qualcomm and others infringed Tessera Technologies patents for methods to package semiconductor chips so they are protected inside portable devices the US International Trade Commission said on Wednesday.

Pfizer strikes deals in generics emerging markets

By Lewis Krauskopf — 20-May-2009

The deals announced by Pfizer on Wednesday with Aurobindo Pharma Ltd and Claris Lifesciences Ltd substantially increase Pfizers offerings in medicines that have lost patent protection in markets around the world.

Pfizer to market off patent injectables with Claris

BS Reporter / Ahmedabad — 21-May-2009

Leading pharmaceutical company Pfizer Inc has entered into a partnership with Ahmedabad based Claris Lifesciences Ltd to commercialise sterile injectible drugs that are off patent and have lost exclusivity in the United States Canada Australia New Zealand and Europe.

We do not foresee much implication of Toshiba suit Moser Baer

Our Bureau — 22-May-2009

The Moser Baer India Chairman Mr Deepak Puri said Thursday that he does not foresee much implication of the Toshiba lawsuit and that as per his preliminary reading the infringement allegations pertain to optical media disk drives whereas his company is into manufacturing of optical storage media.

Drug regulator to expand survey on fake medicines

Thomas K. Thomas — 22-May-2009

The Drug Controller General of India plans to widen the survey to map the prevalence of counterfeit drugs in the country with larger number of samples.

Conceptus files patent suit against Hologic

by Anand Basu — 22-May-2009

Conceptus Inc a maker of contraception devices filed a lawsuit against Hologic Inc alleging that the medical diagnostics companys sterilization system will infringe several US patents owned by Conceptus.

Viral Genetics issued patent for novel cancer therapies

Medical Patent News — 22-May-2009

Biotechnology firm Viral Genetics Inc has been issued a patent for novel cancer therapies.

Amsterdam authorities release Ind Swift exports

P.T. Jyothi Datta — 23-May-2009

Diplomacy and legal channels have helped the Chandigarh based Ind Swift get its export consignment released from customs authorities in Amsterdam about six months after it was seized.

Epistar Soars to 16 Month High After Winning Patent Appeal

By Weiyi Lim — 25-May-2009

Epistar Corp. jumped to its highest in 16 months after winning its appeal in a patent infringement case in which Royal Philips Electronics NV s Lumileds unit was trying to block the Taiwanese companys chips from US markets.

AAU for patent of mechanised production of basundi

Shubhlakshmi Shukla — 25-May-2009

Anand Agriculture University authorities plan to patent the mechanised production of basundi.

Television brands turn tangible

Shuchi Bansal / New Delhi — 25-May-2009

Piracy that is infringement of IPR is our other challenge in the market place adds Jibi George.

Fake drugs

Sudhir Chowdhary — 25-May-2009

Recently enforcement officials of the European Union seized a consignment of fake drugs which included not just Viagra but also other serious medicines such as anti cholesterols anti osteoporosis and anti hypertensives.

Supplies delay Ranbaxy may take $50 mn hit

Radhieka Pandeya — 26-May-2009

This follows from a manufacturing agreement that was part of a bigger patent infringement settlement between Ranbaxy and AstraZeneca in April 2008.

Advaxis Receives US Patent and Trademark Office Approval on Act A Protein Patent Pending Rights

NORTH BRUNSWICK, N.J — 26-May-2009

The US Patent and Trademark office approved Advaxis Incorporated patent application Compositions and Methods for Enhancing the Immunogenicity of Antigens Application US20050118184 A1.

Ranbaxy shares spurt 20% on BSE

BS Reporter / Mumbai — 26-May-2009

Daiichi Sankyo has strength in developing patented products for lifestyle diseases such as hypertension diabetes mellitus autoimmune disorders hyperlipidemia or atherosclerosis and bacterial infections

Samsung may win dual SIM patent case

C.H. Unnikrishnan — 26-May-2009

The Chennai patent office had in January 2008 granted a patent to Ramkumar for mobile phones with the capability of using two SIM cards.

US District Court Orders Hynix to Post Security for Infringing Rambus Patents

LOS ALTOS, Calif — 26-May-2009

Rambus Inc today announced that the US District Court for the Northern District of California has ordered Hynix Semiconductor to secure the judgment amount of approximately $397 million through a combination of a bond and a lien on a Hynix property in South Korea for infringing Rambus patents.

Medicis Announces New Patents for SOLODYN

SCOTTSDALE, ARIZ — 26-May-2009

Medicis announced in a Tuesday press release that the United States Patent and Trademark Office has advised the company that US Patent No 7541347 directed to the use of SOLODYN in 90mg tablet form will issue on June 2 2009 and that US Patent No 7544373 directed to SOLODYN in 90mg tablet form will issue on June 9 2009.

Bajaj Auto to move SC on TVS issue

T E Narasimhan & Swaraj Baggonkar / Chennai/mumbai — 27-May-2009

The High Courts ruling had come as a big relief for TVS Motor which was restricted by an earlier verdict from the same court that did not allow the company to produce or sell the disputed motorcycle Flame a 125cc bike sporting twin spark plugs as Bajaj Auto held patent rights for the same.

Your genes Not on your life

Latha Jishnu / New Delhi — 27-May-2009

In a first of its kind a motley group of interests from cancer patients and civil liberties activists to clinic pathologists and researchers have challenged the gene patents granted to a US biopharmaceutical company.

New US patent issued for Limbrel in osteoarthritis

Medical Patent News — 27-May-2009

Primus Pharmaceuticals Inc has announced the issuance of a new composition of matter patent for Limbrel the first prescription medical food product to safely meet the distinctive nutritional requirements of patients with osteoarthritis.

US reexamines Mercks Singulair patent

By Ransdell Pierson — 28-May-2009

Merck & Co said on Thursday the US Patent Office is reexamining the patent on its biggest product $4.5 billion a year asthma treatment Singulair.

Osteologix Receives Key US Patent Allowance for Novel Osteoporosis Drug

GLEN ALLEN, Va. BUSINESS WIRE — 28-May-2009

Osteologix Inc today announced that is has received a Notice of Allowance from the US Patent and Trademark Office for its US Patent Application Number 11269289 titled Water Soluble Strontium Salts for Use in Treatment of Cartilage and or Bone Conditions reporting allowance of claims covering the treatment of osteoporosis and related bone conditions using NB S101 the Companys lead osteoporosis drug candidate.

Indian court uses blog reference to solve TVS Bajaj patent issue

Soumya Shanker & Malathi Nayak — 29-May-2009

Ablog post by a student was instrumental in TVS Motor Co Ltds victory over Bajaj Auto Ltd in their recent legal skirmish over patent infringement issues setting a precedent for the use of blog content by the countrys courts.

Citigroup upgrades Sanofi Aventis to buy

By Sarah Turner — 29-May-2009

They noted that data at the upcoming ASCO meeting could be significant and that patent challenges are not insurmountable.

Unigen\'s First Site Directed Bone Growth Patent Issues

BOONTON, NJ — 30-May-2009

Unigene Laboratories Inc reported that its first patent covering its Site Directed Bone Growth technology has been issued a press release by Unigene stated.

Venus Remedies gets patent for anti pneumonia drug

Corporate,NEW DELHI — 01-Jun-2009

Pharmaceutical firm Venus Remedies on Monday said it has received a patent right in South Korea for its drug which is used for the treatment pneumonia.

Supreme Court to Review Business Method Patents

By Michael Orey — 01-Jun-2009

The high court will decide if such things as financial products and Internet commerce systems deserve intellectual property protection

Medtronic announces appeal decision in patent case with DePuy Spine

Medical Patent News — 01-Jun-2009

Medtronic Inc has announced results from a Federal Circuit Court review of a December 2007 patent infringement verdict regarding the Vertex line of multiaxial screws which are no longer on the market.

Top court to hear business method patent case

by Diane Bartz — 1-Jun-2009

The Supreme Court said on Monday it would hear the Bilski patent case which would tell high tech and software companies how far they could go in patenting software financial strategies and other abstract processes.

First Product Patent Granted to Venus Remedies in South Korea

ag-IP-news ,HARYANA — 1-Jun-2009

The Korean Intellectual Property Office has granted a Product Patent to one of the research products of Venus used for the treatment of pneumonia.

Sanofi has winning cancer drug but short patent

By Ben Hirschler — 1-Jun-2009

Sanofi Aventis may have bagged a winning cancer drug when it agreed to buy privately held BiPar Sciences for up to $500 million in April but a short patent could limit the French groups scope to cash in on sales.

BASF Sues DuPont for Patent Infringement

Mark Stephenson, BASF Corporation — 1-Jun-2009

BASF Plant Science GmbH seeks an injunction and damages against DuPont and its subsidiary Pioneer Hi Bred International for this unlawful use of BASFs patented technology.

GraphOn Announces Settlement Resolving Legal Dispute with Google

SANTA CRUZ, Calif — 1-Jun-2009

GraphOn Corporation today announced a settlement that resolves the legal dispute between GraphOn and Google Inc.

Microsoft Lucent battle in huge patent case

by Diane Bartz — 02-Jun-2009

Microsoft Corp argued before an appeals court on Tuesday that its Outlook calendar date picker tool did not infringe an Alcatel Lucent patent and asked for a $358 million jury verdict to be overturned.

Zydus Teva end patent disputes

Nina Mehta — 2-Jun-2009

Ahmedabad based ZydusCadila and Israeli generic major Teva have settled their patent disputes over active pharmaceutical ingredients used to make generic versions of GlaxoSmithKlines heart drug and Johnson & Johnsons anti psychotic drug.

InterDigital Nokia finish patent fight hearing

By Diane Bartz — 02-Jun-2009

Wireless technology firm InterDigital and the worlds top cellphone maker Nokia wrapped up hearings on Tuesday at the International Trade Commission in a battle over four patents said InterDigital spokesman Jack Indekeu.

They opposed Novartis on Glivec but now seek patent

Priyanka Golikeri — 02-Jun-2009

If you thought only multinational drugmakers were monopolistic and fought fiercely to secure patents for new forms of known molecules you are so wrong.

Nvidia US patent office rejects Rambus claims

SANTA CLARA, Calif. — 2-Jun-2009

Nvidia Corp said Tuesday the US Patent and Trademark Office has rejected 41 claims against the chip maker brought by Rambus Inc a company that licenses semiconductor technology.

Top court to hear business method patent case

By Diane Bartz — 2-Jun-2009

The Supreme Court said on Monday that it would hear the Bilski patent case which will tell high tech and software companies how far they can go in patenting software financial strategies and other abstract processes.

Denial of patent to Gilead beneficial for Indian firms

BS Reporter / Mumbai — 3-Jun-2009

The Indian Patent Offices decision to reject a product patent for Gilead Sciences Incs adefovir dipivoxil variant a new form of its Hepatitis B drug Hepsera has come as a boon for Indian copy cat drug makers such as Ranbaxy Cipla and Sun Pharma.

Vical Announces Issuance of US Patent for Universal Influenza Vaccine Approach

SAN DIEGO — 03-Jun-2009

Vical Incorporated announced in a Wednesday press release the issuance of US Patent No 7537768 covering the use of influenza virus gene sequences in a universal vaccine that could provide protection against circulating seasonal strains as well as emerging pandemic strains of influenza viruses.

Echostar To Pay TiVo Another $103 Million In Patent Case

By Rory Maher — 03-Jun-2009

In the latest chaper of a patent infringement case on its DVR technology that dates back to 2004 TiVo was awarded an additional $103 million by the United States District Court in Texas after a failed appeal by Echostar.

ARIAD Announces Updates On NF kB Patent Appeals

CAMBRIDGE, MASS — 03-Jun-2009

ARIAD Pharmaceuticals Inc and its co plaintiffs announced that they are filing a petition for an en banc rehearing of an April decision by the US Court of Appeals for the Federal Circuit in its patent infringement case against Eli Lilly and Company.

Rallis India seeks patent for three new biomolecules

C.H. Unnikrishnan — 3-Jun-2009

In a move that could help extend its presence in the global crop protection market Rallis India Ltd a Tata group agrochemical company has developed at least three new biomolecules for use in fungicides

Novocell Obtains US Patent for Drug Screening Human Embryonic Cell Derived Endoderm Cells

SAN DIEGO — 3-Jun-2009

Novocell Inc a stem cell engineering company today announced that it has received US Patent No 7541185 with method claims covering the use of endoderm cells derived from human embryonic stem cells for drug discovery.

Almirall gets FDA approval for migraine drug

by Tracy Rucinski — 3-Jun-2009

Almiralls patent on Almotriptan in the United States has been extended to November 2015.

Mylan Again Calls for an End to Authorized Generics During 180 Day Exclusivity Period

PITTSBURGH — 3-Jun-2009

The committees hearing Pay to Delay Are Patent Settlements That Delay Generic Drug Market Entry Anticompetitive was called to gather information about the effects of settlements.

Vical Receives US Patent For Universal Influenza Vaccine Approach

By Staff Reporter — 3-Jun-2009

Vical has received US Patent No 7537768 covering the use of influenza virus gene sequences in a universal vaccine that could provide protection against circulating seasonal strains as well as emerging pandemic strains of influenza viruses.

Agilent wins patent fight with Affymetrix

by Maggie Fox and Diane Bartz — 04-Jun-2009

A US patent appeals court ruled on Thursday in favor of Agilent Technologies which had been involved in a patent fight with Affymetrix Inc.

German market for Indian drugs shrinks

C.H. Unnikrishnan — 4-Jun-2009

Orchid is currently focusing on products that enjoy patent protection but once they go off patent the company will be affected.

J&J upbeat on drugs business cites new medicines

By Ransdell Pierson — 04-Jun-2009

J&J whose first quarter earnings fell slightly due to generic competition for its Risperdal schizophrenia drug and waning demand for its anemia medicines is now under even greater pressure due to the expiration in March of the US patent on its $2.5 billion a year Topamax epilepsy drug.

Crash boom bax the rise & fall of Ranbaxy

Radhieka Pandeya — 4-Jun-2009

And the Ranbaxy story is as characteristic of what happens in most family owned and run businesses in India as it is of the Indian pharma industrys evolution from makers of cheap illegal copycat drugs and suppliers of raw material to respected manufacturers of generics legal copies of off patent drugs and ultimately to research driven firms.

Takeda to delay European application for key drug

By Yumiko Nishitani — 04-Jun-2009

Actos accounts for roughly a quarter of Takedas revenues and will lose US patent protection in 2011.

Curbs on Amul Vadilal to use American Dry Fruits trade name for their products

Virendra Pandit — 5-Jun-2009

About Vadilals argument that the plaintiff had not obtained registration of trademark till date Mr Sheikh observed that evidence proved that the company had obtained proprietary rights to use trade name and it cannot be termed as pirator of trade name.

Neuralstem Receives Patent Allowance for Compounds That Promote Neurogenesis

ROCKVILLE, Md.(BUSINESS WIRE) — 05-Jun-2009

Neuralstem Inc announced today it received a notice of allowance from the US Patent and Trademark Office for a patent on four new chemical entities that boost the generation of new neurons.

Playing defense on patents

By Kenneth Klee — 5-Jun-2009

The idea of developing patents as a kind of asset class is still new and controversial.

Vizio files TV patent suit against LG in US

by Rhee So-eui — 07-Jun-2009

US TV brand Vizio Inc has filed a patent infringement suit against South Koreas LG Electronics Inc seeking an injunction to ban LG from importing and selling certain TVs in the United States.

16 out of 17 drug consignment seizures in the Dutch were from India

P.T. Jyothi Datta — 8-Jun-2009

There were 17 incidents of drug seizure last year in the Netherlands on the grounds of patent infringement and 16 of them were Indian medicine exports says Health Action International a Dutch network that works on increasing access to medicines.

Row over generic drugs intensifies after seizure in Germany

Khomba Singh — 8-Jun-2009

German authorities last month seized a large consignment of antibiotic Amoxicillin made by Chennai based Medopharm during transit at Frankfurt over alleged trademark infringement in the latest incident of European Union nations interfering in legitimate trade of generic medicine.

IITs to market patents with help from investment firms

Kalpana Pathak & Shivani Shinde / Mumbai — 8-Jun-2009

Sitting on a pool of close to 900 patents the Indian Institutes of Technology are for the first time planning to monetise these intellectual properties by exploring tie ups with firms that invest in inventions.

Pharma firms continue to face patent violation charges in Europe

Rupali Mukherjee — 8-Jun-2009

Even after India raised concerns with EU troubles of generic companies which export drugs to developing countries through Europe are far from over as seizures by Dutch customs still continue.

Bulk pharma imports to go under DCGI scanner

Radhieka Pandeya — 9-Jun-2009

Regulator acts after evidence of attempts to evade import duty and bring in spurious drugs to Mumbai Chennai

Purdue KV settle OxyContin drug patent dispute

Edwin Chan — 09-Jun-2009

Purdue Pharma LP has settled a patent dispute over OxyContin with KV Pharmaceutical agreeing to let KV sell generic versions of the popular painkiller on a limited basis in the United States.

Impliant granted two new US patents successfully defends European patent

Medical Patent News — 09-Jun-2009

Impliant Inc a developer of novel spine arthroplasty alternatives to fusion surgery today announced that the European Patent Office has confirmed the validity of one of its key patents following an Opposition by Archus Orthopedics Inc that concluded with oral proceedings on May 12 2009 in Munich Germany.

India can become a global pharma innovation hub experts say

PTI,WASHINGTON — 09-Jun-2009

William Chin Vice President Discovery Research & Clinical Investigation Eli Lilly felt the pharma industry is under siege with flood of patent expiries higher safety hurdles and pricing pressure.

New Mashelkar report has well little new

Priyanka Golikeri — 10-Jun-2009

The Mashelkar committee report on pharmaceutical and micro organism patents has reared its controversial head again.

Pfizer exec reinforces companys generic drug plancos

Associated Press — 10-Jun-2009

Dave Simmons Pfizers president of established products told analysts at Goldman Sachs Healthcare Conference in New York that part of the companys strategy includes focusing on the off patent marketplace.

Access Pharmaceuticals Receives Two US Patents For MuGard

By Staff Reporter — 10-Jun-2009

Access Pharmaceuticals has announced that the company has received issue notifications from the US Patent and Trademark Office that two US patents relating to MuGard the companys approved oral rinse product for the management of mucositis will issue in June as US Patent numbers 7544348 and 7547433.

BUY OR SELL Daiichi Sankyo to rebound from rocky Ranbaxy ride

By Yumiko Nishitani — 10-Jun-2009

Analysts reckon Daiichi Sankyo is the top long term pick among Japans drug stocks with Takeda Pharmaceutical and Astellas Pharma more exposed to the impact of patent expirations on key drugs.

Vitro Obtains US Adult Stem Cell Patent

By Staff Reporter — 10-Jun-2009

Vitro declared that it has received US Patent number 7527971 entitled Generation and Differentiation of Adult Stem Cells.

Solvay challenged in US on male hormone therapy

Aaron Gray-Block — 10-Jun-2009

Solvay said Perrigo Israels application with the US Food and Drug Administration challenged a United States patent relating to its treatment Androgel which runs through the next decade.

Collegium Pharmaceutical Inc Announces Submission of a Request for Special Protocol Assessment to FDA for Pivotal Trial for Tamper Resistant Extended Release Opioid COL 003

CUMBERLAND, R.I — 10-Jun-2009

COL 003 is a tamper resistant formulation of extended release oxycodone that incorporates the Companys patented DETERx™ delivery technology.

India to prepare case on drug confiscations at European ports

Amiti Sen & Deepshikha Sikarwar — 11-Jun-2009

India is preparing its case on the repeated seizures at European ports of its consignments containing off patent drugs meant for other developing nations before it moves the European Union and the World Trade Organisation according to a commerce ministry official.

Watson Files ANDA For Generic Mucinex D

By Staff Reporter — 11-Jun-2009

Watson has filed an Abbreviated New Drug Application with the FDA seeking approval to market its guaifenesin pseudoephedrine HCI extended release 600mg 60mg and 1200mg 120mg tablets prior to the expiration of patents owned by Reckitt Benckiser.

EU seeks greater commitment on IPR

Radhieka Pandeya and Asit Ranjan Mishra — 12-Jun-2009

The EU is also demanding that India should extend the monopoly accorded by a patent for up to 5 additional years in order to compensate for the time required for the marketing approval of a medicinal product

Take strong action against fake drugs India to China

BS Reporter — 12-Jun-2009

India has asked China to take strong action against Chinese pharma manufacturers who are exporting fake drugs under Made in India label.

Satoris Receives Patent Allowance for Use of Plasma Biomarkers in Alzheimers Disease Detection

PRWeb — 12-Jun-2009

Patent acknowledges utility of blood biomarkers in diagnosing Alzheimers.

RPT Pfizer eyes deals to raise emerging markets presence

By John Irish — 14-Jun-2009

Pfizer which posted $48 billion in revenue last year faces severe sales declines in the coming years from patent expirations to its own products including its blockbuster Lipitor cholesterol treatment.

Apex Court overrules HC order favouring Gufic Ltd

15-Jun-2009

The Supreme Court today set aside the Delhi high court order which had allowed the Indian company, Gufic Ltd, to use the name ‘Cliniq’ in its skin care product. The bench headed by Justice B Sudershan Reddy vacated the order on the appeal of Clinique Laboratories against the high court order.

Sharp wins US patent fight with Samsung

by Diane Bartz — 15-Jun-2009

Japanese electronics maker Sharp Corp has won a fight with South Koreas Samsung Electronics Co over patented technology for liquid crystal displays according to an administrative law judges ruling from the US International Trade Commission.

US Patent Office Provides Re Examination Office Action for US Patent No 5735844

press release — 15-Jun-2009

Palomar also added 27 new claims to the 844 patent and the PTO confirmed these new claims as patentable.

Report on pharma innovation to be released at USIBC meet

Lalit K Jha — 16-Jun-2009

A report identifying a broad range of potential benefits of incremental pharmaceutical innovation for India would be released later this week by the US India Business Council (USIBC). Commissioned by the USIBC and Coalition for Healthy India (CHI), and funded by the US Chamber of Commerce\'s Innovation, Development and Employment Alliance, the report \'The Value of Incremental Pharmaceutical Innovation: Benefits for Indian Patients and Indian Business\' was produced by White & Case LLP and Dua Consulting.

Martek European regulator upholds patent with narrower claims

by Jennifer Robin Raj in Bangalore — 16-Jun-2009

Martek Biosciences Corp a health and nutritional supplements maker said the European Patent Office upheld its arachidonic patent granted in 2007 but with narrower claims.

DuPont fires back at Monsantos patent lawsuit

By ERNEST SCHEYDER — 16-Jun-2009

DuPont fired back at Monsantos patent lawsuit Tuesday telling a federal court it did not err in combining its genetically modified soybeans with Monsantos herbicide product.

MicroFluidic Systems Receives Patent for Method to Selectively Process Different Biological Cell Types for Analysis.

M. Allen Northrup,MicroFluidic Systems — 16-Jun-2009

Microfluidic Systems a privately held company announced today that they received patent number 7541166 entitled Sonication to Selectively Lyse Different Cell Types.

India losing 2,000 patents every year: Jairam Ramesh

17-Jun-2009

India is losing about 2,000 patents every year in the US and Europe on traditional formulations as the knowledge on these is not documented, said union minister of state for environment and forests Jairam Ramesh

Drug industry expects final EU probe report July 8

By Ben Hirschler — 17-Jun-2009

There could also be a couple of positive recommendations he added such as backing for a common European patent applicable in all EU countries and the introduction of a specialised patent litigation system.

US firm files patent infringement case against Ranbaxy

18-Jun-2009

Medicis Pharmaceutical Corporation, a US-based skincare drug manufacturer, has filed a lawsuit against Daiichi Sankyo-owned Ranbaxy Pharmaceuticals for alleged infringement of its patent on Solodyn, a minocycline hydrochloride extended-release tablet used to treat acne.

Sanofi says US court ruled against it on Eloxatin

by Deena Beasley — 18-Jun-2009

Sanofi Aventi SA on Thursday said a US court ruled against the French pharmaceutical company by granting summary judgment motions brought by generic drugmakers in patent litigation over the cancer drug Eloxatin.

Novartiss Sandoz Sued by J&J Over Contraceptive Pill Patent

By Susan Decker — 19-Jun-2009

J&Js Ortho McNeil Janssen Pharmaceuticals unit wants a federal judge to prevent Sandoz from getting regulatory approval until a patent expires in 2019.

Big Pharma comes calling to India

P B Jayakumar / Mumbai — 19-Jun-2009

Thanks to the favourable patent regime in India till 2005 his team of scientists and he worked in small research and development laboratories in Hyderabad and successfully reverse engineered patented drugs of multinationals to make low cost generic drugs.

Pfizer Wins Canadian Patent Protection for Viagra

By Joe Schneider — 19-Jun-2009

Pfizer Inc the worlds biggest drugmaker has a valid Canadian patent on the impotence pill Viagra a federal judge ruled dismissing a bid by Novopharm Ltd to introduce a generic version of the drug.

Generic cos board biosimilars wagon

Priyanka Golikeri — 19-Jun-2009

Move over off patent chemical drugs.

Elder signs deal with US co for human trials of anti cancer drug

Sushmi Dey — 19-Jun-2009

The company follows the non infringing business model of either in licensing products of innovator companies or manufacturing off patented drugs.

Madras HC stays customs order on dual SIM phones

C.H. Unnikrishnan — 19-Jun-2009

The leading parties in the legal case were Samsung India Electronics Ltd and Hansum India Ltd which were arguing against Madurai based engineer S. Ramkumar who holds a patent for dual SIM phones in India.

Prices of essential drugs may drop by 30 70%

Gireesh Chandra Prasad & Sushmi Dey — 19-Jun-2009

The government is likely to revise the plan to have a comprehensive new drug policy which would extend a milder form of price control to 354 essential medicines.

Advinus seeks approval for trials of new diabetes molecule

Our Bureau — 19-Jun-2009

Advinus Therapeutics has filed its first investigational new drug application with the Drugs Controller General of India to start clinical trials on humans for a new diabetes type 2 molecule.

Cannabis Science To File Patent For Cannabis Processing and Drug Delivery Systems

By Staff Reporter — 19-Jun-2009

Cannabis Science has announced that patent filings are expected for two of its key innovations.

Chavez may end patents on medicine in Venezuela

by Frank Jack Daniel — 21-Jun-2009

President Hugo Chavez has vowed to shake up the rules governing intellectual property rights on medicines and other products in Venezuela the socialists latest move against the private sector.

Pfizer charges Sun with another patent violation

Nina Mehta — 22-Jun-2009

A legal battle between US pharma giant Pfizer and Indian company Sun Pharmaceutical has escalated with the worlds largest maker of medicines alleging in court filings that in addition to the original patent that it claims Sun violated it infringed another patent when it sought approval for its generic version of Lyrica a blockbuster drug used to treat seizures.

Pharma sector told to focus on improving HR quality

22-Jun-2009

Finishing schools in the information technology industry are creating more awareness towards the Intellectual Property Rights environment and the pharma industry should emulate it said panellists at the Bangalore Bio 2009 here Saturday.

i2india hopes to bridge industry academia gap

L.N. Revathy — 22-Jun-2009

i2india an IPR Intellectual Property Rights commercialisation and investment company is striving to bridge the gap between the industry and academia by providing the nucleus for growing such companies in India.

Intellectual property issues in school franchising

Anuradha Salhotra — 22-Jun-2009

Emergence of school franchises bodes well for the several thousand students all over the country who scramble to study in well known schools.

A Scholar Activist Challenges US Patent Law

By Michael Orey — 22-Jun-2009

John Duffy wants courts to rethink what can be patented and how to calculate damages.

ION sues WesternGeco for patent infringement

by Arup Roychoudhury in Bangalore — 22-Jun-2009

ION Geophysical Corp said it filed a patent infringement lawsuit against privately held WesternGeco LLC over technology related to steering devices and control systems for marine seismic streamers.

Ericsson signs LTE patent deals

by Sven Nordenstam — 22-Jun-2009

Swedish telecom equipment maker Ericsson has signed its first license agreements for LTE technology patents allowing other companies to use the technology an Ericsson official said on Monday.

U.S. Patent Infringement Lawsuit Filed by Aperio Technologies Inc.

David A. Leinwand — 23-Jun-2009

A U.S. patent infringement lawsuit was filed on June 10 2009 against Hamamatsu Photonics K.K. Hamamatsu Corporation and Olympus America Inc.

UNITAID to meet Indian drug manufacturers

Press Trust of India / New Delhi — 23-Jun-2009

The UNITAID patent pool initiative seeks to ensure that patents do not prevent the production of generic ARVs particularly the development and production of fixed dose combinations and AIDS medicines for children.

A global patenting model for India

PK Vasudeva — 24-Jun-2009

The United Nations arm on intellectual property is planning to implement a global patenting model which will pave the way for global firms to obtain patents in India easily.

CEL SCI Files Patent Application For LEAPS Immune Therapy Drugs

By Staff Reporter — 24-Jun-2009

CEL SCI has filed a provisional US patent application covering its LEAPS immune therapy drugs vaccines.

Actavis Launches Finasteride As Patent Expires In France

By Staff Reporter — 24-Jun-2009

Actavis has launched Finasteride in France just one day before the patent expired.

DRDO records jump in patents filing

General — 24-Jun-2009

The Defence Research and Development Organisation DRDO has registered a substantial jump in filing patents and set a 10 per cent growth target for the current year.

Vicious sting in the tail of FTAs

Latha Jishnu / New Delhi — 24-Jun-2009

Because FTAs have more stringent provisions than those mandated by the World Trade Organisation under the TRIPS for protecting the intellectual property rights IPRs of the developed world such agreements can directly impact access to affordable medicines

Drug patent pool proposal gets a push

P. T. Jyothi Datta — 25-Jun-2009

Concerned over the changing intellectual property environment where medicines are getting patented across the world UNITAID had proposed a patent pool to make drugs more accessible.

Sharp may appeal ruling in patent row with Samsung

by Mayumi Negishi in TOKYO and Diane Bartz in WASHINGTON — 25-Jun-2009

Sharp Corp said it may appeal a ruling by a US trade panel that said the Japanese electronics maker had violated an LCD patent held by South Koreas Samsung Electronics.

Japan approves first generic biotech drug

Reuters — 25-Jun-2009

Biosimilars are viewed as a promising new market given the pent up demand for cheaper versions of extremely expensive biotech drugs some of which are coming to the end of their patent life.

Irish court invalidates patent on Glaxos top drug

by Ben Hirschler — 26-Jun-2009

An Irish court has ruled that a key patent protecting GlaxoSmithKlines biggest selling medicine is invalid the British based drugmaker said on Friday.

The Real Reason Big Pharma Mergers Are Wise

Charles Farkas and Tim van Biesen — 26-Jun-2009

Thats important because of the looming patent cliff as blockbuster drugs lose their patent protection faster than new ones can emerge.

Takeda fails to get US approval for diabetes drug

by Leika Kihara — 27-Jun-2009

Takeda Pharmaceutical Japans largest drugmaker said on Saturday a key diabetes drug had failed to get approval from U.S. regulators who had asked for additional safety tests a process the company predicts could take at least two years.

Takeda shares down on diabetes drug setback

by Mayumi Negishi — 28-Jun-2009

Actos patent expires in 2011.

Now Kinnauri shawl to get a patent

Pratibha Chauhan — 28-Jun-2009

After the Kullu shawl Kangra tea and the Chamba rumaal it is now the turn of the Kinnauri shawl to acquire a patent and a GI Geographical Indication stamp a hallmark for quality and authenticity.

Glenmark banks on new drugs to recover losses

C.H. Unnikrishnan — 29-Jun-2009

While the generics or off patent drug business of Glenmark has been growing it had to write off in the March quarter at least Rs130 crore on account of stock withdrawals following delayed US market approvals and Rs117 crore for price erosion of distributor stock after the expiry of US market exclusivity of its anti epilepsy drug oxcarbazapine.

India needs a brilliant wave of entrepreneurs

ET Bureau — 29-Jun-2009

Koshy has been working towards his dream for seven years now and had applied for a patent as well.

US study wants India to allow frivolous patenting

Priyanka Golikeri — 29-Jun-2009

Multinational drug makers seem hell bent upon forcing the government to alter the patent regulations in their favour.

14 years of data exclusivity is crazy

Nina Mehta — 29-Jun-2009

Founder of the generic trade association in the US William Haddad chairman and CEO of Biogenerics initiated and negotiated the Drug Price Competition and Patent Restoration Act Hatch Waxman.

Make it a criminal violation Japan

Priyanka Golikeri — 29-Jun-2009

But a bigger demand from Japan is stringent enforcement of intellectual property laws including criminal procedures against patent infringement.

Indian firm sues South Africa after losing AIDS drug contract

AGENCIES,JOHANNESBURG — 29-Jun-2009

An Indian manufacturer of drugs to treat HIV AIDS is suing the South African government after failing to clinch a $400 million tender South African media reported on Monday.

Jury returns $1.67B drug verdict against Abbott

by Ransdell Pierson and Jonathan Spicer — 29-Jun-2009

A U.S. federal jury returned a $1.67 billion verdict against Abbott Laboratories in a patent suit brought by Johnson & Johnson related to arthritis treatments the drug companies said on Monday.

Aurobindo Pharma sues SA govt over AIDS drug bids

BV Mahalakshmi — 30-Jun-2009

The balance was awarded to the patent holding companies.

Sun Pharma Inclement weather

Shobhana Subramanian / Mumbai — 30-Jun-2009

Sales of Para IV products those abbreviated new drug applications that face a patent challenge fetch a larger amount estimated at $150 million.

Biocon Mylan team up for global biogenerics play

C Chitti Pantulu — 30-Jun-2009

An initial list of products has been identified that includes a basket of biologics that will go off patent by 2016 he said.

Collegium Pharmaceutical Announces the Sale of AllerNaze to Lupin

CUMBERLAND, R.I. — 30-Jun-2009

COL 003 is a tamper resistant formulation of extended release oxycodone that utilizes the Companys patented DETERx™ delivery technology.

Abbott Loses Drug Patent Suit

By THE ASSOCIATED PRESS — 30-Jun-2009

A unit of Johnson & Johnson said Monday that a jury has ordered Abbott Laboratories to pay $1.67 billion in a patent infringement suit over rheumatoid arthritis drugs.

U.S. group questions AstraZenecas Crestor patent

by Diane Bartz — 1-Jul-2009

A U.S. patent research group says it has uncovered evidence that could be used to declare AstraZeneca Plcs patent for its cholesterol fighter Crestor invalid.

LG and Hitachi Settle Patent Fights Over TVs and Servers

By Susan Decker — 2-Jul-2009

Hitachi Ltd Japans largest electronics maker and South Koreas LG Electronics Inc. have settled their U.S. patent disputes over plasma televisions computer servers and car radio and navigation systems.

Pharma not IT is Indias next big thing

Pallavi Aiyar — 2-Jul-2009

Indian companies know they cant survive on the generic model alone forever. So once they have a serious self interest in protecting patents that will be the tipping point.

Dish wins stay in TiVo patent fight

The Associated Press — 02-Jul-2009

Dish Network satellite TV customers can keep using their digital video recorders while a court battle continues with TiVo Inc.

Bayer Files Lawsuit Against Teva

By Staff Reporter — 02-Jul-2009

Bayer Schering and Bayer HealthCare together with Schering have filed a patent infringement lawsuit in the US Federal Court in the District of Delaware against Teva Pharmaceuticals and Teva Pharmaceutical Industries.

Glenmark gets first to file status for 3 drugs in US

Nina Mehta — 3-Jul-2009

First to file status typically recognises a generic company as being the first to file a para IV application challenging a particular patent and seeking to manufacture generic versions of a drug which at present does not have generic competition.

Biotechnology can be the next big driver for the pharma sector

Pillman — 03-Jul-2009

The authors of the study noted The fact that a biotech product will assume Lipitors crown in 2012 after the cholesterol lowering drug phenomenon goes off patent is indicative of the increasing dominance of biotech products and specifically cancer antibodies.

Ayurveda drug for cancer Experts

Minati Singha — 03-Jul-2009

Lavekar said they have the credit of obtaining as many as 22 patents including one international patent right on drugs.

Bitter Pill Novartis patent plea for cancer drug Gilvec rejected

REUTERS — 05-Jul-2009

Novartis Indias application to patent its cancer drug Glivec has been rejected by the Intellectual Property Appellate Board IPAB.

Emami plans to make 50 Ayurvedic drugs from Zandu stable

Aveek Datta — 6-Jul-2009

The company had even tried to secure patent for some of its formulations but couldnt because of unfriendly patent offices Bhatt added.

Novartis may challenge verdict denying patent for cancer drug

C.H. Unnikrishnan — 6-Jul-2009

The Indian tribunal had cited non compatibility with domestic patent laws and unaffordable pricing as reasons

Fake drugs reach Kenya now

Amiti Sen — 6-Jul-2009

Africa is an important market for Indian drug producers as it accounts for over 15% of Indias total generic off patent drugs exports worth Rs 30000 crore annually.

Precision BioSciences Issues Update Regarding Recent U.S. Patent Office Action Concerning Cellectis Patents

RESEARCH TRIANGLE PARK, N.C (BUSINESS WIRE) — 06-Jul-2009

The United States Patent and Trademark Office is reexamining two currently issued U.S. patents owned by the Institut Pasteur and the Universite Pierre et Marie Curie and licensed to Cellectis SA.

Takeda Sues Torrent to Stop Generic Copy of Actos Diabetes Pill

By Susan Decker — 06-Jul-2009

Takeda Pharmaceutical Co. sued Indias Torrent Pharmaceuticals Ltd. to prevent it from selling a copy of the Actos diabetes pill in the U.S. until 2016.

A Prescription for Saving Big Drugmakers

By Mark Schneider — 6-Jul-2009

But concerns over patent expirations of blockbuster drugs generic drug competition regulatory problems and a lack of promising new products are giving investors caution.

Dor BioPharma Receives European Patent For Drug Delivery Technology

By Staff Reporter — 8-Jul-2009

Dor BioPharma has received a European patent for its Lipid Polymer Micelle technology for the improved oral delivery of drugs.

Astellas wins OK for broader use of key drug in Japan

by Yumiko Nishitani — 07-Jul-2009

In the United States where Prograf lost patent protection in April last year Astellas expects competition from a generic rival in the financial year ending in March 2010.

U.S. court to rehear spat over patent office rules

by Diane Bartz — 07-Jul-2009

A U.S. appeals court has said it would rehear a fight between drugmaker GlaxoSmithKline Plc and the patent office over new rules aimed at cutting a backlog of patent applications.

Star Scientific seeks to overturn Reynolds verdict

By Ian Sherr — 07-Jul-2009

Tobacco company Star Scientific Inc is seeking reversal of a jury ruling that cleared a Reynolds American Inc unit of violating a Star patent for reducing cancer causing agents in tobacco.

DOJ Shifts Policy on Generic Drug Patent Settlements

By BRENT KENDALL — 7-Jul-2009

The U.S. Department of Justice on Monday took a skeptical view on the legality of pharmaceutical patent settlements that delay the introduction of generic drugs the latest change in antitrust policy under the Obama administration.

Teva stops shipping generic birth control pill

The Associated Press — 7-Jul-2009

The worlds largest generic drug maker said it agreed to stop shipping the drug pending a preliminary injunction hearing in a patent infringement lawsuit from Johnson & Johnson.

Glivec patent ruling a welcome turn for Novartis

Priyanka Golikeri & KV Ramana — 8-Jul-2009

The rejection of Novartis patent application for the beta crystalline version of cancer drug Glivec by the Intellectual Property Appellate Board on the ground that it is priced beyond the reach of the common man may have given the company new ground to challenge Indian patent rules.

Alnylam Joins GSK In Patent Pool For Neglected Tropical Diseases

By Staff Reporter — 8-Jul-2009

Alnylam shall contribute more than 1500 issued or pending patents on its RNA interference technology patent estate to the patent pool established by GlaxoSmithKline.

Alnylam Joins GSK in Donating IP to Patent Pool

CAMBRIDGE, MASS & LONDON — 08-Jul-2009

GlaxoSmithKline and Alnylam Pharmaceuticals Inc. announced on July 8 2009 that Alnylam will contribute more than 1500 issued or pending patents on its RNA interference technology patent estate to the patent pool established by GSK earlier this year according to Alnylam.

Dilemma on traditional knowledge

Latha Jishnu / New Delhi — 8-Jul-2009

Last Friday the World Intellectual Property Organisation ended a five day meeting of the Inter governmental Committee on Intellectual Property and Genetic Resources Traditional Knowledge and Folklore without Indias participation.

Ranbaxy faces new legal trouble in US

Radhieka Pandeya — 9-Jul-2009

Ranbaxy Laboratories Ltd whose share price has been roiled by its troubles with the US drug regulator suffered a further blow with Canadian generic or off patent drug maker Apotex Inc. questioning in court the companys ability to launch two generic drugs on schedule.

Nestle Takeda sue Lupin Torrent over patents

PB Jayakumar / Mumbai — 9-Jul-2009

Cases aimed at stopping approval of new generics

EU raps Big Pharma Indian copycat kings boosted

Priyanka Golikeri — 9-Jul-2009

Though it does not actually mention the term evergreening it details the primary patents and secondary patents which Big Pharma seek said an intellectual property expert based in New Delhi who is closely monitoring the report.

Lupin Matrix face antitrust probe in EU

BS Reporter / Mumbai — 9-Jul-2009

The Commission said it would continue to probe whether use of patents to delay generics violated antitrust rules as companies used a variety of techniques to delay introduction of generics.

Teva Servier Face EU Antitrust Probe for Drug Delays

By Matthew Newman and Naomi Kresge — 9-Jul-2009

The commission called for a community patent that would be valid in all of the EUs 27 member states.

Knotted patent litigations inflict medical devices mkt

Soma Das — 9-Jul-2009

The lucrative domestic medical devices industry estimated to touch $1.7 billion in 2010 and expected to grow at an annual growth rate of around 23% is getting mired in entangled patent litigation cases with companies dragging each other to courts.

Drug firms come under EU lens over antitrust practices

Foo Yun Chee / Reuters — 09-Jul-2009

The EU executive said it would examine current EU rules on price and reimbursement urged European countries to introduce legislation to facilitate the entry of generics and stress the need for a Europe wide patent.

3 Indian pharma cos face EU anti trust probe

fe Bureau, Agencies — 09-Jul-2009

In April 2007 Lupin had sold certain patent and intellectual property rights of perindopril to French firm Laboratories Servier for Rs 115.31 crore euro 20 million.

Europe Is Studying Delays in Access to Generic Drugs

By JAMES KANTER — 09-Jul-2009

Commission officials said that generic versions of drugs often were unavailable for at least seven months after the patent on the original version expired a factor that drove costs up by at least 3 billion euros from 2000 to 2007 in 17 European Union countries.

Lupin 2 others face Europe anti trust probe

Our Bureau — 10-Jul-2009

The investigation is still at an early stage and the EC has said that the publication of its statement does not imply it has proof of an infringement of the competition rules Lupin told the media.

Matrix drags Israeli co Teva to court over patent issue

Chandra Ranganathan & Sai Deepika Amirapu — 10-Jul-2009

The dust hasnt settled yet on the Novartis case and another patent dispute has emerged in the pharma space.

Cipla gets notices for alleged overcharging

Our Bureau — 10-Jul-2009

The issue has been under litigation for over five years and the total alleged overcharging amount on Cipla at present is over Rs 1000 crore.

Ranbaxy recalls drug in US

Khomba Singh — 10-Jul-2009

Industry experts say consumer litigation are unlikely for such drug recalls.

Forest Lundbeck settle patent row over Lexapro

by Lewis Krauskopf — 10-Jul-2009

Forest Laboratories Inc and H Lundbeck AS have settled patent infringement litigation with two generic drugmakers on their blockbuster Lexapro anti depressant the companies said on Friday.

STOCKS TO WATCH Infosys Matrix Labs Ranbaxy

ET Bureau — 10-Jul-2009

Matrix Laboratories has filed an application against Israeli drugmaker Teva Pharmaceuticals Industries challenging a process patent used to make Tevas blockbuster drug Copaxone.

Pfizer CEO Braces For Changes

Arlene Weintraub — 10-Jul-2009

Thats particularly a challenge in light of drugs going off patent.

Dark clouds loom on Big Pharma horizon

By Sam Cage — 10-Jul-2009

Consolidation was the major theme of early 2009 as some companies tried to escape the patent crunch by splashing the cash aiming for synergies to offset the depressed outlook for growth over the next few years.

Ranbaxy plans to launch growth hormone drug

Mohit Bhalla — 11-Jul-2009

Ranbaxy Laboratories is planning a new growth hormone product to target the emerging global market for new versions of patent expired biotech drugs a person familiar with the development said.

Efficacy point in Glivec ruling impractical

Pillman — 11-Jul-2009

The controversy over patent to Novartis magic bullet Glivec continues to deepen.

Foreign copycats rattle Gujarat brands

Vishal Dutta — 11-Jul-2009

The US trademark office turned down the Patel familys request for registration.

Team heads to Africa on quality mission

Amiti Sen — 13-Jul-2009

Africa accounts for over 15% of Indias total generic off patent drugs exports worth Rs 30000 crore annually.

Delhi HC rejects German pharma cos plea

Legal,NEW DELHI — 13-Jul-2009

The Delhi High Court has rejected the plea of German pharma company B Braun Melsungen AG claiming patent rights to an item sold by healthcare products manufacturer Eastern Medikit.

We have a conservative generic policy

Nina Mehta — 13-Jul-2009

We do make generic versions of our previously patented products.

Sun Pharmaceutical Rises Most in Three Weeks on Suit Settlement

By Rajhkumar K Shaaw — 13-Jul-2009

Sun Pharmaceutical Industries Ltd. rose the most in three weeks after it reached an agreement with Forest Laboratories Inc. to drop a lawsuit challenging patents on the antidepressant Lexapro.

India Inc finds stem cells a healthy business

PB Jayakumar / Mumbai — 14-Jul-2009

The company already owns seven patents.

West uses Africa in war against generic drugs

Priyanka Golikeri — 14-Jul-2009

Now the developed world is using this vulnerability and turning it into a campaign against legitimate generics by branding them counterfeits which has to do more with IPR and patent violations than quality.

Sun Pharma up on patent deal with Forest Labs

BS Reporter / Mumbai — 14-Jul-2009

Sun Pharma rose 2.6 per cent to Rs 1149.75 after the company and its subsidiary Caraco Pharma entered into agreement with Forest Labs and H Lundbeck over Lexapro.

Merck to revise labelling on cervical cancer vaccine

P.T. Jyothi Datta — 14-Jul-2009

Multinational drug major Merck Sharp & Dohme will revise the labelling on its cervical cancer vaccine Gardasil after it informs the Indian drug regulatory authority later this month.

PE & VC firms bullish on Healthcare investments

ET Bureau — 14-Jul-2009

In the Life Sciences segment investors concerns are focused on the high risk of failure especially in new drug R&D stiff competition from inside and outside India as well as patent related issues.

Sun Pharma A dose of good news

Shobhana Subramanian / Mumbai — 14-Jul-2009

The US authorities still need to bless the settlement that Sun Pharma has entered into with Forest Laboratories Holdings over the patent litigation for Lexapro an anti depressant.

Kenya gives clean chit to imported drugs from India

Sushmi Dey — 14-Jul-2009

The legislation recognises intellectual property rights registered in any country of the world and not necessarily in Kenya.

Retailer Knockoffs Abound in India

By HEATHER TIMMONS — 15-Jul-2009

The United States has long tussled over intellectual property rights with China where counterfeiters crank out knockoffs of designer bags and iPhones and manufacturers have even made entire vehicles that look just like foreign cars.

R&D gets a boost

ET Bureau — 15-Jul-2009

In tandem whats required is to promptly update the norms on royalty payment for use of trademark or brand and fees for technology transfer.

Bisleri Coke may smoke peace pipe

Monica Behura — 16-Jul-2009

Last year the Delhi High Court was prima facie of the view that Coca Cola was the owner of the Maaza trademark in India.

Indian pharma firms swallow bitter pill in US Europe

PB Jayakumar / Mumbai — 16-Jul-2009

Regulators tighten net on safety grounds

US amendment may leave Indian biopharma cos shaken & stirred

Nina Mehta — 16-Jul-2009

Once a patent is filed it takes a company almost 10 years to develop the product and reach the market.

IPL teams to now bat for trademark rights

Monica Behura — 16-Jul-2009

All eight franchises of the Indian Premier League including Shahrukh Khans Knight Riders Deccan Chargers and Delhi Daredevils have filed applications before government authorities in 12 13 cricket playing countries seeking exclusive trademark rights for their names.

Madras HC stays appellate board order on dual SIM patent

Niranjana Ramesh — 16-Jul-2009

The Madras High Court on Wednesday set aside an interim order passed by the Intellectual Property Appellate Board suspending the patent held by Madurai based engineer Somasundaram Ramkumar for the technology that enables usage of more than one SIM card in mobile handsets popularly called a dual SIM.

Roche set to move SC against high court ruling on Tarceva

C.H. Unnikrishnan — 16-Jul-2009

Roche had appealed against a ruling that allowed Cipla to continue selling a generic version of the cancer drug Tarceva despite having a patent of it in India.

Patents will only benefit patients claim drug cos

Priyanka Golikeri — 17-Jul-2009

As the issue of patent protection assumes centrestage not only in India but also in the countrys free trade agreements with different countries multinationals are dredging up a number of reasons to support their demand for patent protection.

Pvt equity venture capital cos turning to healthcare Report

Our Bureau — 17-Jul-2009

Another issue is the high risk of failure especially in new drug discovery competition from within and outside India as well as patent related issues.

Govt orders recall as Natco cancer drug fails toxin test

Sushmi Dey — 18-Jul-2009

Natco has filed pre grant opposition on the patents in India which are yet to be granted.

IT firms push for IPR multiple standards for e gov projects

Vivek Seal — 18-Jul-2009

There are a couple of points in the policy that I think needs further debate one is single standard versus multiple standard and the role of intellectual property rights IPR.

Novartis set to appeal move on Glivec

Our Bureau — 18-Jul-2009

Novartis looks set to appeal the recent decision by the Intellectual Property Appellate Board IPAB against its cancer drug Glivec.

Novartis to challenge IPABs patent decision on Glivec

Nina Mehta — 20-Jul-2009

The Indian subsidiary of Swiss drugmaker Novartis will challenge a decision by the Intellectual Property Appellate Board IPAB that said its cancer drug Glivec was not patentable.

Dual SIM dispute highlights flaws in Indias patent process

C.H. Unnikrishnan — 20-Jul-2009

Patent experts expressed surprise that Ipab passed an interim order instead of deciding the patents validity

Earnings Preview: Pfizer preps for Wyeth deal

By LINDA A. JOHNSON — 20-Jul-2009

It also broadened its partnership with an Indian generic drugmaker and started a new one with an Indian maker of injected medicines part of an effort to boost sales of off patent drugs and of products in developing countries.

A Trips plus agenda at WIPO

D Ravi Kanth — 21-Jul-2009

Those who cannot remember the past are condemned to repeat it is a timely reminder for key actors who are bent on pushing failed agendas.

Its an MNC agenda to prevent competition

Anand Grover — 21-Jul-2009

The recent anti counterfeiting measures worldwide seizures of generic drugs in Holland the proposals in the WHO the moves in the East African Anand Grover Director Lawyers Collective HIV AIDS Unit region and in the Andean community to criminalise patent infringements etc.

18230 patents granted in 2008 09

Press Trust of India / New Delhi — 21-Jul-2009

The Indian Patent Office has granted 18230 new patents in 2008 09 Lok Sabha was informed today.

Incidence high in countries where access to medicines is poor

Tapan Ray — 21-Jul-2009

Incidents like recent detention in transit of DRL shipment of the generic version of Losartan in the Netherlands or a consignment of Amoxicillin at the Frankfurt airport on the ground of patent infringement cannot be considered as attempts of MNCs to brand Indian generic drugs as counterfeit medicines.

Cadila loses Mexate trademark case

BS Reporter / Mumbai/ Ahmedabad — 21-Jul-2009

Ahmedabad based Cadila Healthcare Ltd has lost the case in a civil suit which it had filed for its brand Mexate against Wallace Pharmaceuticals Pvt Ltd.

DSM in talks to supply Lipitor ingredient

Khomba Singh — 23-Jul-2009

Pfizers patent for Lipitor in the US expires in 2011.

Barking up the wrong tree

By René B. Azurin — 23-Jul-2009

For the pharmaceutical companies that own patents to various drugs this meant that they are deemed to have no further legal claims insofar as the resale of their products is concerned.

Sun Pharma arm faces class action suit in US

Khomba Singh and Nina Mehta — 23-Jul-2009

Caraco Pharmaceuticals the US arm of Sun Pharma has been slapped with a class action suit in the United States for allegedly Top 10 Drugmakers by sale not disclosing adequate information about US regulatory action that hurt its shares rendering Indias most valuable drugmaker vulnerable to the prospect of hefty payouts as damages.

Costly drugs prompt exclusivity debate

Andrew Pollack — 23-Jul-2009

For starters whatever the exclusivity period biologic drugs would also continue to be protected from copycats by patents.

Moser Baer Philips settle patent dispute

BS Reporter / New Delhi — 23-Jul-2009

Global technology company Moser Baer has settled a patent and licence dispute with global electronics giant Philips.

Give info on counterfeit drugs get rewarded

Kounteya Sinha — 23-Jul-2009

Informing the government about spurious drugs could soon earn you big money.

Non market strategies making a comeback in West

Dibeyendu Ganguly — 24-Jul-2009

A blood cancer drug called Glivec has been a money spinner for Novartis all over the world except in India where the patent authorities have turned down the Swiss companys application for a product patent on the grounds that it does not offer sufficient improved efficacy over its predecessor.

Teva J&J settle oral contraceptive patent case

By Lewis Krauskopf — 24-Jul-2009

Teva Pharmaceutical Industries Ltd said on Friday it settled a patent infringement lawsuit with Johnson & Johnson over Tevas U.S. generic version of J&Js Ortho Tri Cyclen Lo birth control pill.

Ranbaxy net jumps 30 fold to Rs 693 cr

ET Bureau — 25-Jul-2009

FTFs are the main growth drivers for most leading Indian companies that make generic versions of expensive drugs that have gone off patent.

Quality stamp for drugs in works

Sushmi Dey — 27-Jul-2009

A generic drug is not protected by patents and can be manufactured without paying royalty.

How pharma companies can be better long term bets

Kiran Kabtta Somvanshi and Santanu Mishra — 27-Jul-2009

Over dependence on cost competitiveness however comes with its own set of risks increased scrutiny and clamps from drug regulators legal risks in challenging patented drugs and rising pricing pressure as regulated markets overhaul their healthcare systems.

Anna University IPR centre files 53 patents

D Suresh Kumar — 27-Jul-2009

Inventors and innovators including college students who are keen on getting their work patented no longer need to spend time and money undertaking a taxing documentation process or familiarising themselves with legal jargons.

Global drug cos set sights on Indias veterinary market

Nina Mehta — 27-Jul-2009

Animal healthcare in India is no longer an afterthought as global pharmaceutical companies facing loss in revenues due to expiring drug patents are looking for new growth markets.

Sanofi Aventis to acquire Indian vaccine company

PARIS — 27-Jul-2009

It aims to refill a development pipeline that analysts see as woefully light on new drugs to replace those that will soon go off patent and face competition from cheaper copies.

An incubator that takes care of everything

Deepti Chaudhary — 27-Jul-2009

In India i2india has signed patent agreements with institutions such as Indian Institutes of Technology and Indian Institute of Science.

IT firms speed up patent filing

Vishwanath Kulkarni,Shamik Paul — 28-Jul-2009

Stepping up efforts to commercialise their intellectual property IP Indian IT services firms have accelerated their patent filing process.

Lunch with BS Malvinder Mohan Singh

Bhupesh Bhandari / New Delhi — 28-Jul-2009

What made you sell I ask Malavs friends say the patent litigations switched him off pharmaceuticals such litigation can be expensive and nerve wracking.

Drug sector fears bias in Tamiflu sourcing

P.T.Jyothi Datta — 28-Jul-2009

India did not grant a patent to innovator Gilead on Oseltamivir.

GITAM varsity plans IPR cell

Our Bureau — 28-Jul-2009

The GITAM Institute of International Business is setting up an intellectual property rights IPR cell with the assistance of the National Research and Development Corporation according to Prof V.K Kumar the Director.

Right and wrong medicines

Business Standard / New Delhi — 29-Jul-2009

One recent step has been to hire more inspectors another to float the idea of a quality mark for generic medicines which have no patent cover.

Sanofi profits soar prepared for Plavix Taxotere patent losses

By Kevin Grogan — 29-Jul-2009

Sanofi Aventis has posted a strong set of figures for the second quarter this morning and says it has laid the groundwork to cope with patent expiries.

India Patent Rights and Wrongs

By ROGER BATE — 29-Jul-2009

India promised to protect intellectual property when it signed up to the World Trade Organizations rules in 2005.

SemBioSys shares soar after insulin patent granted

by Nina Lex — 30-Jul-2009

Shares of SemBioSys Genetics Inc soared as much as 74 percent on Thursday morning after the company announced it had been granted a U.S. patent for commercial production of insulin by using oil from the seeds of safflower plants.

Takeda swings back to profit keeps forecast

By Yumiko Nishitani — 31-Jul-2009

Takeda launched Kapidex ahead of the patent expiration in November for its predecessor drug Prevacid in the United States but analysts expect competition to keep Kapidex from compensating fully for a likely drop in Prevacid sales.

$70 bn worth drugs to go off patent benefiting India Report

PTI — 02-Aug-2009

The Indian drug industry would make huge gains as over $70 billion worth of drugs are expected to go off patent in the US the worlds largest pharma market in the next three years according to a report.

The French connection

BV Mahalakshmi, Sudhir Chowdhary — 3-Aug-2009

The fact that Shantha Biotech was able to attract Sanofi with its intellectual property and good manufacturing facilities is a sign of the maturity of the Indian vaccine industry.

Copycat Indian drug cos turn MNC partners

Khomba Singh — 3-Aug-2009

This seems to be the strategy of multinational pharmaceutical companies vis a vis the highly Top 10 Drugmakers by sales successful Indian drug industry that makes a living out of copying off patent blockbuster drugs.

Indias Sun Pharma MedImmune settle on ethyol

by Bharghavi Nagaraju — 3-Aug-2009

Indias Sun Pharmaceutical Industries Ltd said on Monday it has settled a patent dispute with AstraZenecas MedImmune unit for generic version of Ethyol resolving all litigation between them.

India set to sign pharma export deal with Nigeria

Sushmi Dey & Gireesh Chandra Prasad — 3-Aug-2009

The government is set to sign an exhaustive deal with Nigeria to boost pharmaceutical exports to its eighth largest global consumer where the reputation of Indian drugs was recently dented by fake drugs from China bearing Made in India labels.

Daiichi wins court battle against Mylan Matrix

Press Trust of India / Tokyo/ New Delhi — 03-Aug-2009

Japanese drug major Daiichi Sankyo said today a US Court has ruled in its favour in a patent litigation related to the anti hypertensive drug Benicar against Mylan Inc and its Indian subsidiary Matrix Laboratories.

A patent case for invention

P. V. INDIRESAN — 3-Aug-2009

India needs improved patent laws that will protect genuine inventors better and minimise disputes on trivial grounds.

India grants 3500 pharma patents in three yrs

Press Trust of India / New Delhi — 03-Aug-2009

The Indian Patent Office has granted 3506 patents relating to pharmaceutical innovations over the last three years the government said today.

Combating spurious drugs

Pharmaceutical — 4-Aug-2009

The whistle blower scheme outlined by the Union Health Minister is a workable idea but only a consistent multi level approach can snuff out spurious drug makers.

Roche prepares to defend local patent for Valcyte

C.H. Unnikrishnan — 04-Aug-2009

Firm facing at least five post grant oppositions at Chennai patent office it has cut price of the drug by 35%

India may move WTO to protest drug seizures

Joe C Mathew / New Delhi — 4-Aug-2009

The government is planning to approach the dispute settlement body of the World Trade Organization against frequent seizure of Indian medicines at various European ports.

Interpol scans fake drugs with Made in India label

PTI,New Delhi — 04-Aug-2009

Recently fake drugs carrying the Made in India label were seized in Nigeria but were allegedly manufactured in China.

MNCs eye Indian pharma

ET Bureau — 5-Aug-2009

Till a few years ago it was believed Indian pharma companies highly profitable generic business model they were able to corner a large share of market for drugs going off patent and occasionally challenged patents through Para IV filings in the US would allow them to build financial muscle.

A singular victory for open innovation

Latha Jishnu / New Delhi — 5-Aug-2009

At the conference sponsored by the World Intellectual Property Organisation on July 13 and 14 he would launch his Initiative for Open Innovation globally to promote transparency in the patent system a disruptive democratising cyber infrastructure to make it possible to turn the patent system into a transparent fixable part of society as he called it in his letter.

Nigerian drug regulator to open Indian offices

ET Bureau — 05-Aug-2009

Reacting to the seizure of fake Chinese drugs carrying a made in India tag the Nigerian drug regulator has decided to set up its offices in India.

US exclusivity law may hit Indian biotech cos

Nina Mehta — 6-Aug-2009

These companies will have to choose their products carefully and focus on those products which are already off patent or scheduled to go off patent soon said Sanjay Singh associate director KPMG.

India may get its first novel drug by 2014

Priyanka Golikeri — 6-Aug-2009

From the last few years almost every Indian company worth its name is talking of having novel molecules new chemicals entities and a few new biological entities in its kitty.

Lupin to launch more branded generics in US

Khomba Singh — 6-Aug-2009

Branded generics are rip off versions of off patent drugs but since they incorporate added advantages such as lower dosages the US drug regulator allows them to be sold under a brand.

Ailing drugmakers may seek foreign cure

By Pratish Narayanan — 6-Aug-2009

Global heavyweight Pfizer is seen as the most likely suitor of Indian rivals as it looks to replace revenue lost from the lapse of key patents while Merck and Sanofi Aventis may also seek to shake hands with Indian producers analysts said.

BR Films pays up Rs1 crore in copycat case

Anshika Misra, Mumbai — 6-Aug-2009

Bollywood will now think twice before getting inspired by Hollywood again. BR Films,which was dragged to court by Twentieth Century Fox for alleged plagiarism, on Wednesday agreed to pay a settlement amount of $200,000 (a little less than Rs1 crore)to the American studio.

Roche will only help itself by making drugs affordable

Pillman — 7-Aug-2009

In a recent judgment by the Intellectual Property Appellate Board on Novartis Glivec the need to make the drug affordable was emphasised.

GSK to up output of inhaler drug

Nina Mehta — 7-Aug-2009

GSK and Biota which invented the drug and holds the patent till the end of 2014 are not the only ones who have been approached to supply the drug.

Pfizer agrees to cut price of TB drug

By Andrew Jack in London — 7-Aug-2009

Mylan will reduce the price of four HIV drugs that are off patent atazanavir ritonavir tenofovir and lamivudine to $475 a year falling to $425 a year from 2010 which is 28 per cent less than current prices.

US court to hear Glenmarks patent dispute on Aug 19

ET Bureau — 7-Aug-2009

Glenmark Pharmaceuticals patent challenge against Schering Ploughs cholesterol lowering drug Zetia will come up for hearing in the US district court of New Jersey on August 19.

Oppn to officials taking up plum posts in WTO WIPO

Joe C Mathew / New Delhi — 8-Aug-2009

Civil society groups have complained against the practice of senior commerce ministry officials taking up plum posts with international agencies such as the World Trade Organization and World Intellectual Property Organisation with whom they have been involved in direct negotiations on issues of national interest.

HC bans MNS Pharma from lipid control drug sale

Khomba Singh — 8-Aug-2009

Rosuva is a registered trademark of Ranbaxy.

Old medicine new patents

Gaurav Choudhury — 08-Aug-2009

Slowly but surely India Inc is waking up to the virtues of traditional wisdom.

Low costs a draw for foreign drug makers

C.H. Unnikrishnan — 09-Aug-2009

Low costs high technical capabilities and a skilled work force are making India an attractive destination for research and contract manufacturing of drugs.

Human clinical trials for stem cell research on cards

Vishal Dutta — 10-Aug-2009

StemCyte has patented the plasma depletion technology that helps in collecting higher volume of stem cells and better cell counts resulting in successful therapeutic applications for over 70 diseases.

GI tags sought for veena lock

Our Correspondent — 10-Aug-2009

The Tamil Nadu State Council has taken steps to get Geographical Indication Tags of Thanjavur Veena and Dindigul Lock establishing their place of origin.

Indian companies may pitch in with generic version of Tamiflu

Khomba Singh & Sushmi Dey — 10-Aug-2009

US Patent and Trademark Office Issues Key Patent For OncoGenexs OGX 011

By Staff Reporter — 10-Aug-2009

US Patent and Trademark Office has issued US Patent Number 7569551 entitled Chemo and Radiation sensitization of Cancer by Antisense TRPM 2 Oligodeoxynucleotides on the method of using OncoGenexs OGX 011 to treat certain cancers.

Azad says wont wait for desi swine flu vaccine will import

Kounteya Sinha — 11-Aug-2009

At present only one US based company Biosystem has the patent of the real time PCR kits for detection of H1N1 being used globally.

India warned on moving WTO over drug seizures

Joe C Mathew / New Delhi — 11-Aug-2009

Even as India considers the European Union directive that allows seizure of goods in transit by its member countries as violative of the World Trade Organizations TRIPS trade related aspects of intellectual property rights agreement legal experts caution against the central governments plans to approach the dispute settlement body of WTO.

HC returns appeal on dual SIM card case

C.H. Unnikrishnan — 11-Aug-2009

The Madras high court on Friday returned an appeal filed by Madurai Tamil Nadu based electronics engineer S. Ramkumar to the Customs Appellate Tribunal in a case related to his patent on dual SIM card mobile phones.

immatics gets European patent for IMA901 product & US patent for MUC 1 peptide

Martinsried, Munich — 11-Aug-2009

immatics biotechnologies GmbH has obtained European patent protection for the composition of matter for its drug candidate IMA901.

Swiss firm moves apex court against Cipla

C.H. Unnikrishnan — 11-Aug-2009

Swiss drug maker F. Hoffmann La Roche Ltd has petitioned the Supreme Court against a Delhi high court order in a patent violation lawsuit regarding its cancer drug Tarceva with Indian pharma firm Cipla Ltd.

Schering settles final Clarinex patent litigation

LOS ANGELES — 11-Aug-2009

Drugmaker Schering Plough Corp SGP.N said on Tuesday it settled patent litigation with Orchid Chemicals & Pharmaceuticals Ltd related to generic versions of its allergy medication Clarinex.

Strides Arcolab ready to supply Swine Flu drug

PTI — 11-Aug-2009

Oseltamivir Capsules are the generic version of Roches patented drug Tamiflu.

Novartis hits Astellas with transplant drug generic

Yumiko Nishitani — 11-Aug-2009

Astellas lost U.S. patent protection for Prograf in April 2008 but until now has not faced any generic competition.

China admits its companies involvement in fake drugs case

PTI — 11-Aug-2009

China has admitted that its pharmaceutical companies were involved in shipping fake drugs labeled Made In India to Nigeria.

Ranbaxy gets USFDA nod for Sumatriptan Succinate Tablets

Agencies — 11-Aug-2009

The office of generic drugs USFDA has determined that the Ranbaxy formulations to be bio equivalence and have same therapeutic effect as that of GlaxoSmithKlines patented drug Imitrex Ranbaxy said.

Sun Pharma gets US nod for two generic drugs

REUTERS — 12-Aug-2009

Sun Pharmaceutical Industries has got the US Food and Drug Administrations approval to launch its generic version of GlaxoSmithKlines Imitrex tablets to treat migraine the Indian drugmaker said.

India emerging global pharma outsourcing hub Study

Our Bureau — 12-Aug-2009

Of the total global outsourcing custom manufacturing phase IIb to the off patent stage including intermediates API and formulations contributes almost 65 per cent of the $51 billion market in 2008.

Swine Flu H1N1- Prevention & Treatment

12-Aug-2009

There is no vaccine available right now to protect against novel H1N1 virus. However, a novel H1N1 vaccine is currently in production and may be ready for the public in the fall. As always, a vaccine will be available to protect against seasonal influenza. There are everyday actions that can help prevent the spread of germs that cause respiratory illnesses like influenza.

Courtesy: Jimmy George

Information on Swine Flu - II

12-Aug-2009

Important Information on Swine Flu H1N1.

Courtesy: Mr. Amit Didwania, Drishya Holidays Pvt. Ltd.

Information on Swine Flu - I

12-Aug-2009

Government Authorized Hospitals For Treatment Of Swine Flu

Courtesy: Mr. Amit Didwania, Drishya Holidays Pvt. Ltd.

Stricter law on fake drugs now in force

Radhieka Pandeya — 13-Aug-2009

India finally has a law to combat the menace of fake and adulterated drugs and not all pharma companies are happy with it.

IDMA urges law makers to initiate measures to save Indian generic drugs

Ramesh Shankar, Mumbai — 13-Aug-2009

The products had no Patent or Trade Mark problem either in India origin country or the destination country.

Orchid settles Schering lawsuit

Our Bureau — 13-Aug-2009

Orchid Chemicals and Pharmaceuticals has reached an out of court settlement with the US based Schering Plough Corporation on a 2006 patent lawsuit regarding allergy medicines Clarinex and Clarinex Reditabs.

Sun Pharmas US arm reliant on generic launches

Manas Chakravarty and Mobis Philipose — 13-Aug-2009

In the previous year two such Para IV filings for abbreviated new drug applications which challenge an existing patent in order to launch a slightly different generic version of the same product with one off revenue potential accounting for 57% of revenues.

Macro gain for ASEAN micro pain for India

G. Srinivasan — 14-Aug-2009

Effectively this implies that India has less than 50 60 items in its negative list for each ASEAN country a patent asymmetric pact from negotiation angle leaving legions of domestic industries vulnerable to dumping and material injury.

Allow retail sale of drug say domestic pharma players

P B Jayakumar & Joe C Mathew / Mumbai & New Delhi — 14-Aug-2009

The central governments decision to continue controlling supply of the swine flu drug oseltamivir will help the drug innovator Swiss multinational Hoffmann La Roche and its Indian licencee Hetero Drugs maintain their effective monopoly in the country even as the drug lacks patent protection in India fear domestic industry circles.

Remedy for a malady

By Andrew Jack — 14-Aug-2009

He cites as symptomatic the large scale takeovers this year of Wyeth by Pfizer and Schering Plough by Merck which he argues were primarily designed to defer patent expiries and cut costs rather than provide a solution to falling research productivity.

Novartis reportedly sues GlaxoSmithKline over patent

By Polya Lesova — 16-Aug-2009

Swiss drugmaker Novartis AG has filed a legal action against rival GlaxoSmithKline over a vaccine patent according to a media report Sunday.

Pharma patents Mashelkar report gets Centre approval

Amitabh Sinha — 16-Aug-2009

Mashelkar as head of a Technical Expert Group that had four other members had been asked by the government in 2005 to examine whether the grant of patents for pharmaceutical substances could be limited only to new chemical entities and new medical entities involving one or more inventive steps or they could be granted to incremental innovations on existing drugs as well.

Big pharma companies join outsourcing queue

PB Jayakumar / Mumbai — 17-Aug-2009

Diminishing numbers of new drugs as against existing drugs going off patent high research and development costs and pressure to reduce healthcare costs are forcing Big Pharma to rope in strategic partners to contain manufacturing and drug development expenses.

Maker of fake drugs has fled to Hong Kong

S Balakrishnan — 17-Aug-2009

Chairman and MD of Phikon Biotech Pvt Ltd D J Vaidya who is allegedly involved in the manufacture of fake drugs for heart ailments and cancer has fled to Hong Kong.

Patently right

The Indian Express ,Mashelkar report — 17-Aug-2009

Should patents be granted to incremental changes on existing drugs not just to completely new medical and chemical entities Yes said the government appointed Mashelkar Committee report and yes says the Centre by accepting the reports findings.

Indian generics profit from Glaxo patent expiry

P B Jayakumar / Mumbai — 18-Aug-2009

GlaxoSmithKline Plcs anti migraine drug brand Imitrex is turning out to be a good revenue earner for Indian generic companies as the US Food and Drug Administration has given almost half of the final approvals for the reverse engineered or generic versions of the drug made by Indian pharmaceutical companies following its patent expiry.

Govt wont tweak drug patent rules

Khomba Singh & Sushmi Dey — 18-Aug-2009

The commerce ministrys decision to accept the Mashelkar committees revised report that recommends not to restrict patenting to new drugs has come in for strong criticism from health activists and some generic drugmakers even as patent experts supported the move thats in line with international norms.

Govt accepts panel report against narrowing of Indian patent law

BS Reporter / New Delhi — 18-Aug-2009

The central government has accepted the recommendations of an expert committee headed by former Council of Scientific and Industrial Research chief R A Mashelkar on patent laws.

We have filed a world patent for a new energy saving technology

Business Standard / New Delhi — 18-Aug-2009

Deepak Pahwa Managing Director of Pahwa Enterprises Indias largest private sector SME in the HVAC&R heating ventilation air conditioning and refrigeration industry tells Business Standard that some of his key customers are pharma units and since dehumidification machines are at the heart of pharma units his company was unaffected by the downturn.

Major win for Indian pharma cos as HC dismisses Bayer petition

ET Bureau — 18-Aug-2009

In a major win for Indian pharmaceutical companies the Delhi High Court on Tuesday dismissed German drug major Bayer Healthcares attempt to stop Drug Controller General of India from giving marketing approval to Indian company Cipla for the generic version of Bayers patented kidney cancer drug Nexavar.

Lilly shares fall after court invalidates patent

by Toni Clarke — 18-Aug-2009

Shares of Eli Lilly & Co fell 1.4 percent in premarket trading on Tuesday after a court invalidated a key patent governing its cancer drug Gemzar.

Daiichi Sankyo Lupin in talks for marketing tie up

Radhieka Pandeya — 19-Aug-2009

Today MNCs are looking at how they can create opportunities after patent expiry and joining hands with generic companies.

Microsofts Patent Dust Ups

Aaron Ricadela — 19-Aug-2009

For the past half dozen years Microsoft has been busily getting its patent house in order.

Courts being used to stifle generic challengers

Joe C Mathew / New Delhi — 19-Aug-2009

Patent fights are becoming more difficult for domestic pharmaceutical companies as multinational drug giants which obtain patent protection for medicines that are vulnerable to post grant oppositions are increasingly approaching Indian courts to stall competition from low cost local manufacturers.

Govt in talks with Roche for cheaper Tamiflu

Soma Das — 19-Aug-2009

Last month Roche the patent holder of Tamiflu not in India started a new initiative to supply the anti viral drug to select developing countries at a reduced cost of $2.80 and $8.50 in consultation with the WHO.

Glenmark faces patent infringement case in US

Press Trust Of India / Mumbai — 19-Aug-2009

Drug maker Glenmark Pharmaceuticals today said it was facing a lawsuit in a US District Court for a patent infringement case of an anti malaria product.

Bayers attempt to stop Cipla drug sale fails

BS Reporter / New Delhi — 19-Aug-2009

Court rejects bid to introduce a linkage between regulatory approval of a medicine and its patent status

Big Pharma must mend its ways to succeed in India

Pillman — 20-Aug-2009

Close on the heels of the Intellectual Property Appellate Board halting Novartis Glivec patent application and linking it to threatening public disorder on account of its high prices, the Delhi High Court has dealt a body blow to German drug maker Bayers ambitions to monopolise the Indian market with its kidney cancer drug Nexavar.

M&M wins disputed internet site case at WIPO

Press Trust Of India / New Delhi — 20-Aug-2009

Mahindra & Mahindra has won a cybersquatting case at the World Intellectual Property Organisation against a US based person who was using the name Mahindra in an internet domain.

Incremental innovations

ET Bureau — 20-Aug-2009

It is hard to quibble with the Mashelkar Committees report on patenting of pharmaceutical substances for its main theme that it is wrong to deny patents to incremental innovations if they have significantly better safety and efficacy standards over the known molecule.

Sun wins US court ruling in Eli Lilly patent challenge

BS Reporter / New Delhi — 20-Aug-2009

Clears way for low cost cancer drug launch in 2010.

Sun Pharma wins Gemzar patent case

NewsWire18 — 20-Aug-2009

The US district court for the eastern district of Michigan delivered a partial summary judgement on Monday invalidating Eli Lillys patent for method of use for Gemzar.

Bayer beaten in Indian court over patent law

By Kevin Grogan — 20-Aug-2009

Bayer has suffered a setback after a court in India dismissed the German firms attempt to prevent the countrys regulator from approving a generic version of its kidney and liver cancer drug Nexavar that is being prepared by Cipla.

Mashelkar report runs into fresh controversy

Joe C Mathew / New Delhi — 21-Aug-2009

Patent expert says his views were misinterpreted to support conclusion that Indias patent laws could not be tightened.

Merck wins Singulair patent infringement suit against Teva

Whitehouse Station, New Jersey — 21-Aug-2009

Merck & Co Inc announced that the US District Court for the District of New Jersey has ruled in Mercks favour in a patent infringement suit against Teva Pharmaceuticals USA Inc.

Drug makers face penalty for overcharging

Sushmi Dey — 21-Aug-2009

Drug manufacturing companies such as Cipla Ranbaxy Johnson & Johnson and Dr Reddys Laboratories may have to pay over Rs 2038 crore to the government for overcharging consumers on price controlled medicines.

Govt plans retail clamp on Ciplas Tamiflu substitute

Joe C Mathew & Pb Jayakumar / New Delhi — 22-Aug-2009

Relenza a pre 1995 molecule lacks patent protection in India and legally Cipla can manufacture and sell the drug.

Hetero bags deal for 10 m Tamiflu

Khomba Singh — 22-Aug-2009

Roches application seeking patent for Tamiflu in India was rejected in March allowing Indian companies to market the generic versions in India and other countries where Roche does not hold the patent.

We must look to avoid grant of frivolous patents at all costs

Priyanka Golikeri — 22-Aug-2009

With the government accepting the Mashelkar Committee Report on pharmaceutical patents the stage is now set for a new battle over patents and public health.

North Indian pharma Focusing on R&D and tie ups to meet challenging conditions

Sanjay Pingle, Mumbai — 24-Aug-2009

It has set up five R&D centers and got 24 product patents valid in more than 60 countries worldwide.

Dump the Mashelkar report

Business Standard / New Delhi — 24-Aug-2009

Even as the government accepts the revised report of the technical expert group on patent law issues headed by RA Mashelkar a key conclusion of the group has run into fresh controversy over the reasoning on which it is based.

India Infoline maintains Reduce rating on Sun Pharma

ET Bureau — 24-Aug-2009

The company received US FDA approval for Eloxatin only to be suspended soon after on account of continuing patent litigation.

The R&D debacle

Ram Prasad Sahu / Mumbai — 24-Aug-2009

One of the four is the anti malarial drug Malarone on which the company is facing a patent infringement suit by Smithkline Beecham.

Stem cell therapy market picking up as 4 new firms look to expand

C.H. Unnikrishnan — 24-Aug-2009

The recent government decision to allow patenting of micro organisms and its processes and increased awareness about cord blood cell banking are giving a boost to the new therapy.

Verva licenses FGFR intellectual property rights to Isis Pharma to treat obesity & other diseases

Geelong, Australia — 24-Aug-2009

Verva Pharmaceuticals Ltd and Isis Pharmaceuticals Inc announced the completion of an agreement providing Isis an exclusive license to Vervas intellectual property rights targeting the Fibroblast Growth Factor Receptor with antisense technology for the treatment of diseases including obesity and other metabolic disorders.

Govt should not succumb to the WIPO pressure

Dr.Y.K.Hamied — 25-Aug-2009

I strongly subscribe to the view that the ongoing reform of the Patent Cooperation Treaty at the behest of WIPO is an attempt to undermine the sovereign rights of the Indian government to make laws to suit its domestic needs.

The treaty is a cornerstone of multilateral cooperation

Claus Matthes — 25-Aug-2009

Recently articles have surfaced in the Indian press about international efforts to reform the Patent Cooperation Treaty an agreement that binds 141 countries in a pact that facilitates the process of seeking protection for an invention in multiple countries.

Concerns of WIPOs members and its customers differ

D G Shah — 25-Aug-2009

WIPO like other UN organisations is a member driven organisation.

Sanofi sues Sun Pharma over Taxotere generic

Bloomberg — 26-Aug-2009

Sun is pursuing approval from the US FDA to market two dosage forms of the drug before the patents expire in 2012 according to the complaint filed by Sanofi Aventis SA.

US pharma association disapproves Customs seizure of generics

Joe C Mathew / New Delhi — 26-Aug-2009

The response comes after 17 consignments of genuine generic medicines from India were recently seized at various European ports alleging intellectual property violations.

Stringent IP enforcement will limit access to generic drugs

fe Bureaus — 26-Aug-2009

Civil society organisations led by Centre for Trade and Development have sent a strong missive to the Confederation of Indian Industry urging it to be careful about associating with multinational corporations and developed countries that are keen to push more stringent intellectual property enforcement laws in India .

Biocon mulls listing of two of its arms by next yr

Press Trust of India / Chennai — 26-Aug-2009

Biocons patent portfolio totals close to 942 applications worldwide with over 182 granted patents.

Indian patent laws not conducive to domestic R&D OPPI

Agencies — 26-Aug-2009

The countrys pharmaceutical industry today said the present patent laws do not value incremental innovations and are not conducive to the research and development activities of domestic firms.

Drug Biotech Research Spending Hangs Tough

By Emily Thornton and Frederick Jespersen — 27-Aug-2009

With billions of dollars worth of branded drugs losing their patent protection the pharmaceutical industry is under pressure to boost its pipeline of innovative new drugs.

Incremental pharma innovation in patent regime to benefit local firms

fe Bureaus — 27-Aug-2009

Expanding the scope of Indias current patent regime to include incremental pharma innovation would benefit the domestic pharma players according to a study commissioned by the US India Business Council which was released on Wednesday.

Even European Union doesnt link regulatory approval for generics to innovator patent

Priyanka Golikeri — 27-Aug-2009

German healthcare giant Bayer is determined to introduce in India a system that can prevent early entry of low cost generics despite the Delhi High Court quashing its plea to link regulatory approval to last week saying the company was trying to tweak public policy.

Patent regime poses new challenges for health Minister

IANS — 27-Aug-2009

Minister of State for Health Dinesh Trivedi Thursday called for taking a serious look at the intellectual property rights regime so that Indian patients are not adversely affected.

GSK to launch promecta in India by 2009 end

Agencies — 27-Aug-2009

Glaxo SmithKline Pharmaceutical said it is looking at launching its patented medicine promecta used in treatment of depleted platelet count in India by this year end or early next year.

Encouraging drug innovation

Shamnad Basheer — 28-Aug-2009

The Mashelkar committee report on drug patent law may have stirred controversy but it sets the right tone

Cipla gets relief as SC rejects Roche plea

ET Bureau — 29-Aug-2009

The Supreme Court on Friday rejected Swiss drugmaker Roches petition to stop Indian firm Cipla from selling the generic version of its cancer drug Tarceva to ensure that Indians have access to the medicine at a lower cost till the Delhi High Court decides on Ciplas patent challenge plea.

Sharma to take up drug seizures issue with EU commissioner

Asit Ranjan Mishra and Radhieka Pandeya — 29-Aug-2009

According to European Commission laws if a consignment of drugs is not patented either in the country of origin or its final destination it could be seized.

Novartis moves SC in Glivec patent case

ET Bureau — 29-Aug-2009

Swiss major Novartis AG has moved the Supreme Court challenging Intellectual Property Appellate Board decision to reject its patent application of blood cancer drug Glivec in India.

Cipla calls off marketing alliance with Avesthagen

Nina Mehta — 29-Aug-2009

Cipla has terminated its marketing agreement with Avesthagen and is looking at selling its 5.8% stake in the Bangalore based company.

Govt curbs sale of flu drug Zanamivir

Khomba Singh — 29-Aug-2009

The government is set to put Zanamivir the only swine flu drug that is freely available in the market currently under restricted sale category.

Tata Sons wins trademark case against MakeMyTrip

Shubhra Tandon — 30-Aug-2009

Tata Sons recently won a trademark case at the World Intellectual Property Organisation against New Delhi based travel portal MakeMyTrip for the use of the word TATA in the latters sister Web site okaytatabyebye.com an online networking forum for the travel community.

Lack of clarity in drugs Act may hit generic companies

Nina Mehta — 31-Aug-2009

Ambiguity in the amended Drugs and Cosmetics Act over the definition of the terms adulterated and spurious drugs could affect Indian generic drug players.

Insurance firm told to pay up

BS Reporter / New Delhi — 31-Aug-2009

The Supreme Court will on Monday hear Swiss drug maker Novartis AGs plea against denial of patent for its blood cancer drug Glivec in its beta crystal form.

DRL seeks USFDA help to make cancer drug clone

Sai Deepika Amirapu — 31-Aug-2009

Dr Reddys Laboratories Indias second largest drug maker by sales has approached the US Food and Drug Administration to overcome impediments in making the generic version of Revlimid an expensive drug used to treat blood cancer.

GSK plans to launch H1N1 drug in India

Press Trust Of India / New Delhi — 31-Aug-2009

UK based drug maker GlaxoSmithKline is in talks with the Indian government for introducing its patented drug Relenza which is used for the treatment of Influenza A H1N1.

Big multinationals dumping excess vendor baggage

Shelley Singh — 31-Aug-2009

Companies doing R&D remotely also try to limit the number of third party vendors to protect intellectual property and any infringements of patents.

Britannia settles Tiger brand tangle with US firm

IANS — 31-Aug-2009

The Nusli Wadia led Britannia was embroiled in a bitter intellectual property right violation litigation with its partner Groupe Danone after the Indian company charged the French dairy major with using its Tiger trademark a key intellectual property in the overseas market without prior consent.

SC to hear Novartis case next week

Press Trust of India / New Delhi — 31-Aug-2009

The Supreme Court will hear Swiss drug maker Novartis AGs plea against denial of patent for its blood cancer drug Glivec next week.

Swiss NGO flays Novartis Glivec appeal

Priyanka Golikeri — 01-Sep-2009

A Switzerland based NGO has come out strongly against Swiss pharma giant Novartis appeal to the Supreme Court last week over the rejection of its patent for cancer drug Glivec.

Britannia to sharpen focus on global biz

BS Reporter / Kolkata — 01-Sep-2009

Biscuits major Britannia Industries plans to focus on strengthening its international business and expand its brand presence in the aftermath of its settlement with Danone on the intellectual property rights issue over the Tiger brand.

Novartis Glivec case to be heard by another Bench

Our Bureau — 01-Sep-2009

Swiss drug maker Novartis challenge in the Supreme Court on being denied a patent for its cancer drug Glivec will now be re assigned to another Bench by the Chief Justice of India.

Bayer CropScience Wins Patent Litigation

By Staff Reporter — 01-Sep-2009

Under the settlement Tian Rong and Hua Dong to cease the infringing acts.

India refuses patent protection for AIDS drug of US company

Joe C Mathew / New Delhi — 2-Sep-2009

More appeals pending domestic manufacturing some way off.

Setting aside Bayers spurious claims

Latha Jishnu / New Delhi — 2-Sep-2009

Two weeks ago Justice S Ravindra Bhat of the Delhi High Court dismissed with costs the writ petition filed by the German pharmaceuticals giant Bayer Corporation against the Union of India the Drug Controller General of India and Cipla.

Govt may move WTO on EU drug seizures

Priyanka Golikeri — 3-Sep-2009

The government plans to file a complaint to the World Trade Organisation against seizures of its legitimate low cost generic drugs by the European Union according to people in the know.

NGO asks govt to further amend Patent Act to avoid frivolous patent filings

Ramesh Shankar, Mumbai — 03-Sep-2009

The National Working Group on Patent Law an NGO working on patent issues in the country has asked the government to further amend the Amended Patent Act 1970 to avoid frivolous and questionable patent claims being filed by the industry and are being granted by the Patent Offices.

HC asks DGCI to grant licence to Ciplas anti cancer drug

Press Trust of India / New Delhi — 04-Sep-2009

The Delhi High Court today directed the drug regulator of the country to go ahead with the process of granting a licence to Cipla for producing a generic version of the anti cancer medication Nexavar against which global drug maker Bayer Corp is fighting a legal battle.

Protecting the Patent System for Entrepreneurs

By Scott A. Shane — 04-Sep-2009

Recently a number of companies from the information technology and financial services sectors have been pushing Congress to change the patent system.

India rejects patent claims on two HIV AIDS drugs

R. Prasad — 04-Sep-2009

The Indian Patent Office has rejected applications from two US pharmaceutical companies on grounds of evergreening raising hopes of a further lowering of prices of two life saving drugs used by HIV AIDS patients in the country.

Revamping legal mechanism alone cant stop spurious drug makers

Pillman — 4-Sep-2009

Excessive pressure from global agencies pushed India to make significant changes in the Drugs and Cosmetics Act that will now subject perpetrators of spurious drugs to harsher punishments.

Ayurvedic remedies gain ground in India

Saikat Chatterjee and Arush Chopra / Bloomberg — 4-Sep-2009

Residents have switched to traditional Ayurvedic healing used for hundreds of years to boost immunity as well as unproven remedies being sold to take advantage of the outbreak

Process Ciplas licence for Soranib HC

Press Trust Of India / New Delhi — 5-Sep-2009

The Delhi High Court today directed the Drug Controller General of India to process the licence application of Cipla for production and sale of the generic version of global pharma major Bayer Corporations liver and kidney cancer drug Nexavar.

Toyota patent trade case

Bloomberg / Washington — 5-Sep-2009

Toyota Motor Corp the world’ biggest seller of autos powered by a combination of gasoline and electricity faces a patent infringement claim that may result in a US import ban on its Prius and other hybrid models.

Bayers bid to stay Cipla cancer drug foiled next hearing on Oct 6

ET Bureau — 5-Sep-2009

Germanys largest drug maker Bayer failed to get a court stay on Cipla from seeking permission to launch the European companys copycat of cancer treating drug Nexavar in India.

Process Ciplas licence for Soranib HC

Press Trust Of India / New Delhi — 5-Sep-2009

EU will take steps to resolve drug seizure cases says Ashton

ET Bureau — 06-Sep-2009

The EU has assured India that it will take steps to resolve the issue related to the recent cases of life saving generic or off patent medicines exported from India to other countries being seized at European ports.

IT dept takes drug companies to court

Khushboo Narayan and C.H. Unnikrishnan — 7-Sep-2009

Barring the top 300 pharma firms most of the 15000 drug units operating in India are engaged in contract manufacturing.

Pfizer India arm to launch 2 3 generic drugs by Dec

MUMBAI (Reuters) — 07-Sep-2009

Drug maker Pfizer Ltd plans to launch two or three generic drugs in India by December as part of its efforts to widen its portfolio and market share its managing director said late on Friday.

Innovation can benefit Indian drug industry

ENS Economic Bureau — 07-Sep-2009

Extending patent protection to incremental pharmaceutical innovation should encourage Indian pharmaceutical companies to expand further their investment in innovation and ultimately become major sources of new products for both the Indian and global markets.

U.S. court backs Synthes in U.S. patent case

by Lisa Jucca — 07-Sep-2009

Switzerland based medical device maker Synthes Inc has won a key ruling in an ongoing U.S. patent case against U.S. competitor Medtronic the Swiss company said on Monday.

Venus Remedies gets Indian patent for Potentox

Our Bureau, Mumbai — 08-Sep-2009

Venus Remedies a mid cap Rs 260 crore plus Chandigarh based pharma company has received first ever injectable FDC product patent for Potentox a research product of the company from the Indian Patent Office Government of India.

3 provisions helped India cull frivolous patents study

C.H. Unnikrishnan — 8-Sep-2009

Three patent provisions that have come under flak from foreign companies and governments for not being compliant with global intellecutual property regimes have actually helped India weed out frivolous patents since 2005 when the country moved to a new patent regime.

McDonalds loses trademark fight against McCurry

The Associated Press — 8-Sep-2009

U.S. fast food giant McDonalds lost an eight year trademark battle to prevent local restaurant McCurry from using the Mc prefix in a precedent setting judgment by Malaysias highest court.

Cipla to produce biotech drugs

BS Reporter / New Delhi — 8-Sep-2009

Cipla the countrys second largest drug company will foray into the production of biotechnology medicines soon.

DCGI asks states to effect fake drug norms

Sushmi Dey — 8-Sep-2009

The recent amendments in the Drugs & Cosmetics Act prescribes stricter punishment for companies guilty of manufacturing adulterated or spurious drugs.

Suven gets milestone payment from Eli Lilly

KV Ramana — 8-Sep-2009

Once it is launched we will keep getting the royalty till the drug is covered by the patent he said.

India patent rejections welcomed by HIV AIDS groups

By Bappa Majumdar — 09-Sep-2009

Indias rejection of patent applications on two life saving HIV AIDS drugs last week has been welcomed by health officials who say it will ensure wider access to the medicines.

Marico Agro Tech in trademark tussle

T Knight Ridder/Tribune — 09-Sep-2009

Marico India the maker of cooking oils Saffola and Sweekar has sued Agro Tech Foods an affiliate of American foods giant ConAgra Foods over what it believes is trademark violation by the latter.

Pfizer plans major push into generics

C.H. Unnikrishnan — 11-Sep-2009

Pfizer Ltd the Indian subsidiary of the worlds largest drug maker Pfizer Inc. is making an aggressive play in the Indian generics or off patent drugs market.

Mid cap pharma firms focus on LatAm market

Nina Mehta — 11-Sep-2009

Indian companies faced with increased competition in developed markets and stiff standards set by the US Food and Drug Administration are looking to markets where rules are less stringent as governments focus on affordability of healthcare rather than defending patents on billions of dollars of drugs.

SC notices to Centre pharma companies on Novartis petition

PTI — 11-Sep-2009

The Supreme Court on Friday issued notices to the Centre pharma major Cipla Ranbaxy Lab Hetero Drugs Natco Pharma and others on a pettion filed by Swiss firm Novartis AG challenging the denial of patent for its blood cancer drug Glivec in beta crystal form.

IPA calls for amendment to D&C Act to exclude IPR issues from Sec 17

Joseph Alexander, New Delhi — 12-Sep-2009

In a recent meeting jointly held by different departments including health pharma and commerce on the issue the IPA has suggested that the terms of counterfeit and spurious be defined separately and the IPR related issues e.g misbranded should be removed from Section 17 of the Drugs and Cosmetic Act.

Pfizer Indias new strategy for emerging markets

Manas Chakravarty and Ravi Ananthanarayan — 12-Sep-2009

Profitability improvements would come from a higher share of products that have patent protection.

IPRS issues notices to hotels mall for copyright violation

BS Reporter / Mumbai/ Ahmedabad — 12-Sep-2009

We have sent legal notices to the hotels and the mall for violating copyright under Section 33 of the Copyright Act 1957.

SC issues notices in Novartis patent case

Manish Ranjan — 12-Sep-2009

The apex court sought replies from the commerce ministry the comptroller general of patents the Cancer Patient Aid Association and the four pharma firms that state their objections on why the patent should not be granted to Novartis.

Biocon joins hands with US co Amylin for diabetes drug

ET Now — 12-Sep-2009

Even as Amylin will own the intellectual property rights to the molecule and phybrid technology Biocon will hold the IP for manufacturing.

Fake drugs WHO body rejects MNC argument

Rupali Mukherjee — 12-Sep-2009

The World Health Organisation regional committee has rejected the counterfeit drugs agenda propagated by developed countries and pharma MNCs which is already threatening the entry of legitimate generics exported from India.

Lupin Novartis end patent row for Lotrel

Khomba Singh, — 12-Sep-2009

Mumbai based pharma firm Lupin has reached an out of court settlement with Swiss pharma major Novartis for the latters hypertension drug sold under the brand name Lotrel which will allow the Indian firm to launch the generic version of the drug ahead of its patent expiry in 2017 and get a one time revenue upside said a person familiar with the development.

Suven gets two US patents for neurodegenerative disorder drugs

Our Bureau, Mumbai — 14-Sep-2009

Suven Life Sciences Ltd announced that the US Patent Office has issued two Patents US 7507835 and US 7388024 corresponding to two New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid until 2022 & 2024 respectively.

WHO SEARO rejects counterfeit agenda of pharma MNCs

Ramesh Shankar, Mumbai — 15-Sep-2009

The meeting noted that the term and definition of counterfeit relates to infringement of intellectual property rights and should not be equated with substandard medical products.

Major growth will come from generics business

C.R. Sukumar — 15-Sep-2009

Dr. Reddys Laboratories Ltds vice chairman and chief executive G.V. Prasad shares the drug makers future ambitions.

Patent expiry to open huge opportunity for Indian pharma

PTI — 15-Sep-2009

Patent expiry will be a major avenue of growth for the Indian pharmaceutical industry as products worth $235 billion are going off patent within horizon of five years from 2009 to 2014 a top pharma company official said here today.

Mega deals boost pharma in crisis

Rupali Mukherjee — 15-Sep-2009

With the so called patent cliff and stagnating pipelines of big pharma companies are trying to augment their portfolios and revenues like Pfizer gets the biotech and OTC business of Wyeth to augment revenues.

DRL faces patent suit in US over allergy generic

ET Bureau — 15-Sep-2009

NYSE listed Dr Reddys Laboratories is embroiled in a fresh patent infringement row with US based drug discovery firm Albany Molecular Research.

India Wins European Patent Battle For Jute

FE Reporter — 15-Sep-2009

In a major victory for the ailing jute industry Jute Manufacturers Development Council successfully fought to revoke a UK based firms patent for use of hessian cloth to cover waste and dumping grounds.

The IPR icing on Brazils cotton victory

Latha Jishnu / New Delhi — 16-Sep-2009

The more significant aspect of the arbitration panels ruling is that it allows cross retaliation by Brazil against intellectual property rights which is protected by the WTOs Agreement on Trade Related Aspects of Intellectual Property Rights TRIPS or on services.

Vedi asked not to use Le Passage trademark

Manish Ranjan — 16-Sep-2009

Delhi high court on Tuesday restrained Vedis International Tours and Travels from infringing on the registered trademark and the domain name of another tour operator Le Passage to India Tours and Travels.

Tirupati laddu gets global patent

TNN — 16-Sep-2009

Temple sources said the Tirupati laddu got the patent rights under the Geographical Indications of Goods Registration and Protection Act on Tuesday.

SC reserves judgement on Bajaj TVS patent case

Legal — 16-Sep-2009

The Supreme Court on Tuesday reserved its judgement on the patent case between two wheeler rivals Bajaj Auto and TVS Motor.

Centre plans action against EU customs rules

Amiti Sen — 16-Sep-2009

India is not willing to take the European Commissions verbal assurances on sorting out the issue of seizure of Indian drugs at European ports.

India has immense potential to take on global pharma markets

PTI — 16-Sep-2009

Primary problems faced by the Indian pharma sector today are issues of intangibles namely lack of skilled manpower lack of consistency and quality lack of clarity on IPR and patenting regulatory failures and a highly fragmented sector it said.

Sun Pharma Caraco plan to file 30 patent pleas for generics

BS Reporter / Mumbai — 17-Sep-2009

Sun Pharmaceutical Industries and its troubled US subsidiary Caraco Pharmaceuticals plan to together file 30 Abbreviated New Drug Applications with the US Food and Drug Administration to market generic drugs despite regulatory issues for the US company.

TVS can sell Flame with twin spark plug

Press Trust Of India / New Delhi — 17-Sep-2009

A Supreme Court Bench asks the Madras High Court to decide the matter before November 30.

Counterview A laddu is a laddu is a laddu

Amrith Lal — 17-Sep-2009

But these are not convincing reasons to claim that the Tirupati laddu is an exceptional item like the Darjeeling tea or Goan feni to have geographical indications patent rights.

View Good candidate for GI status

Amrith Lal — 17-Sep-2009

After Darjeeling tea champagne and Florida oranges its the turn of Tirupati laddus to get a geographical indications patent.

Dr Reddys Promoter exit wont come cheap

Pillman — 17-Sep-2009

The one off windfall gains through patent challenges of the last few years are also not so much talked about as more and more companies increasingly shake hands and call truce to save spiralling litigation costs.

The Apex Court of India Sets Guidelines for All IP Litigation in Lower Courts

ag-IP-news Agency — 17-Sep-2009

A landmark Judgment has been passed by the Supreme Court of India which could change the course of Intellectual Property litigation in India.

Appeals court affirms patent infringement rulings against Roches peg EPO product

Thousand Oaks, California — 18-Sep-2009

Amgen announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Courts decision that Roches peg EPO product Mircera infringes four Amgen patents relating to recombinant erythropoietin and processes for making it.

Skype founders file a copyright suit against eBay

New York Times — 18-Sep-2009

The founders of Skype are escalating their legal battle with eBay.

Reliance Life trims pharma plans to keep cash in hand

C.H. Unnikrishnan — 18-Sep-2009

The pharma arm will now focus on selected high value but low volume specialty drugs.

Banarasi silk sarees get copyright cover

Binay Singh — 18-Sep-2009

Banarasi silk products have now joined the league of Pochampalli Tirupati laddu and Darjeeling tea under the registered name of Banaras Brocades and Sarees by securing Geographical Indication rights.

Glaxo seen eyeing 5% stake in Dr Reddys

REUTERS — 18-Sep-2009

Dr Reddys will get a lot of mileage in terms of selling their products in new markets while Glaxo will get access to a basket of generics at a time when a large numbers of drugs are going off patent.

Merck to launch 13 innovator drugs here

Khomba Singh — 19-Sep-2009

Besides the drugs launch we would go to smaller towns and cities where nobody has gone.Our growth will be driven by patented drugs.

Patented drugs market in India to touch $8 bn by 2015 Report

Press Trust Of India — 20-Sep-2009

The increasing population of higher income group in the country will open a potential $ 8 billion market for multi national companies selling costly patented drugs by 2015 a FICCI Ernst & Young study said.

Now an Invention Inventors Will Like

By STEVE LOHR — 20-Sep-2009

The world can be a rough place for independent inventors.